Copyright © and Moral Rights for this thesis and, where applicable, any accompanying data are retained by the author and/or other copyright owners. A copy can be downloaded for personal non-commercial research or study, without prior permission or charge. This thesis and the accompanying data cannot be reproduced or quoted extensively from without first obtaining permission in writing from the copyright holder/s. The content of the thesis and accompanying research data (where applicable) must not be changed in any way or sold commercially in any format or medium without the formal permission of the copyright holder/s.

When referring to this thesis and any accompanying data, full bibliographic details must be given, e.g.

Thesis: Author (Year of Submission) "Full thesis title", University of Southampton, name of the University Faculty or School or Department, PhD Thesis, pagination.

Data: Author (Year) Title.
UNIVERSITY OF SOUTHAMPTON

FACULTY OF MEDICINE

Clinical & Experimental Sciences

VASCULAR DEMENTIA AND FAILURE OF INTRAMURAL PERIARTERIAL DRAINAGE – THE ROLE OF THE DYSTROPHIN ASSOCIATED PROTEIN COMPLEX

by

Matthew Thomas MacGregor Sharp

ORCID ID 0000-0002-6623-5078

Thesis for the degree of Doctor of Philosophy

OCTOBER 2020
Introduction: Cerebral small vessel disease (CSVD), a key aspect of vascular dementia (VaD), consists of pathological modifications to cerebral vessel walls and associated white matter lesions. Cerebral vessels have a dual function: perfusion of the brain and drainage of interstitial fluid and solutes along the walls of capillaries and arteries as Intramural Periarterial Drainage (IPAD). IPAD fails with age resulting in cerebral amyloid angiopathy (CAA), part of the spectrum of CSVD. Most animal models designed to study CAA are modified to overexpress amyloid proteins, but this is in contrast to the majority of CAA cases which occur due to a failure of clearance of soluble amyloid, rather than genetic mutations. The conduit for IPAD is the capillary and arterial basement membrane. This basement membrane is synthesised by cells of the vessel wall and its modification leads to a failure of IPAD and CAA. Polarised astrocytic extensions form end feet projections that encircle the abluminal side of the vessel wall attaching to basement membrane by the dystrophin associated protein complex (DPC), of which alpha dystrobrevin (α-DB) and aquaporin 4 (AQP4) are key components. Alterations to this complex disrupt the morphology of vessel walls, causing abnormalities to basement membranes and altering blood-brain barrier function.

This thesis aims to investigate the role of the DPC in the morphology and dynamics of IPAD pathways and to ascertain if mice with altered DPC can be used to model: 1) a failure of ISF fluid clearance by IPAD and 2) the features of CSVD and VaD. The following hypothesis are tested: 1) In mice that do not express glial AQP4 the morphology of capillary IPAD pathways is altered; 2) In mice genetically modified
for α-DB, the morphology and dynamics of IPAD pathways and cerebral perfusion are impaired.

Methods: A detailed morphological study on the capillary wall from the white and grey matter in AQP4 and α-DB deficient mice was performed using quantitative electron microscopy and immunohistochemistry for collagen IV. The pattern of IPAD in white and grey matter was imaged and quantitatively measured in α-DB deficient and wild-type control mice. Cerebral perfusion under resting state and when challenged with hypercapnia was measured in α-DB deficient mice.

Results: 1) AQP4 deficient mice showed a reduction in the percentage surface area of basement membranes and an increase in the percentage surface area of intramural cells in the white matter. 2) In α-DB deficient mice, the percentage surface area occupied by basement membrane was increased in capillary walls in both grey and white matter, accompanied by an increased expression of collagen IV in the grey matter. 3) The pattern of IPAD in the grey matter of α-DB deficient mice showed fewer arterioles with fluorescent soluble Aβ in their walls compared to age matched controls. 4) Solutes from the normal white matter drain preferentially along the basement membranes of capillaries. 5) Absence of α-DB is associated with a normal perfusion but a lower capacity for adaptation to hypercapnia.

Conclusions. The results highlight an important role for α-DB and the DPC in maintaining the structural integrity of basement membranes, which is reflected in the capacity for draining interstitial fluid and solutes via IPAD. The localisation of AQP4 to astrocyte endfeet by its indirect association with α-DB and the DPC is not critical for the morphology of the basement membrane in the grey matter. As the capillary walls in the grey matter appear normal and the intramural cells in the white matter are enlarged, in contrast to the findings in human disease, AQP4 deficient mice do not replicate features of CSVD and may not be a suitable model for mechanistic insights into CSVD or VaD. Since this work highlighted that IPAD occurs preferentially along the capillary walls in the normal white matter with little involvement from arteries, it is important to consider the failure of IPAD as a key mechanistic feature of white matter hyperintensities. It remains to be seen if there are changes to α-DB and the DPC in the spectrum of CSVD in human brains, as this work points to it as a suitable model for further hypothesis-based studies of CSVD.
# Table of Contents

List of Tables ........................................................................................................................................... i
List of Figures .......................................................................................................................................... iii
Research Thesis: Declaration of Authorship ......................................................................................... vii
Acknowledgements ............................................................................................................................... ix
Definitions and Abbreviations ............................................................................................................ xi

## Chapter 1 INTRODUCTION ............................................................................................................... 1

1.1 Vascular dementia is the second most common type of dementia ............................ 3
  1.1.1 Risk factors ............................................................................................................................ 4
  1.1.2 Subtypes ..................................................................................................................................... 5
    1.1.2.1 Cerebral small vessel disease is a key feature of dementia and stroke ...................... 5
    1.1.2.1.1 Cerebral small vessel disease: Cerebral amyloid angiopathy is represented by the deposition of amyloid protein 7

1.2 Vascular dementia and alterations to the blood-brain barrier and the vessel wall .............................................................................................................................. 11
  1.2.1 The vessel wall: Endothelia .................................................................................................... 12
    1.2.1.1 Endothelial disruption alters permeability of the blood-brain barrier .......................... 12
  1.2.2 The vessel wall: Extracellular matrix ............................................................................... 13
    1.2.2.1 Extracellular matrix remodelling ................................................................................. 15
  1.2.3 The vessel wall: Pericytes ................................................................................................. 17
  1.2.4 The vessel wall: Astrocytes ............................................................................................. 17
    1.2.4.1 Astrocytes are anchored to the extracellular matrix by the dystrophin associated protein complex 18
    1.2.4.2 Astrocytes and the transmembrane water channel aquaporin 4 19
    1.2.4.3 Aquaporin 4 is anchored to astrocyte cell membrane by the dystrophin associated protein complex 19
    1.2.4.4 Targeting of aquaporin 4 to astrocyte endfeet is regulated by Dystrobrevin proteins 22
    1.2.4.4.1 Beta dystrobrevin .................................................................................................. 23
    1.2.4.4.2 Alpha dystrobrevin ............................................................................................ 24
    1.2.4.4.3 Alpha dystrobrevin and Aquaporin 4 .................................................................. 24

1.3 Vascular dementia and fluid homeostasis ........................................................................... 27
1.3.1 Regulation of cerebrospinal fluid (CSF) .................................................. 27
  1.3.1.1 Exchange of CSF with interstitial fluid (ISF)................................. 27
1.3.2 Regulation of interstitial fluid ............................................................... 31
  1.3.2.1 The intramural periarterial drainage pathway (IPAD) .................... 31
   1.3.2.1.1 The motive force for IPAD is derived from the contractions of smooth muscle cells within the walls of arteries ............................................................. 34
1.3.3 The role of Aquaporin 4 in fluid homeostasis in the brain ...................... 35
  1.3.3.1 Aquaporin 4 responds to altered cerebral water homeostasis by the formation or prevention of oedema .................................................. 35
   1.3.3.1.1 Aquaporin 4 and cytotoxic oedema ......................................... 36
   1.3.3.1.2 Aquaporin 4 and vasogenic oedema ........................................ 36
   1.3.3.1.3 Aquaporin 4 and hydrocephalic oedema ................................ 37
1.3.4 Fluid homeostasis and the white matter abnormalities in vascular dementia .......................................................... 37
1.4 Modelling Vascular Dementia using animal models ................................... 42
  1.4.1 Modelling macrovascular changes to cerebral blood vessels ............ 42
   1.4.1.1 Hypoperfusion ............................................................................. 42
  1.4.2 Modelling microvascular changes to cerebral blood vessels .......... 43
   1.4.2.1 Hypertension ............................................................................... 43
   1.4.2.2 Hyperhomocysteinemia ................................................................. 43
   1.4.2.3 Vascular deposits of proteins as cerebral amyloid angiopathy ..... 43
1.5 The potential of mice with altered dystrophin associated protein complex to model microvascular changes seen in cerebral small vessel disease ............. 44
  1.5.1 Altered structure and function of the endothelium and the blood-brain barrier .................................................................................... 44
  1.5.2 Altered fluid homeostasis ................................................................. 45
  1.5.3 Basement membrane remodelling ..................................................... 46
  1.5.4 Can mice with altered dystrophin associated protein complex be used to model intramural periarterial drainage to investigate its possible failure in vascular dementia? ................................................... 48
1.6 Aims ............................................................................................................. 49
1.7 Hypotheses ................................................................................................... 51

Chapter 2 MATERIALS & METHODS.......................................................................................... 53
2.1 Animals ........................................................................................................ 55
  2.1.1 Mice deficient for Aquaporin 4 (chapter 3) ............................................. 55
  2.1.2 Mice deficient for Alpha dystrobrevin (B6;129-Dtna tm1Jrs/J) mice
       (chapters 4, 5 & 6)................................................................................. 55
       2.1.2.1 Genotyping mice deficient for alpha-dystrobrevin................. 56
       2.1.2.1.1 Preparation of mouse genomic DNA.............................. 56
       2.1.2.1.2 Polymerase chain reaction............................................. 57
  2.2 Assessment of the capillary wall using transmission electron microscopy
       (chapters 3 and 4) .................................................................................... 60
       2.2.1 Fixation of tissue for electron microscopy.................................... 60
       2.2.2 Preparing perfusion fixed brains for tissue processing.............. 60
       2.2.3 Tissue processing for transmission electron microscopy........... 61
       2.2.4 Sectioning of processed tissue .................................................... 62
       2.2.5 Imaging tissue sections for capillaries....................................... 63
       2.2.6 Calculating percentage surface area of the different components of the
            capillary wall ..................................................................................... 63
       2.2.7 Statistical analysis ....................................................................... 63
  2.3 Analysing the composition of the cerebrovascular basement membranes
       (chapter 4) ................................................................................................ 65
       2.3.1 Fixation of tissue for immunohistochemistry............................. 65
       2.3.2 Tissue sectioning ........................................................................ 65
       2.3.3 Enzyme linked immunohistochemistry for collagen IV ............ 65
       2.3.4 Imaging for DAB staining of collagen IV ................................... 66
               2.3.4.1 Extracting regions of interest......................................... 66
               2.3.4.2 Analysing regions of interest for COL4 staining and vessel density
                                                                        .......................................................... 68
               2.3.4.3 Analysing regions of interest for vessel distribution and vessel
                        specific COL4 staining............................................................... 68
               2.3.4.4 Statistical analysis ............................................................ 69
  2.4 Assessment of intramural periarterial drainage in alpha-dystrobrevin deficient
       mice (chapter 5) ........................................................................................ 73
       2.4.1 Stereotaxic injection of amyloid-beta (1-40) HiLyte Fluor 555...... 73
       2.4.2 Fixation of tissue and tissue sectioning for immunohistochemistry 75
       2.4.3 Tissue processing for immunohistochemistry .............................. 75
       2.4.4 Imaging tissue sections by confocal microscopy ....................... 75
       2.4.5 Assessment of intramural periarterial drainage ......................... 76
Chapter 3 LOSS OF AQUAPORIN 4 FROM ASTROCYTE ENDFEET AND THE MORPHOLOGY OF THE INTRAMURAL PERIARTERIAL DRAINAGE PATHWAY

3.1 Introduction .................................................................................................. 85
3.2 Hypothesis .................................................................................................... 87
3.3 Aims ............................................................................................................. 88
3.4 Materials & methods ..................................................................................... 89
3.5 Results .......................................................................................................... 90
   3.5.1 Ultrastructural assessment of the capillary wall in grey and white matter in AQP4 deficient mice ................................................................. 90
   3.5.2 Image segmentation and surface area measurements ............................ 93
      3.5.2.1 Comparison of capillaries in white and grey matter in wild-type control mice ................................................................................... 93
      3.5.2.2 Comparison of capillaries in white and grey matter in AQP4 deficient mice ........................................................................................................... 93
      3.5.2.3 Comparison of capillaries in white and grey matter between wild-type control and AQP4 deficient mice .......................................... 96
      3.5.2.4 Comparison of vascular wall composition in capillaries from grey and white matter between wild-type control and AQP4 deficient mice ........................................................................................................... 99
3.6 Discussion .................................................................................................. 101
   3.6.1 AQP4 and grey matter ........................................................................... 101
   3.6.2 AQP4 and white matter ........................................................................ 101
   3.6.3 Conclusions ......................................................................................... 102

Chapter 4 LOSS OF ALPHA-DYSTROBREVIN FROM ASTROCYTE ENDFEET AND THE MORPHOLOGY OF THE INTRAMURAL PERIARTERIAL DRAINAGE PATHWAY

4.1 Introduction ................................................................................................ 107
4.2 Hypothesis .................................................................................................. 109
4.3 Aims ............................................................................................................. 110
4.4 Materials & methods ................................................................................... 111
   4.4.1 Transmission electron microscopy ....................................................... 111
   4.4.2 Immunohistochemistry ....................................................................... 111
4.5 Results ................................................................................................................................. 112

4.5.1 Ultrastructural assessment of the capillary wall in grey and white matter in alpha dystrobrevin deficient mice ................................................................. 112

4.5.2 Image segmentation and surface area measurements ................................................. 115

4.5.2.1 Comparison of capillaries in white and grey matter in wild-type control mice ............................................................................................................... 115

4.5.2.2 Comparison of capillaries in white and grey matter in alpha dystrobrevin deficient mice ................................................................. 115

4.5.3 Comparison of capillaries in white and grey matter between wild-type control and alpha dystrobrevin deficient mice ................................................. 118

4.5.4 Comparison of vascular wall composition in capillaries from grey and white matter between wild-type control and alpha dystrobrevin deficient mice ........................................................................................................... 121

4.5.5 Alterations to the biochemical composition of vascular basement membranes in alpha dystrobrevin deficient mice ................................................. 123

4.5.5.1 Comparison of the pattern of collagen IV staining between wild-type control and alpha dystrobrevin deficient mice ................................................. 123

4.5.5.2 Comparison of vessel density and amount of collagen IV staining between wild-type control and alpha dystrobrevin deficient mice ........................................................................................................... 125

4.5.5.3 Comparison of vessel distribution and amount of collagen IV staining in grey matter between wild-type control and alpha dystrobrevin deficient mice ................................................. 129

4.6 Discussion ................................................................................................................................. 131

4.6.1 The morphology of the blood-brain barrier is unaltered in young alpha dystrobrevin deficient mice ................................................................. 131

4.6.2 The capillary basement membrane is thickened in alpha dystrobrevin deficient mice ........................................................................................................... 131

4.6.3 Why does removal of alpha dystrobrevin cause thickening of capillary basement membrane? ................................................................. 132

4.6.4 Conclusions ................................................................................................................................. 133

Chapter 5 LOSS OF ALPHA-DYSTROBREVIN FROM ASTROCYTE ENDFEET AND THE DYNAMICS OF INTRAMURAL PERIARTERIAL DRAINAGE ................................................. 135

5.1 Introduction ................................................................................................................................. 137

5.2 Hypotheses ................................................................................................................................. 140

5.3 Aims .......................................................................................................................................... 141

5.4 Materials & methods ............................................................................................................... 142
Chapter 5

5.5 Results

5.5.1 Assessment of vessel density in grey and white matter

5.5.1.1 Wild-type control mice

5.5.1.2 Alpha dystrobrevin deficient mice

5.5.1.3 Wild-type and alpha dystrobrevin deficient mice – grey matter

5.5.1.4 Wild-type and alpha dystrobrevin deficient mice – white matter

5.5.2 Assessment of intramural periarterial drainage in the grey and white matter

5.5.2.1 Qualitative assessment

5.5.2.2 Quantitative assessment of IPAD between grey and white matter

5.5.2.2.1 Wild-type control mice

5.5.2.2.2 Alpha dystrobrevin deficient mice

5.5.2.3 Wild-type control vs. alpha dystrobrevin deficient mice

5.5.2.4 Assessment of fluorescent intensity of parenchymal amyloid beta

5.6 Discussion

5.6.1 The dynamics of intramural periarterial drainage in the white matter is different from that in the grey matter in wild-type control mice

5.6.2 The dynamics of intramural periarterial drainage are altered in alpha dystrobrevin deficient mice

5.6.2.1 Grey matter

5.6.2.2 White matter

5.6.3 Conclusions

Chapter 6

LOSS OF ALPHA-DYSTROBREVIN FROM ASTROCYTE ENDFEET AND CEREBRAL BLOOD FLOW

6.1 Introduction

6.2 Hypothesis

6.3 Aims

6.4 Materials & methods

6.5 Results

6.5.1 Assessment of resting cerebral blood flow

6.5.2 Assessment of cerebral blood flow in response to hypercapnia

6.6 Discussion

Chapter 7

GENERAL DISCUSSION
Redistribution of AQP4 in α-DB deficient mice has minimal effect on the IPAD pathway........................................................................................................................................180

The cerebral vasculature in α-DB deficient mice show signs of early ageing and reflect early changes seen in CAA......................................................................................................................................181

IPAD in the white matter is less efficient than that in the grey matter.............. 183

IPAD is impaired in α-DB deficient mice.............................................................. 184

The removal of α-DB from the DPC of astrocyte endfeet is associated with normal perfusion but a lower capacity for adaptation to hypercapnia..................... 186

Mice deficient for α-DB show potential as a model for the failure of IPAD in CSVD and VaD .................................................................................................................................................. 187

Limitations and Future work.............................................................................. 187

Overall summary, conclusions and implications .................................................. 189

Appendix A  List of Publications ........................................................................ 191

Co-authored publications that include data generated as part of this thesis.... 193

Co-authored publications in which some of the data has been presented in the main introduction .................................................................................................................................................. 193

Appendix B  PUBLICATION - Demonstrating a reduced capacity for removal of fluid from cerebral white matter and hypoxia in areas of white matter hyperintensity associated with age and dementia .................................................. 195

Appendix C  METHOD FOR CEREBRAL BLOOD FLOW MEASUREMENTS USING ARTERIAL SPIN LABELLING ................................................................................................................................. 211

C.1  Aim ............................................................................................................ 213

C.2  Method ....................................................................................................... 213

C.3  Theory ........................................................................................................ 213

C.4  Data Processing .......................................................................................... 215

List of References ............................................................................................... 217
List of Tables

Table 1: Comparison of capillary size metrics between grey and white matter in wild-type control mice .................................................... 94
Table 2: Comparison of capillary size metrics between grey and white matter in AQP4 deficient mice ....................................................... 95
Table 3: Comparison of capillary size metrics between grey and white matter in wild-type control mice .................................................. 116
Table 4: Comparison of capillary size metrics between grey and white matter in α-DB deficient mice ...................................................... 117
Table 5: Comparison of vessel density between grey and white matter in wild-type control and α-DB deficient mice .......................... 145
Table 6: Comparison of the density of vessels with fluorescent Aβ in their vessel walls between grey and white matter in wild-type control and α-DB deficient mice .................................................. 153
Table 7: Comparison of area and mean pixel density of fluorescent amyloid beta remaining in the parenchyma of grey and white matter ......................................................................................... 157
List of Figures

Figure 1.1 Summary of the risk factors for vascular dementia and subtypes ......................................................................................... 5
Figure 1.2 Classification of lesions related to small vessel disease as per Wardlaw et.al. ................................................................. 6
Figure 1.3 Diagram of an arterial wall showing deposition of Aβ as cerebral amyloid angiopathy ........................................................... 9
Figure 1.4 The Modified Boston Criteria ....................................................... 10
Figure 1.5 The neurovascular unit ................................................................. 11
Figure 1.6 The extracellular matrix ............................................................... 14
Figure 1.7 Regional specific thickening of capillary basement membranes with age in wild-type mice ............................................. 16
Figure 1.8 The structure of AQ4 ................................................................. 21
Figure 1.9 Interactions of dystrophin associated proteins and AQP4 ............... 22
Figure 1.10 The structure of dystrobrevin .................................................... 23
Figure 1.11 α-DB targets AQP4 to astrocyte endfeet .................................... 25
Figure 1.12 The dystrophin associated protein complex at astrocyte endfeet ................................................................................. 26
Figure 1.13 The pathway in which nanoparticles enter the brain after injection into mouse CSF via cisterna magna .............................. 29
Figure 1.14 Arterioles in the midbrain have enlarged pial-glial basement membranes ........................................................................ 30
Figure 1.15 The intramural periarterial drainage pathway ............................ 32
Figure 1.16 Flow of biotinylated Aβ 40 after injection into mouse hippocampus ................................................................................ 33
Figure 1.17 The pattern of IPAD in the hippocampus after administration of the beta blocker Atenolol ......................................................... 34
Figure 1.18 Dilated perivascular space .......................................................... 39
Figure 1.19 The two leptomeningeal layers of the pial-glial basement membrane .................................................................................. 40
Figure 1.20 Leptomeningeal layers form a distinct perivascular compartment that has the potential to expand forming dilated perivascular spaces .......................................................................... 41
List of Figures

Figure 1.21 Summary of the microvascular changes observed in mice deficient for dystroglycan, AQP4, dystrophin and α-DB ............... 47

Figure 2.1 Overview of the α-DB gene and its deletion in α-DB null (B6;129-Dtna tm1Jrs/J) mice .......................................................... 58

Figure 2.2 PCR results for the genotyping of α-DB null (B6;129-Dtna tm1Jrs/J) mice ............................................................................... 59

Figure 2.3 Dissection of mouse brain for TEM analysis ........................................................... 62

Figure 2.4 Demarcation and analysis of components of the capillary wall ................................................. 64

Figure 2.5 Sample sites for immunohistochemistry of collagen IV .................................................. 67

Figure 2.6 Custom macros used in Image J to analyse COL4 staining .............................................. 70

Figure 2.7 Analysing regions of interest for number of vessels and COL4 staining ............................................................... 71

Figure 2.8 Analysing regions of interest for distribution of vessels and COL4 staining ................................................................. 72

Figure 2.9 Stereotaxic injection sites ....................................................................................... 74

Figure 2.10 Selection of regions of intertest for assessment of intramural periarterial drainage ........................................................................ 78

Figure 2.11 Assessment of the density of amyloid beta (1-40) in the parenchyma .......................................................... 79

Figure 3.1 AQP4 and its deletion from the dystrophin associated protein complex in astrocyte endfeet ........................................................................ 88

Figure 3.2 The structural appearance of the capillary wall in the grey matter appears unaltered in mice deficient for AQP4 .......... 91

Figure 3.3 The structural appearance of the capillary wall in the white matter appears unaltered in mice deficient for AQP4 .......... 92

Figure 3.4 Summary of capillary size metrics in grey matter between wild-type control and AQP4 deficient mice .................. 97

Figure 3.5 Summary of capillary size metrics in white matter between wild-type control and AQP4 deficient mice .................. 98

Figure 3.6 Summary showing overall mean values for the percentage of the vessel wall occupied by endothelium, intramural cells and basement membrane between wild-type control and AQP4 deficient mice in white and grey matter .................................................. 100

Figure 4.1 alpha dystrobrevin and the dystrophin associated protein complex ................................................................. 110

Figure 4.2 The structural appearance of the capillary wall in the grey matter appears altered in mice deficient for α-DB ......... 113
Figure 4.3 The structural appearance of the capillary wall in the white matter appears altered in mice deficient for α-DB .......................... 114

Figure 4.4 Summary of capillary size metrics in grey matter between wild-type control and α-DB deficient mice ........................................... 119

Figure 4.5 Summary of capillary size metrics in white matter between wild-type control and α-DB deficient mice .............................. 120

Figure 4.6 Summary showing overall mean values for the percentage of the vessel wall occupied by endothelium, intramural cells and basement membrane between wild-type control and α-DB deficient mice in white and grey matter ...................................... 122

Figure 4.7 Immunostaining for COL4 in wild type control and α-DB deficient mice ............................................................................. 124

Figure 4.8 Vessel density and COL4 staining per vessel between grey and white matter in wild-type control mice ............................... 126

Figure 4.9 Vessel density and COL4 staining per vessel between grey and white matter in α-DB deficient mice ....................................... 127

Figure 4.10 Vessel density and COL4 staining per vessel in grey and white matter between wild-type control and α-DB deficient mice .......... 128

Figure 4.11 Vessel distribution and COL4 staining in grey matter wild-type control and α-DB deficient mice ................................................... 130

Figure 5.1 The IPAD pathway and accumulation of amyloid proteins as CAA ............................................................................................ 138

Figure 5.2 alpha dystrobrevin, the dystrophin associated protein complex and the intramural periarterial drainage pathway ..................... 141

Figure 5.3 Vessel density in grey and white matter between wild-type control and α-DB deficient mice .......................................................... 146

Figure 5.4 Composite tile scan of the distribution of Aβ injected into left hippocampus of wild-type control mice ........................................ 148

Figure 5.5 Composite tile scan of the distribution of Aβ injected into left hippocampus of α-DB deficient mice ............................................. 149

Figure 5.6 Composite tile scan of the distribution of Aβ injected into the corpus callosum of wild-type control mice ........................................ 150

Figure 5.7 Composite tile scan of the distribution of Aβ injected into the corpus callosum of α-DB deficient mice ............................................. 151

Figure 5.8 Comparison of the density of vessels with fluorescent Aβ in their vessel walls between wild-type control and α-DB deficient mice .......................................................... 155
List of Figures

Figure 5.9 Comparison of mean fluorescent area and mean pixel density of parenchymal fluorescent Aβ in grey and white matter between wild-type control and α-DB deficient mice ...................... 158

Figure 6.1 alpha dystrobrevin, the dystrophin associated protein complex and assessing cerebral blood flow ......................................................... 167

Figure 6.2 Assessment of cortical CBF between wild-type control and α-DB deficient mice ................................................................. 169

Figure 6.3 Assessment of hippocampal CBF between wild-type control and α-DB deficient mice ................................................................. 170

Figure 6.4 Visualisation of the relative change in cortical CBF in response to hypercapnia in wild-type control and α-DB deficient mice ....... 171

Figure 6.5 Visualisation of the relative change in hippocampal CBF in response to hypercapnia in wild-type control and α-DB deficient mice ........................................................................... 172
Research Thesis: Declaration of Authorship

Print name: Matthew MacGregor Sharp

Title of thesis: Vascular dementia and failure of intramural periarterial drainage – the role of the dystrophin associated protein complex

I declare that this thesis and the work presented in it are my own and has been generated by me as the result of my own original research.

I confirm that:

1. This work was done wholly or mainly while in candidature for a research degree at this University;
2. Where any part of this thesis has previously been submitted for a degree or any other qualification at this University or any other institution, this has been clearly stated;
3. Where I have consulted the published work of others, this is always clearly attributed;
4. Where I have quoted from the work of others, the source is always given. With the exception of such quotations, this thesis is entirely my own work;
5. I have acknowledged all main sources of help;
6. Where the thesis is based on work done by myself jointly with others, I have made clear exactly what was done by others and what I have contributed myself;
7. Parts of this work have been published as:


Signature: .................................................................. Date: .....................
Acknowledgements

This work is funded by a Stroke Association Priority Programme Award (PPA 2016/01, ARCP003059) entitled “Failure of drainage of fluid from the brain along the walls of blood vessels in vascular dementia”. Tissue from aquaporin 4 deficient mice were kindly supplied by colleagues at Keio University, Japan. Mice deficient for alpha dystrobrevin were generated by colleagues in the Biomedical Research Facilities of the University of Portsmouth and the University of Southampton.

Unless specifically stated otherwise, all animal work, data analysis and interpretation of results was performed by myself, but I am extremely grateful for the help of James Lyles, who performed some of the electron microscopy (chapter 4), Jordan Cassidy who helped with immunohistochemistry (chapter 4) and Maureen Gatherer who has provided expert advice on all aspects of immunohistochemistry and performed confocal microscopy (chapter 5). Special thanks go to Jack wells and Yolanda Othene who kindly performed arterial spin labelling on alpha dystrobrevin deficient mice at University college London (chapter 6). I am grateful to David Johnston who has provided expert assistance with the confocal microscope and my mentor Professor Roxana Carare whose guidance, support and patience are valued enormously.

Finally, I would like to acknowledge my wife Helen, for her continuous encouragement, support, and strength. I would also like to say an enormous thank you to my daughter Harriet, her infectious smile and wicked sense of humour has helped me tremendously during some of the most challenging of times.
## Definitions and Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aβ</td>
<td>Amyloid beta</td>
</tr>
<tr>
<td>α-DB</td>
<td>α-dystrobrevin</td>
</tr>
<tr>
<td>ACAS</td>
<td>Asymmetrical common carotid artery stenosis</td>
</tr>
<tr>
<td>AD</td>
<td>Alzheimer’s disease</td>
</tr>
<tr>
<td>APP</td>
<td>Amyloid precursor protein</td>
</tr>
<tr>
<td>AQP4</td>
<td>Aquaporin 4</td>
</tr>
<tr>
<td>BCAS</td>
<td>Bilateral common carotid artery stenosis</td>
</tr>
<tr>
<td>BMD</td>
<td>Becker muscular dystrophy</td>
</tr>
<tr>
<td>CAA</td>
<td>Cerebral amyloid angiopathy</td>
</tr>
<tr>
<td>CADASIL</td>
<td>Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy</td>
</tr>
<tr>
<td>COL4</td>
<td>Collagen IV</td>
</tr>
<tr>
<td>CNS</td>
<td>Central nervous system</td>
</tr>
<tr>
<td>CSF</td>
<td>Cerebrospinal fluid</td>
</tr>
<tr>
<td>CSVD</td>
<td>Cerebral small vessel disease</td>
</tr>
<tr>
<td>CT</td>
<td>computer tomography</td>
</tr>
<tr>
<td>DAB</td>
<td>3,3'-Diaminobenzidine</td>
</tr>
<tr>
<td>DMD</td>
<td>Duchenne muscular dystrophy</td>
</tr>
<tr>
<td>DNA</td>
<td>Deoxyribonucleic acid</td>
</tr>
<tr>
<td>DPC</td>
<td>Dystrophin associated protein complex</td>
</tr>
<tr>
<td>DP71</td>
<td>Dystrophin isoform 71</td>
</tr>
<tr>
<td>DPVS</td>
<td>Dilated perivascular space</td>
</tr>
</tbody>
</table>
Definitions and Abbreviations

ECM  Extracellular matrix
EDTA  Disodium ethylenediaminetetraacetic acid
HHcy  Hyperhomocysteinemia
HOTSHOT  Hot Sodium Hydroxide and Tris
ICP  Inter cranial pressure
IPAD  Intramural periarterial drainage
ISF  Interstitial fluid
KIR4.1  Potassium channel
LOX  Lysyl oxidase
MDX  Dystrophin deficient mice
MMP  Matrix metallopeptase
MPTP  1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
MRI  Magnetic resonance imaging
NAOH  Sodium hydroxide
NVU  Neurovascular unit
OAPS  Orthogonal array of particles
PCR  Polymerase chain reaction
PDZ  Post synaptic density protein, Drosophila disc large tumor suppressor and Zonula occludens-1 protein
PBS  Phosphate buffered saline
PFA  Paraformaldehyde
PIPES  Piperazine-N,N'-bis(2-ethanesulfonic acid)
ROI  Region of interest
SHR  Spontaneously hypertensive rat
### Definitions and Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>SHRSP</td>
<td>Spontaneously hypertensive stroke prone rat</td>
</tr>
<tr>
<td>SMC</td>
<td>Smooth muscle cells</td>
</tr>
<tr>
<td>TEM</td>
<td>Transmission electron microscopy</td>
</tr>
<tr>
<td>TGN-020</td>
<td>Inhibitor 2-(nicotinamide)-1,3,4-thiadiazole</td>
</tr>
<tr>
<td>TRIS-HCL</td>
<td>Tris (hydroxymethyl) aminomethane hydrochloride</td>
</tr>
<tr>
<td>VaD</td>
<td>Vascular dementia</td>
</tr>
<tr>
<td>WMH</td>
<td>White matter hyperintensities</td>
</tr>
</tbody>
</table>
Chapter 1  INTRODUCTION
Chapter 1: Introduction

1.1 **VASCULAR DEMENTIA IS THE SECOND MOST COMMON TYPE OF DEMENTIA**

The umbrella term “dementia” encompasses a wide range of neurodegenerative disorders characterised by a progressive decline in cognitive ability and capacity for independent living. It is a devastating disease that not only affects the individuals with the condition, but also friends and family who often have to respond to the changes in their loved ones needs while at the same time witnessing their decline. The disease has a large effect on wider society as sufferers of dementia require continual health and social care [1] and the economic burden is huge. In the UK, the current cost of dementia including healthcare, social care and unpaid care is £36.7 billion. This is predicted to rise by 172% to £94.1 billion by 2040 [2].

Dementia is an ever-growing worldwide problem. The biggest risk factor is ageing and here lies the main issue: the world’s population is ageing. As of 2015, the worldwide population of people aged 60 or over was estimated to comprise over 900 million people. The number of people suffering from dementia was estimated to be around 47 million [3, 4]. As longevity and life expectancy continues to rise, this number is set to increase.

According to the World Alzheimer report 2019, almost 80% of the general public are concerned about developing dementia and there are currently no preventative measures [5]. In the UK, dementia is currently predicted to affect 883,100 people, increasing by 80% to 1,590,100 by 2040. Because of this, the UK and many other high-income countries now prioritise dementia for funding and research and have developed several specific plans and strategies to combat the health and social care burdens that arise from the condition.

Vascular dementia (VaD), the second most common type of dementia accounting for 17-20% of all dementia patients [6] is the most severe form of vascular cognitive impairment (VCI), an umbrella term that is used to emphasise the vascular origins of cognitive deficits. VCI has recently been reconceptualised, with the severity of cognitive impairment subdivided into “minor” and “major (VaD)” divisions [7]. VaD is a mixed group of brain disorders in which cognitive abnormalities such as behavioural symptoms, locomotor abnormalities, dysarthria and autonomic dysfunction are attributable to pathological changes to the cerebrovasculature.
Chapter 1: Introduction

These include microvascular changes (e.g. arteriolosclerosis or microvascular protein deposition of amyloid, tau, alpha synuclein or TAR DNA-binding protein-43), macrovascular changes (e.g. atherosclerosis) and parenchymal changes (e.g. large and small infarcts, microinfarcts, haemorrhages or white matter abnormalities) [8]. VaD is associated with impaired cerebral blood flow (CBF) supplying the brain (hypoperfusion), that may or may not be associated with a stroke. The hippocampus, periventricular white matter and basal ganglia are particularly susceptible, with pathology in the basal ganglia strongly associated with the cognitive deficits typical of VaD [9].

1.1.1 RISK FACTORS

Similar to Alzheimer’s disease (AD), ageing is the predominant risk factor for VaD. However, the incidence of VaD is higher in males. Age and vascular risk factors such as hypertension, diabetes, obesity, smoking and high plasma cholesterol [10] (Figure 1.1) lead to chronic hypoperfusion and thromboembolic events (development of a blood clot) that reduce CBF and perfusion. Impaired CBF initiates a cascade of hypoxic events that culminate in inflammation having a deleterious effect on the homeostasis of the brain. An example of this is the activation of matrix metalloproteinases which degrade vascular extracellular matrix and tight junction proteins to open the blood-brain barrier. This results in vasogenic oedema that in the white matter damages myelinated fibres [11, 12].

Alterations to cerebral perfusion correlates with severity of dementia and can be used as an indicator of disease progression [13, 14]. However, VaD is relatively under-diagnosed and treatment options are hampered by poor mechanistic understanding and identification of therapeutic targets [15].
1.1.2 SUBTYPES

Several subtypes of VaD have been classified including: (1) stroke induced dementia; (2) multi infarct dementia; (3) CADASIL (cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy) and (4) mixed dementia [9] (Figure 1.1). However, the most prevalent cause of VaD is cerebral small vessel disease (CSVD), a syndrome of clinical, cognitive, neuroimaging and neuropathological findings arising from pathology of perforating cerebral arterioles, capillaries and venules [16].

1.1.2.1 CEREBRAL SMALL VESSEL DISEASE IS A KEY FEATURE OF DEMENTIA AND STROKE

CSVD forms a central pathway in the pathogenesis of dementia and stroke, accounting for one fifth of all strokes worldwide [17] and more than 90% of cases of intracerebral haemorrhage, the most devastating form of stroke [16]. Of an estimated 47 million people suffering from dementia globally [3, 4], 45% have CSVD as a major contributing pathology [18].

Current neuroimaging techniques used in clinical practice are restricted to the parenchymal lesions caused by CSVD and cannot easily visualise the small vessels in the brain. Therefore, the term CSVD is best used to describe the pathological
Chapter 1: Introduction

consequences on the brain parenchyma. The exact aetiology of the vessels involved is not fully understood and subsequently, there are no efficient therapies for the syndrome, other than trying to manage metabolic and cardiovascular risk factors, of which age and hypertension are the most prevalent [19]. Nevertheless, diagnosis can be confirmed by neuroimaging the parenchymal lesions by magnetic resonance imaging (MRI) in both white and subcortical matter. A recent paper by Wardlaw et.al [20] (Figure 1.2) has classified these lesions as:

1. recent small subcortical infarcts (formerly categorized as acute lacunar stroke);
2. white matter hyperintensities (WMH) of presumed vascular origin;
3. lacunae (small fluid cavities in the brain) of presumed vascular origin;
4. cerebral microbleeds;
5. dilated perivascular spaces (DPVS);
6. brain atrophy.

![Figure 1.2](image-url) Classification of lesions related to small vessel disease as per Wardlaw et.al.

*Lesions (highlighted in red) are classified as recent small subcortical infarcts (a), white matter hyperintensities (b), lacunae (c), dilated perivascular spaces (d) or cerebral microbleeds (e). Images adapted from [20]*
Further classification has been suggested by Pantoni L [16] in an attempt to summarise the many different forms of CSVD into six different subtypes:

- Type 1 – deep perforator arteriopathy (arteriolosclerosis);
- Type 2 - sporadic and inherited cerebral amyloid angiopathy;
- Type 3 - inherited or genetic small vessel disease distinct from cerebral amyloid angiopathy;
- Type 4 - inflammatory and immunologically mediated small vessel diseases;
- Type 5 - venous collagenosis;
- Type 6 - other small vessel diseases.

Ultimately, progressive vascular age-related changes to vessels such as deep perforator arteriopathy (arteriolosclerosis) and cerebral amyloid angiopathy (CAA) alters cerebral blood flow and perfusion to deep brain structures. This causes lacunar infarcts (small areas (< 15mm) of loss of brain parenchyma traversed by fibrous strands) and microinfarcts (small strokes < 1mm in size) that are damaging to the blood-brain barrier and surrounding parenchyma [21, 22].

1.1.2.1.1 CEREBRAL SMALL VESSEL DISEASE: CEREBRAL AMYLOID ANGIOPATHY IS REPRESENTED BY THE DEPOSITION OF AMYLOID PROTEIN

CAA is represented by the deposition of amyloid proteins including amyloid beta (Aβ), cystatin C, prion protein, Aβri/Adan, transthyretin, gelsolin and immunoglobulin light chain amyloid [23] in the walls of blood vessels. The vast majority (80% - 90%) of AD cases have CAA as a key pathological feature [24]. The disease can be sporadic, and associated with ageing, or hereditary and associated with various genetic mutations such as Down syndrome [25]. Typical characteristics include progressive accumulation of congophilic amyloid peptides of different amino acid lengths in the walls of leptomeningeal arteries, arterioles located in the cortex, capillaries and venules [16, 26] (Figure 1.3). Pathology is mainly observed in the occipital lobe and to a lesser extent in the hippocampus, cerebellum and basal ganglia. Deep central grey matter, subcortical white matter and brain stem are unaffected or involved in the final stages [27].
Chapter 1: Introduction

The exact aetiology of CAA is unclear. The most widely accepted amyloid cascade hypothesis suggests that an overproduction of Aβ is responsible. Indeed, several animal models have been developed that show this. The Swedish amyloid precursor protein (APP) transgenic mouse [28] for instance, has been genetically modified for the human APP by mimicking a mutation first identified in a Swedish family who were predisposed to developing early onset AD. This mutation leads to a 3 - 6 fold increase in the production of Aβ [29] and the mice go on to develop both parenchymal and vascular amyloid deposits [30]. Family forms of AD have known genetic mutations that increase extracellular concentrations of amyloid proteins [31]. While the amyloid cascade hypothesis may explain the pathology observed in the familial form of AD, the hypothesis does not explain the occurrence of CAA in sporadic non-familial AD, the most common form, where there is no evidence of Aβ overproduction [32]. This deviation from the amyloid hypothesis suggests that the deposition of Aβ as CAA could be due to an imbalance between its production and elimination [33, 34]. This theory is supported by the work of Mawuenyega et.al., in which the development of CAA is shown to be most likely driven by failures of the clearance mechanisms of Aβ rather than its overproduction [35]. Such clearance mechanisms include phagocytosis of Aβ by glial cells [36-38]; carrier mediated transport of Aβ across the endothelium into the blood [39] and drainage of soluble Aβ within the interstitial fluid (ISF) along intramural periarterial drainage (IPAD) pathways.

Vessels laden with amyloid show severe ultrastructural abnormalities and alterations to the endothelium [40, 41], smooth muscle cells (SMC) [41, 42] and pericytes [27]. Until recently, definite diagnosis could only be made by the neuropathological grading of the severity of amyloid pathology (mild, moderate or severe) in tissue taken at autopsy or from a cortical biopsy [43]. In mild CAA, amyloid appears as a congophilic rim restricted around SMCs occurring initially in the outer portion of the tunica media. Vessels appear relatively normal with some loss of SMC nuclei [27]. In moderate CAA, amyloid is deposited throughout the tunica media with loss of SMC but no evidence of haemorrhage [27]. In severe CAA, amyloid is extensively deposited within the cerebrovasculature with focal fragmentation of the vessel wall and evidence of haemorrhage [27].
Figure 1.3 Diagram of an arterial wall showing deposition of Aβ as cerebral amyloid angiopathy

In CAA, progressive accumulation of congophilic amyloid peptides (green) of different amino acid lengths occurs in the walls of leptomeningeal arteries, arterioles located in the cortex and capillaries and venules. In mild CAA, amyloid appears as a congophilic rim restricted around SMCs. In moderate CAA, amyloid is deposited throughout the tunica media with loss of SMC. In severe CAA, amyloid is extensively deposited within the cerebrovasculature with focal fragmentation of the vessel wall.

Due to a lack of sensitive diagnostic in vivo techniques, it is difficult to detect CAA early. More recently, advancements in imaging techniques coupled with an increase in awareness of the different acute and progressive clinical syndromes has enabled the creation of diagnostic criteria for CAA known as the Modified Boston criteria [44]. Diagnosis can now be made based on four different severities of disease: 1) definite CAA, 2) probable CAA with supporting pathology, 3) probable CAA and 4) possible CAA (Figure 1.4).
Chapter 1: Introduction

The Modified Boston criteria has increased detection of the disease during life but CAA is still a leading cause of CSVD, occurring in approximately half of elderly individuals and up to 90% of AD cases [24].

**Figure 1.4 The Modified Boston Criteria**

Definite CAA (green), probable CAA with supporting pathology (light blue), probable CAA (orange) and possible CAA (dark blue). Adapted from [44].
1.2 VASCULAR DEMENTIA AND ALTERATIONS TO THE BLOOD-BRAIN BARRIER AND THE VESSEL WALL

The blood-brain barrier is a multicellular structure separating the central nervous system (CNS) from the peripheral blood circulation. As well as a barrier function to toxins and pathogens the blood-brain barrier regulates the influx and efflux of ions, nutrients and oxygen between the blood and brain parenchyma by fine interplay between the endothelium (the core anatomical unit of the blood-brain barrier) and elements of the neurovascular unit (NVU). The NVU is a conceptual model that describes the functional interactions and signalling between neurons, capillaries and glia consisting of cellular (neurons, microglial cells, astrocytes and pericytes) and noncellular (extracellular matrix) elements (Figure 1.5) [9, 45]. In VaD, pathological changes to the vascular wall alter the integrity and function of the blood-brain barrier [46].

Figure 1.5 The neurovascular unit

The NVU consists of endothelia, neurons, microglial cells, astrocytes, pericytes and extracellular matrix (not drawn to scale).
Chapter 1: Introduction

1.2.1 THE VESSEL WALL: ENDOTHELIA

Cerebral endothelia, the core anatomical element of the blood-brain barrier, are highly specialised cells with specific transport receptor proteins [47], high electrical resistance tight junctions and no fenestrations [48]. Lipid-soluble molecules of < 180 Da in size with fewer than 10 hydrogen bonds diffuse passively across the endothelia [49] but tight junctions between neighbouring endothelial cells restrict paracellular diffusion of ions and macromolecules [48]. Instead, essential nutrients like glucose and fatty acids require carrier mediated transport. For example, glucose is transported via the solute carrier transporter GLUT1 [47]. Endothelial cells also release nitric oxide, which reduces contractile tone of SMCs, and the vasoconstrictor endothelin 1 [50].

1.2.1.1 ENDOTHELIAL DISRUPTION ALTERS PERMEABILITY OF THE BLOOD-BRAIN BARRIER

Disruption to normal endothelial function, as is the case in VaD during ischemic stroke and chronic neurodegeneration and in several other neurological diseases such as epilepsy or neuromyelitis [46] leads to leakage of fluid, macromolecules and migration of cells into the vessel wall. This inhibits normal blood-brain barrier regulation of leukocyte trafficking in response to brain infection and immune surveillance [51] or after damage to brain tissue in which macrophages are required to clear debris [52]. Oxidative stress induced damage to endothelia, initiated by chronic hypoperfusion and thromboembolic events, alters mitochondrial function and the balance of antioxidants and reactive oxygen species. Oxidative stress acts as a catalyst by initiating further reductions in CBF [53] and the triggering of inflammatory cascades. Inflammatory events perpetuate endothelial damage, further disrupts permeability of the blood-brain barrier and cause infarcts leading to fibrinoid necrosis (tissue death with accompanying accumulation of proteinaceous material with a staining pattern similar to fibrin) [54]. This results in damage to arteriole SMCs, fibrin deposition, perivascular oedema and damage to surrounding parenchyma [55]. This is typically seen as expansion of perivascular spaces in the white matter with pallor of adjacent myelin and astrocytic gliosis. Deep cerebral structures and white matter are particularly susceptible as vessels within these regions include end arteries with very little branching [8].
1.2.2 THE VESSEL WALL: EXTRACELLULAR MATRIX

Extracellular matrix (ECM) is formed of glycoproteins and proteoglycans that ensheath the abluminal side of endothelia separating the endothelia from pericytes and pericytes from astrocytes, forming basement membranes between different cell types [56]. Each cell type of the vessel wall contributes to the composition of the ECM producing structural and functional diversity between the basement membranes of different vessel types [57]. Basement membranes consist of highly crosslinked complexes of collagen IV (COL4), laminin, nidogen/entactin and heparin sulphate proteoglycan catalysed by the activity of Lysyl oxidase (LOX). Both COL4 and laminin are critical for basement membrane stability and can self-assemble into sheet like structures interacting with each other by nidogen/entactin. However, LOX, an ECM amine oxidase that converts amines into aldehydes, forms covalent crosslinks between fibrillar collagens and elastins ensuring ECM structural integrity [58] (Figure 1.6).

Cells interact with the ECM by the association of the transmembrane proteoglycan dystroglycan and integrin adhesion receptors with laminin networks [59]. Dystroglycan is expressed in astrocytes, neurons and endothelial cells. Integrins are present on all cell types involved in the formation of the blood-brain barrier. These matrix receptors regulate signalling pathways but also anchor cells in place regulating their motility (reviewed in [60]). During ischemic events, such as those caused by occlusion of the middle cerebral artery in mice, expression of astrocyte dystroglycan and select integrins (e.g. $\alpha_6\beta_4$) are significantly reduced. This correlates with loss of dystroglycan expression in primary astrocytes subject to oxygen-glucose deprivation [61] and is thought to be associated with loss of integrity between the astrocyte and vessel wall in response to ischemia [62].
Chapter 1: Introduction

Figure 1.6 The extracellular matrix

Schematic diagram of a typical cerebral capillary (a). Basement membrane (purple) align along the abluminal side of endothelia (green) separating endothelia from pericytes (red) and pericytes from astrocytes (blue) (white arrows in enlarged inset in a). Basement membranes consist of highly crosslinked complexes of collagen IV, laminin, fibronectin, nidogen/entactin, and heparan sulphate proteoglycans (b). Lysyl oxidase reinforces collagen IV networks by forming covalent crosslinks at 7S domains. Diagram b adapted from [63, 64].
1.2.2.1 EXTRACELLULAR MATRIX REMODELLING

Ageing, the predominate risk factor for VaD, causes remodelling of the extracellular matrix. This has been observed as basement membrane splitting, duplication, thickening and presence of abnormal inclusions in ageing animal models and old human brains [65, 66]. Prominent fibrosis of the basement membrane, associated with severe degeneration of vascular SMCs [15, 67] has been linked to upregulation of COL4 [68, 69] and alterations to other key ECM proteins [70].

Expression of ECM proteins that directly interact with Aβ appear to be altered in CSVD creating an environment that favours the development of CAA. These proteins either promote Aβ aggregation (perlecan, fibronectin and agrin) [71, 72] or inhibit Aβ accumulation by destabilising its fibrilisation (laminin / nidogen and COL4) [73]. Studies of the changes to the ECM in the development of CAA in AD show that in the early stages of the disease, thickening of the basement membrane [74] is accompanied by increased levels of COL4, perlecan and fibronectin [70]. In latter stages, COL4 is reduced [75] and heparin sulphate proteoglycans such as agrin are increased [76, 77], promoting Aβ aggregation. We have previously shown a region-specific thickening of capillary basement membranes in aged mice occurring in areas more affected by CAA such as the cortex (young - 65.79 μm vs. old – 97.49 μm, p < 0.05) and hippocampus (young - 62.48 μm vs. old – 109.50 μm, p < 0.05) [74] (Figure 1.7).
Figure 1.7 Regional specific thickening of capillary basement membranes with age in wild-type mice

Transmission electron micrographs showing regional differences in the thickness of capillary basement membranes (arrows) in 2 (A and D), 7 (B and E), and 23 (C and F) month-old mice between striatum (A-C) and frontoparietal cortex (D-F). Note the significant thickening of the capillary basement membrane in 23-month old mice in the cortex (F) compared to young 2-month-old mice (D). Original magnification = ×50 000. Published in [74].
1.2.3 THE VESSEL WALL: PERICYTES

Pericytes project stellate-shaped finger-like elongated processes that ensheath the capillary wall connecting with endothelial membranes via direct peg-and-socket contacts. These contacts contain cell-to-cell junction proteins enabling transfer of metabolites and ions between the two cell types (reviewed in [78]). Pericytes contribute to the integrity of the vessel wall by helping to regulate capillary diameter, CBF and levels of ECM proteins (reviewed in [48]). Pericytes have also been shown to mediate polarisation of astrocytic endfeet by helping to guide astrocyte foot processes to cerebral vessel walls [79]. Injury and degeneration of pericytes is associated with a breakdown of the blood-brain barrier in many neurological diseases including amyotrophic lateral sclerosis, AD, mild dementia and stroke (reviewed in [80]). Recent evidence from human post-mortem studies demonstrate a 35-45% reduction of pericytes in the white matter of VaD or AD [81].

1.2.4 THE VESSEL WALL: ASTROCYTES

Polarised astrocytic extensions form end feet projections that encircle the abluminal side of the vessel wall [45] interacting with intramural cells, extracellular matrix and the endothelium. Interaction with the endothelium is important for synchronising metabolite levels with CBF and vasodilation, and regulating brain water homeostasis [82]. Astrocytes contribute to normal function in the healthy CNS, including regulation of blood flow, participation in synaptic function and plasticity, and maintenance of the extracellular balance of ions, fluid balance and transmitters. They also respond to CNS insults caused by infection, trauma, ischemia and neurodegenerative disease by reactive astrogliosis and glial scar formation (reviewed in [83]). Glial scar formation enables repair to damaged elements of the blood-brain barrier, limits neuronal death, inhibits entry of inflammatory cells into the brain [84-86] but also impairs axonal regeneration [87]. Astrocytes contribute to the integrity of the blood-brain barrier by releasing several effector molecules that enhance and maintain barrier tightness [88-90].

Astrocytes are affected by ageing, changing to a more proinflammatory phenotype [91] that may contribute to decline in brain function by loss of function and neuroinflammation. Furthermore, oxidative stress has been shown to affect astrocytes in parallel to that seen in endothelium [92]. For an extensive overview of possible roles of astrocytes in CSVD see [93].
Chapter 1: Introduction

1.2.4.1 ASTROCYTES ARE ANCHORED TO THE EXTRACELLULAR MATRIX BY THE DYSTROPHIN ASSOCIATED PROTEIN COMPLEX

The cell membrane of astrocyte endfeet are anchored to endothelial or intramural cell ECM via components of a structurally unique protein complex that is associated with dystrophin protein (dystrophin associated protein complex (DPC)). DPCs are expressed in a variety of tissue types such as skeletal muscle, neurons and glia [94, 95]. The complex consists of the transmembrane matrix receptor dystroglycan, the intracellular proteins dystrophin and its associated dystrobrevins and syntrophins and localised transmembrane proteins such as the aquaporins (AQP) (Figure 1.12).

In skeletal muscle, DPCs afford structural integrity to muscle fibres by binding the ECM to the actin cytoskeleton. When this binding is compromised, muscle fibres become dystrophic. The most widely known of the muscle dystrophies are the Duchenne muscular dystrophy (DMD) and its milder form Becker muscular dystrophy (BMD). DMD and BMD are linked to X-linked recessive mutations in the dystrophin gene [96] that generates DPCs that either lack dystrophin entirely (DMD) or have a partially functioning dystrophin component (BMD). In both cases, dystrophic changes in muscle including muscle fibre degeneration and regeneration lead to loss of muscle function.

In the brain, different dystrophin isoforms and DPCs can be found in neurones and glia associated with astrocytic endfeet and GABA receptor clusters in cerebellar Purkinje cells and pyramidal neurons of the neocortex and hippocampus (reviewed in [95]). DPCs are thought to play a role in modulating synaptic function and approximately one third of DMD and BMD cases present with mild to moderate cognitive impairment [97]. While mutations in any part of the dystrophin gene can result in cognitive impairment, distal mutations affecting the dystrophin isoforms DP140 and DP71 appear to be most correlated [98, 99]. Language development is delayed, and IQ is diminished by one standard deviation compared to controls. Boys with DMD are more at risk of developing autism, obsessive compulsive disorder and attention-deficit / hyperactivity disorder [100].

In perivascular astrocytes, dystrophin is mainly expressed in the shorter DP71 isoform. DP71 contains binding sites for β-dystroglycan, the dystrobrevins and syntrophins. β-dystroglycan interacts with α-dystroglycan which in turn anchors the astrocyte end foot to the ECM by binding to a number of ECM proteins including
laminins, perlecan, agrin and the neurexins. Attachment of the astrocyte end foot to the ECM is disrupted in mice deficient for the dystrophin protein suggesting a key role of the DPC in maintenance of the basement membrane [101] (Figure 1.12).

1.2.4.2 ASTROCYTES AND THE TRANSMEMBRANE WATER CHANNEL AQUAPORIN 4

Aquaporin 4 (AQP4) is the predominant AQP in mammalian brain expressed in astrocyte endfeet bordering the ventricles, subarachnoid space, blood vessels, non-endfeet glial processes of the granule cell layer in the cerebellum [102] and to a lesser extent in both adluminal and abluminal endothelial cell membranes [103].

AQP4 expression is upregulated in conditions that alter brain water homeostasis. Elevated levels of AQP4 have been observed in brain tumours [104, 105], cerebral ischemia (including stroke) [106, 107], traumatic brain injury [108] and dementia and other age related pathologies [109-114]. A recent study has shown elevated expression of AQP4 in grey matter from autopsied temporal lobes from eight patients with AD [114]. We have recently shown that in humans AQP4 expression is upregulated in both grey and white matter with normal ageing. However, in cases of moderate CAA, the percentage area immunostained for AQP4 in grey matter is significantly higher compared to age matched controls. In the white matter, the expression of AQP4 expression was reduced in CAA and in tissue from brains that had WMH, suggesting a loss of function of this channel in CSVD [115].

Expression of AQP4 in the white matter of experimental models of stroke and after focal ischemic stroke frequently accompanied by life-threatening cerebral edema in post mortem human brains [116] suggest an involvement of AQP4 in oedema resolution [117]. It has also been proposed that AQP4 expression on astrocytic endfeet represents a pathway in which AQP4 drives a directional clearance of solutes from the ISF into paravenous spaces via extracellular spaces [118]. This has been termed glymphatic flow and is discussed more in section 1.3.

1.2.4.3 AQUAPORIN 4 IS ANCHORED TO ASTROCYTE CELL MEMBRANE BY THE DYSTROPHIN ASSOCIATED PROTEIN COMPLEX

The distribution of AQP4 is polarised and particularly concentrated in the astrocytic endfeet that abut capillaries, the ependymal cells lining the ventricles and the pia [102].
Extensive studies using electron and X-ray crystallography of 2D crystals and 3D crystals, respectively, has revealed the tetrameric arrangement of AQP4. Typically, an AQP monomer contains six transmembrane helical segments oriented in a right-handed bundle. This produces funnel shaped cytoplasmic and extracellular vestibules interconnected by a 1.5 Å central pore, just large enough to allow the passage of a single file of hydrogen bonded water molecules [119-121]. This enables AQPs to respond to changes in osmotic gradients by facilitating passive water transport or sometimes small uncharged solutes, as the case with aquaglyceroporins, across cell plasma membranes. A detailed description of the structural basis of water transport through AQPs is explained in [122].

AQP4 tetramers contain ~30kDa monomeric units that have eight membrane embedded helical segments (M1 – M8), six of which are membrane spanning (M1 – 2, M4 – M6, M8) and two which form shorter segments with an aqueous pore (M3 and M7) all connected by five loops (loops a - e) [121] (Figure 1.8). Seven AQP4 isoforms have been identified in astrocytes (AQP4a – f) [123]. The two main isoforms, Met1 (AQP4a or AQP4M1) and Met23 (AQP4c or AQP4M23) [124] form higher order supramolecular assemblies (OAPs) [125] on astrocytic endfeet, first observed in 1974 by the freeze fracture analysis of astrocytic plasma membranes [126]. OAPs appear as distinctive rectangular particle array assemblies each containing 4 – 60 subunits packed in an orthogonal array with a periodicity of 6 – 7 nm [126]. They contain both AQP4M1 and AQP4M23 but only AQP4M23 can form independent orthogonal lattices [127]. OAPs can be immunogold labelled with antibodies to AQP4 [125] and identified by photoactivation localisation microscopy [128] but they are absent in astrocyte plasma membranes in mice that do not express AQP4 [129].
Figure 1.8 The structure of AQ4

AQ4 has six bilayer spanning domains with five interconnecting loops (a). The proposed molecular structure of a monomeric AQ4 as depicted in (b) contains highly conserved asparagine-proline-alanine (NPA) motifs in loops B and E that form a pore in the membrane bilayer (c).

The subcellular OAP arrangement of AQ4 in the plasma membrane of astrocyte endfeet is maintained by the indirect association with DP71 and α-dystrobrevin (α-DB) of the DPC [94]. α-DB binds directly to DP71 by reciprocal coiled-coil interactions. α-DB interacts with syntrophin which localises AQ4 to the cell membrane [130] (Figure 1.9).
1.2.4.4 TARGETING OF AQUAPORIN 4 TO ASTROCYTE ENDFEET IS REGULATED BY DYSTROBREVIN PROTEINS

Dystrobrevins are a group of dystrophin associated proteins with homology to the cysteine-rich C-terminal region and carboxy-terminal domains of dystrophin, showing similarity with protein binding sites such as ZZ domains, syntrophin binding sites and tandem α-helical coiled coils that binds with the reciprocal regions of dystrophin isoforms (Figure 1.10) [131]. The dystrobrevin protein was originally identified as an 87-kDa phosphoprotein localised to postsynaptic membranes in the Torpedo californica electric organ, copurifying with acetylcholine receptors [132, 133]. It was also found extrasynaptically in the sarcolemma of Torpedo californica electric organ and vertebrate skeletal muscle and in postsynaptic membranes of chick and rat endplates [133]. Two separate genes have been identified: β-dystrobrevin (β-DB) and α-DB [134-136].
The dystrobrevins contain a cysteine-rich domain with two EF hand domains (EF, green) and one ZZ domain (ZZ, orange) and a carboxy-terminal domain with a α-helical region (ah, blue) and two sets of helical leucine-heptad motifs (H1 and H2, Purple). The hairpins of α-helices in EF domains can bind calcium. The zinc fingers of the ZZ domains are believed to bind Calmodium. The α-helical region contains two binding sites for the syntrophins. The helical leucine-heptad motifs can combine to form a coiled-coiled region that interacts with the coiled-coiled region of dystrophin. α-dystrobrevin-1 also contains sites of tyrosine phosphorylation by tyrosine kinase (TK, brown). Diagram adapted from [137].

1.2.4.4.1 BETA DYSTROBREVIN

The β-DB gene has been mapped to mouse chromosome 12 [138] and human chromosome 2p22-23 [139]. β-DB is considered as a non-muscle protein and is most abundant in the lung, liver, kidney and brain. In brain, β-DB is found in hippocampal and Purkinje neurons and postsynaptic densities but not within the microvasculature [140, 141]. β-DB deficient mice show no obvious histological
abnormality and are both viable and fertile [131] but do show a loss of the membrane localisation of DP71 and syntrophin in basolateral region of epithelial cells of cortical renal tubules and collecting tubules [131].

1.2.4.4.2 ALPHA DYSTROBREVIN

The α-DB gene has been mapped to mouse chromosome 18 and human chromosome 18q12.1. α-DB is predominantly expressed in skeletal muscle, lung, heart and brain. In Torpedo, only a single transcript and protein of α-DB has been described. However, the mammalian α-DB gene gives rise to several isoforms by alternative splicing [135, 142] as shown by cloning in mouse [143] and human [144]. In mice, the α-DB gene consists of 24 coding exons. Alternative usage of exons 11, 18 & 24 generates transcripts that encode at least three major C-terminal-truncated α-DB isoforms: α-DB1, α-DB2 and α-DB3 [142].

1.2.4.4.3 ALPHA DYSTROBREVIN AND AQUAPORIN 4

In the brain, α-DBs are found in DPCs in cells forming tissue barriers such as blood-brain and blood-cerebrospinal fluid; mainly in glial end feet and neuroglia of the ependyma and choroid plexus but not endothelium [145]. In astrocyte endfeet, the α-DBs play a key role in the proper assembly of the DPC by targeting AQP4 to the cell membrane. α-DB binds directly to DP71 by reciprocal coiled-coil interactions. Both DP71 and α-DB interact with syntrophin which localises AQP4 to the cell membrane by C-terminal tail binding to PDZ domains (acronym for Post synaptic density protein, Drosophila disc large tumor suppressor and Zonula occludens-1 protein) [139, 146, 147]. Rather than DP71, α-DB is thought to be the key anchoring molecule for AQP4 in astrocyte endfeet. In mice deficient for α-DB, there is no change in overall expression of AQP4 or syntrophin but AQP4 is redistributed to astrocyte cell bodies, impairing its function at the endfeet [146] (Figure 1.11).
Figure 1.11 α-DB targets AQP4 to astrocyte endfeet

AQP4 (red boxes) is anchored to astrocyte endfeet by association with syntrophin and α-DB. When syntrophin is not present, AQP4 expression is redistributed from astrocyte endfeet to astrocyte cell bodies (purple arrows).
Figure 1.12 The dystrophin associated protein complex at astrocyte endfeet

a) Astrocyte endfeet (blue) are anchored to the basement membrane (extracellular matrix) (purple) via the dystrophin associated protein complex located on the astrocyte cell membrane (b, white arrows). c) The dystrophin associated protein complex. Transmembrane proteins are localised to the cell membrane by C-terminal tail binding to PDZ domains of syntrophin. The dystroglycan complex anchors the cell membrane to laminin/agrin of the extracellular matrix. Dystrophin (Dp71) forms a bridge between the cell cytoskeleton and the cell membrane.
1.3 VASCULAR DEMENTIA AND FLUID HOMEOSTASIS

Despite its high metabolic demands [148], the brain lacks a traditional lymphatic system although there are lymphatic vessels within the dura mater [149, 150]. There are several mechanisms involved in the regulation of the two fluids that are associated with the brain; the cerebrospinal fluid (CSF) and the interstitial fluid (ISF). Dysfunction in these mechanisms alters fluid homeostasis and may provide a substrate for the WMH seen in VaD.

1.3.1 REGULATION OF CEREBROSPINAL FLUID (CSF)

CSF acts synergistically with blood circulation within the skull during the cardiac cycle and provides partial buoyancy for the brain affording protection against physical damage [151]. The classical view of CSF physiology assumes that 80% of CSF is secreted by the choroid plexuses in the lateral, third and fourth ventricles and 20% is produced by other structures such as the brain parenchyma [152, 153]. The CSF is then reabsorbed via bulk flow primarily through arachnoid granulations into venous sinuses [154] but also outflows from the brain via routes along olfactory nerves as they leave the central nervous system, draining into the lymphatics of extracerebral tissues such as the nasal mucosa and cervical lymphatics [155, 156]. CSF also mixes with ISF in the brain parenchyma via convective influx along pathways paralleling the intraparenchymal vasculature [157].

1.3.1.1 EXCHANGE OF CSF WITH INTERSTITIAL FLUID (ISF)

Early observations by Rennels et al suggested that tracers within the CSF can mix with ISF throughout the brain by “paravascular” fluid circulation along pathways paralleling the intraparenchymal vasculature [157]. Multiphoton studies by Iliff et al. [118] show that small molecular weight tracers injected into cisterna magna travel by convective flow into the brain along penetrating arteries and can reach the level of capillaries within 30 minutes. From here they mix with ISF within the parenchyma and exit the brain along large calibre veins. Further studies revealed that this movement is inhibited in mice lacking AQP4 [118], reduced by 50% [158] in mice undergoing unilateral carotid artery ligation but enhanced during the transition of wakefulness to sleep [159]. Controversially, Iliff et al. named this process glymphatic flow, concluding that AQP4 on astrocyte endfeet drives a
directional clearance of solutes from the ISF into paravenous spaces via extracellular spaces [118]. Our electron microscopy studies using nanoparticle tracers injected into mouse cisterna magna show these spaces as channels of extracellular matrix that are continuous with the extracellular matrix of the cerebral vasculature and the basement membrane that separates the glia limitans from the outer leptomeningeal sheath of penetrating arterioles (pial-glial basement membrane). However, unlike Iliff et al. we only observed entry of nanoparticles at distances of approximately 100 μm from the meningeal surface of the brain and the nanoparticles remained within pial-glial basement membrane, without diffusion into the parenchyma [160] (Figure 1.13). Our contrast enhanced MRI studies assessing the inflow of tracers from the CSF in a beagle dog brain revealed enhanced penetration of tracers into the midbrain. This correlated with an enlarged arteriole pial-glial basement membrane in vessels within the midbrain, further highlighting the pial-glial basement membrane as an entry route of CSF into brain parenchyma (Figure 1.14) [161].

It has been hypothesised that changes in norepinephrine levels during altered states of consciousness expands extracellular spaces reducing tissue resistance and allowing faster glymphatic flow [159]. Although controversial, there are several schools of thought correlating the failure of glymphatic flow to VaD [162, 163].
Figure 1.13 The pathway in which nanoparticles enter the brain after injection into mouse CSF via cisterna magna

a) A low power electron micrograph of an arteriole near the surface of the cortex showing dense nanoparticles (arrows) in pial-glial basement membrane between the pia mater and the glia limitans, 5 minutes after injection into mouse cisterna magna. b) Higher magnification of the box 1 in (a) showing the layers of the arterial wall. Dense groups and single nanoparticles (np) are located mainly in the pial-glial basement membrane (cvbm) between the pia mater (pm) and the adjacent glia limitans. (lu) lumen, (en) endothelium, (sm) smooth muscle cells, (pm) pia mater, (pa) parenchyma. Scale bars (a) = 1 μm; (b) 500 nm. Published in [160].
Figure 1.14 Arterioles in the midbrain have enlarged pial-glial basement membranes

False coloured electron micrographs showing regional differences in basement membrane thickness between arterioles in the cerebellum (A), hippocampus (B), midbrain (C), periventricular white matter (D), thalamus (E) and cortex (F) of beagle dog brain. The pial-glial basement membrane of arterioles in the midbrain were found to be at least three times the thickness of any other cerebrovascular basement membrane analysed. Abbreviations: lumen (lu); endothelium (en) and smooth muscle (sm). Published in [161].
1.3.2 REGULATION OF INTERSTITIAL FLUID

ISF provides the suitable ionic and nutrient microenvironment to allow the proper function of neurons and associated cells. The extracellular spaces of the brain accommodate ISF that is produced by diffusion of water across the blood-brain barrier driven by osmotic gradients generated by the active transport of solutes across the endothelium [151]. Nutrients, ions, oxygen and other molecules fundamental for metabolism of cerebral tissue cross the blood-brain barrier from the blood and diffuse 8 – 25 µm into surrounding parenchyma. It is also likely that small amounts of recycled CSF and water produced by brain metabolism contribute to ISF production [164].

1.3.2.1 THE INTRAMURAL PERIARTERIAL DRAINAGE PATHWAY (IPAD)

There are no lymphatic vessels in the brain parenchyma. Cerebral endothelium contains specific membrane transporters for the removal of waste substances from the brain into the blood (e.g. lipid soluble toxins) [165] but ISF and solutes are also eliminated from the brain along the walls of capillaries and arteries, via intramural periarterial drainage (IPAD) pathways. Tracers injected into mouse brain parenchyma diffuse at different rate constants, determined by molecular size and diffusion coefficient [166, 167], along extracellular spaces towards the capillary endothelial basement membrane, as observed by confocal microscopy [168]. Tracers enter capillary endothelial basement membrane and after five minutes drain via bulk flow against the direction of blood flow along smooth muscle basement membrane of cerebral arteries towards the surface of the brain and ultimately to the cervical lymph nodes adjacent to arteries under the base of the skull [168, 169] (Figure 1.15).

Our previous work using immuno transmission electron microscopy (TEM) show that after five minutes post injection of biotinylated Aβ 40 into mouse hippocampus the biotinylated Aβ 40 flows in the narrow extracellular spaces between neuronal and glial processes and within the capillary basement membrane [160] (Figure 1.16). This mirrors the deposition of Aβ in capillary basement membranes observed in CAA [16, 26].

Although not directly demonstrated in humans per se, the similarities between the deposition of Aβ within vessel walls in post-mortem human CAA and in
Chapter 1: Introduction

Experimental rodent models strongly support the concept of IPAD. Studies also show that the deposition of proteins as CAA inhibits IPAD along the affected vessel wall [170] and that several CSVD risk factors, such as age, hypertension, hyperhomocysteinemia and type 2 diabetes mellitus have altered IPAD [170-176]. Therefore, failure of IPAD appears to be an important factor of CSVD.

Figure 1.15 The intramural periarterial drainage pathway

Solute (green) diffuse along extracellular spaces and enter capillary basement membranes (purple) via gaps between astrocytic endfeet (blue). Solutes then travel against the direction of blood flow (green arrows) towards arteriole smooth muscle basement membranes towards the surface of the brain and ultimately to the cervical lymph nodes adjacent to arteries under the base of the skull.
Figure 1.16 Flow of biotinylated Aβ 40 after injection into mouse hippocampus

5 minutes after injection into mouse hippocampus, biotinylated Aβ can be observed as darkly stained areas in extracellular spaces of the parenchyma (a) and extending into the capillary basement membrane (b) encapsulating a pericyte (c). d) hippocampal control tissue in which no biotinylated Aβ has been injected. No Aβ is present in the basement membrane (cvbm). Other abbreviations; pericyte (p); endothelium (en); lumen (lu). Scale bars a 500 nm; b – d 200 nm. Published in [160].
Chapter 1: Introduction

1.3.2.1 THE MOTIVE FORCE FOR INTRAMURAL PERIARTERIAL DRAINAGE PATHWAY IS DERIVED FROM THE CONTRACTIONS OF SMOOTH MUSCLE CELLS WITHIN THE WALLS OF ARTERIES

The process of IPAD ceases upon cardiac arrest [168], therefore it was initially assumed that IPAD was driven by the pulsation force of cerebral vessels [177]. However, our mathematical simulations, confirmed by assessing the pattern of IPAD in mice after administrating the pulse modulator Atenolol (10mg kg$^{-1}$) showed that this would not provide sufficient motive force [178] (Figure 1.17). More recently, new mathematical models and in-vivo 2 photon microscopy on awake mice suggest that it is vasomotion generated by cycles of contraction and relaxation of SMCs that drives IPAD. Vasomotion induces deformations of the basement membrane, effectively opening and closing a valve like system allowing for flow of IPAD in the direction of the vasomotion wave [179, 180].

![Figure 1.17 The pattern of IPAD in the hippocampus after administration of the beta blocker Atenolol]

After administrating the beta blocker Atenolol, IPAD in mouse hippocampi was assessed using confocal microscopy (a-d). Assessment of the number of arteries, veins and capillaries with fluorescent Aβ in their vessel walls (e) revealed no statistical difference between mice injected with Atenolol or saline, confirming the findings of our mathematical simulations. a) fluorescent Aβ, b) collagen IV staining, c) smooth muscle actin staining & d) merged tile scan with arrows indicating arteries with Aβ in IPAD pathways. Scale bars = 400 μm. SEM: standard error of mean. Published in [178].
1.3.3 THE ROLE OF AQUAPORIN 4 IN FLUID HOMEOSTASIS IN THE BRAIN

Over the past ten years, the significance of AQP4 to key functional roles in the brain has received much attention. In mammalian brain the function of AQP4 has been linked to memory consolidation and neurotransmission [181-184], neuroinflammation [83-87, 185-189], and cerebral water homeostasis [118, 158, 159, 166, 190], mainly by the formation or prevention of oedema [102, 120, 188, 191-195]. Expression of AQP4 differs between brain regions such as the hippocampus [196], cerebellum [197], hypothalamus [198] and spinal cord [102] and appears to be altered with disturbances in fluid homeostasis [106, 107, 109-112, 186, 199-201], particularly in dementia and other age-related pathologies [109].

1.3.3.1 AQUAPORIN 4 Responds to Altered Cerebral Water Homeostasis by the Formation or Prevention of Oedema

AQP4 expression is upregulated in conditions that alter brain water homeostasis. Elevated levels of AQP4 have been observed in brain tumours [104, 105], cerebral ischemia (including stroke) [106, 107], traumatic brain injury [108] and dementia and other age related pathologies [109-114]. A recent study has shown elevated expression of AQP4 in grey mater from autopsied temporal lobes from eight patients with AD [114]. We have recently shown that in humans AQP4 expression is upregulated in both grey and white matter with normal ageing. However, in cases of moderate CAA, the percentage area immunostained for AQP4 in grey matter is significantly higher compared to age matched controls. In the white matter, the expression of AQP4 expression was reduced in CAA and in tissue from brains that had WMH, suggesting a loss of function of this channel in CAA [115].

Expression of AQP4 in the white matter of experimental models of stroke and after focal ischemic stroke frequently accompanied by life-threatening cerebral edema in post mortem human brains [116] suggest an involvement of AQP4 in oedema resolution [117].

Oedema is a hallmark of most brain diseases. During oedema, an accumulation of excess water in the brain parenchyma causes the brain to swell having a detrimental effect on blood supply, increasing intercranial pressure (ICP) and
Chapter 1: Introduction

disrupting tissue structure. Under normal physiological conditions AQP4 deficient mice show slightly raised basal water content [202, 203] and brain extracellular space volume fraction [204] but ICP is not significantly altered. The potential roles of AQP4 in cytotoxic (cellular), vasogenic and hydrocephalic oedema are summarised below.

1.3.3.1.1 AQUAPORIN 4 AND CYTOTOXIC OEDEMA

Cytotoxic oedema relates to the abnormal uptake of water intracellularly into injured brain cells without blood-brain barrier disruption. A net uptake of water from the blood compartment into the brain parenchyma causes astrocyte swelling, particularly at pre-capillary foot processes. Both white and grey matter regions are affected [192, 205]. AQP4 deficient mice are less affected by this form of brain oedema, evident by reduced astrocyte endfeet swelling, normal brain anatomy and intact blood-brain barrier [188, 191]. Indeed wild-type mice treated with the AQP4 inhibitor 2-(nicotinamide)-1,3,4-thiadiazole (TGN-020) after occlusion of the middle cerebral artery showed a reduction in oedema formation [206]. AQP4 deficient mice have a markedly reduced mortality rate in a model of serum hyponatremia [191] and lower ICP, less cerebral water accumulation and improved neurological status and survival when infected with Pneumococcal meningitis [188]. It has been suggested that a lack of AQP4 protects against cytotoxic oedema due to a reduced blood-brain barrier water permeability and reduced water flow into the brain parenchyma [192].

1.3.3.1.2 AQUAPORIN 4 AND VASOGENIC OEDEMA

Vasogenic oedema is associated with abnormal passage of water and proteins into the extracellular compartment due to a disrupted blood-brain barrier [207]. Differences in hydrostatic pressure drive iso-osmotic fluid and serum proteins from the bloodstream into the brain parenchyma, causing expansion of the extracellular space. This is observed most frequently in the white matter, as the extracellular spaces of the grey matter are tortuous, tight and with a higher resistance to flow of interstitial fluid [192, 193]. AQP4 deficient mice exposed to cortical freeze injury or brain tumor implantation in order to model vasogenic oedema are less effective at clearing the excess of brain water from the parenchyma. They show severe swelling of the brain, raised ICP and accelerated neurological deterioration.
Similarly, AQP4 deficient mice are less effective at eliminating intraparenchymal infusions [202].

1.3.3 AQUAPORIN 4 AND HYDROCEPHALIC OEDEMA

Hydrocephalic oedema refers to the movement of CSF from the ventricles across the ependyma into the interstitial space during hydrocephalus. In hydrocephalus, ventricles become enlarged due to an accumulation of CSF flow or impaired CSF absorption [192]. In a mouse model of hydrocephalus, in which kaolin was injected into the cisterna magna to generate CSF accumulation and ventricle enlargement, AQP4 deficient mice had significantly greater ventricular enlargement at 3 and 5 days post injection [194]. Up to 9% of AQP4 deficient mice produced by heterozygote-heterozygote or knockout-knockout breedings show sporadic obstructive triventricular hydrocephalus with raised ICP and lowered survival rate (most die by 6 weeks of age). The blood-brain barrier is unaffected in these models but the cerebral aqueduct is destroyed. In effect, AQP4 deletion in mice leads to an accelerated progression of obstructive hydrocephalus [194] but the link between AQP4 deficiency and ependymal cell abnormalities is unclear [195].

1.3.4 FLUID HOMEOSTASIS AND THE WHITE MATTER ABNORMALITIES IN VASCULAR DEMENTIA

Damage to the white matter is observed radiologically as white matter hyperintensities or leukoaraiosis [208] and reflects abnormalities in fluid homeostasis in the white matter, frequently observed in cerebrovascular pathology. White matter is highly susceptible to swelling after acute CNS injury [116, 209, 210] and WMH are a common finding on computer tomography (CT) or MRI in the elderly, particularly with stroke or dementia [211]. However, the reason as to why white matter is so susceptible to disturbances in fluid homeostasis has yet to be fully resolved. Various mechanisms for the aetiology of WMH have been proposed, they include ischaemia/hypoxia as a result of CSVD [212], loss of axons in the white matter associated with deposition of tau protein in parent neurons in the overlying grey matter [213] and a failure of elimination of ISF from the affected white matter along peri-capillary and peri-arterial drainage routes [208].
Chapter 1: Introduction

The clinical features of VaD as imaged by MRI (see section 1.1.2.1) suggest that in early stages of WMH the lesions are due to altered fluid homeostasis in the brain that could be reversible [211]. Damage to the endothelia of arterioles and capillaries and disruption to the blood-brain barrier leads to altered dynamics of the interstitial fluid and water content. These changes are typically seen by MRI as early lesion formation in the white matter as WMH [55, 214]. Dilated perivascular spaces (PVS), which can also be observed by MRI, are of particular interest as they are linked to altered fluid clearance by IPAD (see section 1.3.3) and have been described in the white matter of patients with CAA [215, 216]. In a recent electron micrograph study, in which we analysed tissue from the white matter of a patient with CAA, we showed the anatomical location of dilated PVS within an expanded region of the arterial wall in a location consistent with the pial-glial basement membrane (Figure 1.18) [217]. Our morphological studies on the cerebral vasculature in an elderly dog have revealed that this pial-glial basement membrane contains two layers of leptomeninges that forms a distinct perivascular compartment that potentially could be expanded to allow the formation of a dilated PVS (Figure 1.19) [218] (also confirmed with unpublished pilot data, see Figure 1.20). Therefore, a clearer picture of the relationship between the vasculature and the regulation of interstitial and cerebrospinal fluids is necessary in order to better understand the pathogenesis of WMH.
Figure 1.18 Dilated perivascular space

Electron micrograph of an artery from the right frontal subcortical white matter of a patient diagnosed with CAA. The endothelium (en) appears enlarged. The yellow region indicates a dilated perivascular space (dpvs) and expansion of the pial glial basement membrane (pgbm). The pia mater (pm) appears disrupted with only fragments visible. Other abbreviations; smooth muscle (sm); parenchyma (p). Scale bar 2 µm. Published in [217].
Figure 1.19 The two leptomeningeal layers of the pial-glial basement membrane

Electron micrograph of a large arterial in the subcortical WM of the parietal lobe from beagle dog brain. A) Low power image overview. Arrow points into the lumen of an arteriole of approximately 50 μm diameter. B) High power of the wall of the vessel in (A) showing the lumen (lu), endothelial cell (en), two layers of leptomeninges (lm1 and lm2) and the adjacent parenchyma with myelin sheets in the WM. Published in [218].
Figure 1.20 Leptomeningeal layers form a distinct perivascular compartment that has the potential to expand forming dilated perivascular spaces

False coloured freeze fracture scanning electron micrograph of a normal arteriole (a) and an arteriole with a dilated space (b). The normal arteriole (a) shows two leptomeningeal layers (Lm 1, red & Lm 2, purple) that envelop the vessel wall (blue). There is very minimal space between the outer leptomeningeal layer (LM 2) and the pial-glial basement membrane (pgbm). The dilated perivascular space in (b) can be seen separating the vessel wall and the Lm1 (red) from the pgbm (brown). Only fragments of Lm2 (purple) are visible. Transmission electron microscopy of an arteriole also showing a dilated space (c) demonstrates the potential for the two leptomeningeal layers to separate (red and purple colours in d) as shown in the boxed region and higher power in (d). Green; endothelium, Brown; basement membrane, Blue; smooth muscle cells. Data generated as part of a pilot study using tissue from the parietal lobe of beagle dog brain.
1.4 MODELLING VASCULAR DEMENTIA USING ANIMAL MODELS

A good animal model should mimic the particular disease conditions and outcomes as close as possible to human findings. Although an animal model will never truly recapitulate the exact aetiology of VaD as seen in humans, these models are needed to understand the role of the vascular risk factors in the microvascular, macrovascular and parenchymal changes observed in VaD with a view to identifying novel therapeutic targets. Due to the multi-factorial nature of VaD, it is difficult to model the disease to accurately reflect all the pathological changes. Rather, it is usual to isolate and focus on one specific aspect of the disease. This allows a more targeted approach which is vital to clearly identify the pathological mechanisms.

The majority of animal models currently available to investigate VaD all appear to target macrovascular or microvascular changes to cerebral blood vessels that lead to cerebral hypoperfusion. Most show white matter lesions and microinfarcts. However, other key pathology changes associated with VaD, such as break down of the blood-brain barrier, microhemorrhages and CAA are limited to specific models. All models share a similar end loss in cognitive abilities (for recent reviews see [9, 12, 219, 220]).

1.4.1 MODELLING MACROVASCULAR CHANGES TO CEREBRAL BLOOD VESSELS

1.4.1.1 HYPOPERFUSION

Macrovascular models include bilateral common carotid artery stenosis (BCAS), asymmetrical common carotid artery stenosis (ACAS) and 2, 3 or 4 vessel occlusion models (2-VO, 3-VO and 4-VO). These models require invasive surgical intervention using chronic cerebral hypoperfusion surgery to reduce blood flow to the brain triggering transient or prolonged hypotension. Both BCAS and ACAS models present with subcortical ischemic injury as the primary pathology whereas occlusion models present with global ischemia and neurodegeneration [219]. The key pathological features of these models are disruption to the blood-brain barrier, white matter lesions and microinfarcts.
Chapter 1: Introduction

1.4.2 MODELLING MICROVASCULAR CHANGES TO CEREBRAL BLOOD VESSELS

Microvascular models are used to replicate the changes to the walls of cerebral vessels observed in human dementia. Current models include the spontaneously hypertensive rat (SHR) [221], hyperhomocysteinemia (HHcy) [171] and amyloid precursor protein transgenic (APP) mice such as the Swedish APP transgenic mouse [28]. Although differing in their aetiology, the below models all appear to show failure of IPAD and the accumulation of Aβ in the perivascular drainage pathway as CAA.

1.4.2.1 HYPERTENSION

Arterial hypertension in young (<10 weeks) spontaneously hypertensive rats leads to arterial wall thickening, blood-brain barrier dysfunction and enlarged perivascular spaces [219]. In spontaneously hypertensive stroke prone rats (SHRSP), the thickening of the cerebrovascular basement membrane is in part, due to increased expression of Coll IV. There is also the accumulation of endogenous vascular Aβ deposits resembling CAA [173, 222].

1.4.2.2 HYPERHOMOCYSTEINEMIA

Elevated plasma levels of homocysteine are a major risk factor for VaD. The most common cause is vitamin B deficiency which is frequent in the elderly (reviewed in [223]). Mice modified for HHcy show thickened cerebral arteriolar walls [224], endothelial damage [225] and blood–brain barrier dysfunction [226]. A diet-inducing high homocysteinemia [227] in a transgenic mouse model of early AD (APP/ presenilin) appears to increase CAA [227].

1.4.2.3 VASCULAR DEPOSITS OF PROTEINS AS CEREBRAL AMYLOID ANGIOPATHY

Secondary vascular changes associated with CAA have been modelled in transgenic mice modified for the overexpression of Aβ. Degeneration of SMCs, endothelial cell loss and basement membrane thickening have been observed in Tg2576, PSAPP [228], APPDutch and TgSw/DI mutant mice [28, 229]. Interestingly, the blood-brain barrier often remains intact in APP mice [220].
Chapter 1: Introduction

While these models have provided key insights into vascular and parenchymal amyloid pathology [28] the significance of overexpression of Aβ to the development of CAA has been questioned. Findings show that in humans, the amyloid pathology observed in sporadic AD is likely due to reductions in the clearance mechanisms of Aβ40 and Aβ42 rather than its rate of production [35]. CAA occurs in approximately 80% of AD cases [230] suggesting a strong link between the failures of Aβ clearance and its accumulation in vessel walls. There is no reason to believe that this would not be the case in VaD but further models are required to confirm this.

1.5 THE POTENTIAL OF MICE WITH ALTERED DYSTROPHIN ASSOCIATED PROTEIN COMPLEX TO MODEL MICROVASCULAR CHANGES SEEN IN CEREBRAL SMALL VESSEL DISEASE

Although not currently considered as models of CSVD, mice genetically modified for DPC show features of CSVD that are associated with microvascular changes to the cerebral vasculature (summarised in Figure 1.21). Alterations to the DPC alter the fine interactions between the astrocytes and the basement membrane of the ECM but also disturb the endothelium and the blood brain barrier. Blood brain barrier disruption leads to altered fluid homeostasis.

1.5.1 ALTERED STRUCTURE AND FUNCTION OF THE ENDOTHELIUM AND THE BLOOD-BRAIN BARRIER

Disruption to normal endothelial function, as is the case in VaD during ischemic stroke and chronic neurodegeneration [46] leads to leakage of fluid, macromolecules and migration of cells into the vessel wall. Mice deficient for dystrophin (mdx) and α-DB show alterations to endothelial tight junctions resulting in a leaky blood-brain barrier [146, 231]. Electron microscopy analysis of cerebral blood vessels from aged α-DB deficient mice show a damaged endothelium with numerous pinocytotic vesicles in the cytoplasm, microvilli on the abluminal surface, tight junction abnormalities and hyperplasia (multi-layered endothelium). These features were not observed in aged-matched controls. Analysis of blood-brain barrier permeability in these mice show abundant perivascular extravasations of
both injected Evans blue and blood-borne proteins into the brain [146] indicating impaired blood-brain barrier function. Mdx mice show cognitive decline with decreased hippocampal spatial learning and memory which progressively worsens with age [232]. Cognitive function in α-DB deficient mice has not been investigated.

1.5.2 ALTERED FLUID HOMEOSTASIS

In a recent study, we showed a reduction of AQP4 in post-mortem human tissue from patients diagnosed with CAA and WMH, suggesting a loss of AQP4 regulated fluid homeostasis in CAA [115]. Both α-DB deficient and mdx mice show altered fluid homeostasis in the brain with loss of AQP4 function, particularly at astrocyte endfeet. In α-DB deficient mice, there is a redistribution of AQP4 and the potassium channel KIR4.1 from astrocyte endfeet to the astrocytic cell body [146]. This correlates with similar changes in AQP4 expression in experimental models of ischaemia and in the deep white matter of post stroke dementia [233, 234]. α-DB deficient mice appear to show altered fluid homeostasis that initially presents as swollen astrocyte endfeet but then extends into the surrounding parenchyma as oedema as the mice age [146]. This is most likely due to vasogenic oedema as a lack of AQP4 has protective effects against cytotoxic oedema [192]. Indeed, mdx mice also show swollen endfeet, and vasogenic oedema in the cortex and caudate putamen [101, 232].

It is not clear if the lack of AQP4 at astrocyte endfeet alone is solely responsible for the altered fluid homeostasis in these mice. Of the many different AQP4 deficient mouse models, only one shows any evidence of altered fluid homeostasis with abnormalities in the blood-brain barrier and swollen endfeet (Zhou et al.) [235]. The majority of AQP4 deficient mice show no alterations to the blood-brain barrier related to the absence of AQP4 [188, 191, 195, 203]. Even observations by Zhou et al. [235] have been questioned as further studies on the same AQP4 deficient model by Feng X et al. show no abnormalities in the blood-brain barrier [195]. A possible explanation for the altered blood-brain barrier function in mice with altered DPC has been suggested by Lien et al. They propose that a loss of both the AQP4 and KIR4.1 channel from astrocytic endfeet impairs ion and water homeostasis leading to osmotic opening of tight junctions in response to changes in cell volume [146]. Ideally, the blood-brain barrier would need to be assessed in
KIR4.1 deficient mice to help confirm this but this is difficult as these mice suffer severe ataxia, stress induced seizures and premature death [236].

### 1.5.3 BASEMENT MEMBRANE REMODELLING

Attachment of astrocyte endfeet to basement membrane appears to be regulated, in part, by dystrophin as this attachment is broken in mdx mice [101]. These mice also show a thickened and incomplete basement membrane [231] with significant reductions in laminin and agrin which may help to explain the disrupted astrocyte anchoring to the vessel wall [101].

Mice with partial deletion of the dystroglycan gene (DAG1) show an incomplete basement membrane [237]. Dystroglycan is essential for forming cross links between the DPC and the basement membrane as GFAP-Cre/DG-null mice show a substantial reduction in dystroglycan – laminin binding [237].

Aged α-DB deficient mice show a modified basement membrane that appears thicker but the biochemical changes responsible are not known [146].
Figure 1.21 Summary of the microvascular changes observed in mice deficient for dystroglycan, AQP4, dystrophin and α-DB

Other than AQP4, alterations to components of the DPC all appear to affect the vascular basement membrane. Modifications to dystrophin or alpha dystrobrevin alter the endothelium and blood-brain barrier resulting in abnormal fluid homeostasis and oedema. Changes due to deletion of AQP4 remain controversial.
1.5.4 CAN MICE WITH ALTERED DYSTROPHIN ASSOCIATED PROTEIN COMPLEX BE USED TO MODEL INTRAMURAL PERIARTERIAL DRAINAGE TO INVESTIGATE ITS POSSIBLE FAILURE IN VASCULAR DEMENTIA?

As the accumulation of amyloid proteins in the walls of cerebral blood vessels as CAA is the most frequent form of CSVD, it is evident that the process of IPAD and its failure must play a significant role in the development of VaD. Experimental models highlighted in section 1.4.2 show that changes to the cerebral vasculature induced by hypertension [173], hyperhomocysteinemia [227], and overexpression of Aβ [28, 228, 229] all favour the accumulation of amyloid proteins in the IPAD pathway. All these models show a thickening of blood vessel walls that is most likely altering the compliance of the vessel wall for IPAD. Subsequently in these models, elimination of ISF by IPAD appears to have failed.

As demonstrated by the similarity between tracer studies in mice and the location of CAA in blood vessels in humans (see section 1.3.2) it has been established that the central component for IPAD is the cerebrovascular basement membranes. Pathological alterations to these membranes most likely alter IPAD. Perivascular cells, such as astrocytes, maintain the basement membrane and hence the IPAD pathway (see section 1.2.2.1) [57]. Therefore, regulation of the fine interaction between the astrocyte endfeet and the ECM of the basement membrane by the DPC must play a key role in ensuring the integrity and function of the IPAD pathway. This is evident in the altered basement membrane and hence IPAD pathway in mice deficient for dystrophin [231], dystroglycan [237] and α-DB [146].

Mice deficient for α-DB show promise as a potential model to test the role of the DPC in IPAD as the basement membrane, although thickened in older mice, remains intact [146] and is therefore a suitable target to assess IPAD. Changes in the basement membrane in mice deficient for dystrophin [231] and dystroglycan [237] are more severe. The incomplete basement membrane in these mice would most likely impede any investigative studies.

If α-DB deficient mice demonstrate a significant role for the DPC in the dynamics of IPAD, they may also provide an opportunity to further investigate the causes of failed ISF fluid clearance by IPAD and its significance to CSVD and VaD.
1.6 AIMS

The objective of the work presented in this thesis is to ascertain if the vascular DPC plays a key role in ensuring the integrity and efficiency of the IPAD pathways. The overall aim is to test if mice with altered DPC can be used to model failed ISF fluid clearance by IPAD and investigate if these mice show features of CSVD and VaD. This may help facilitate the identification of new novel therapeutic targets for the prevention or management of VaD.

Two existing animal models are analysed: 1) mice deficient for AQP4 and 2) mice deficient for α-DB (B6;129-Dtna\textsuperscript{tm1Jrs/J}). Expression of AQP4 on astrocyte endfeet is reliant on α-DB and is lost in α-DB deficient mice. Therefore, to assess the integrity and function of the IPAD pathways in α-DB deficient mice, the effect of AQP4 loss in these mice on the cerebral vasculature need to be assessed first.

**The first aim is to test if loss of AQP4 in α-DB deficient mice affects the morphology of IPAD pathways.** A specific mouse model with a knockout for AQP4 will be used to perform a detailed ultrastructural study of the vessel wall at cerebral capillary level, the first entry point for IPAD. Even though extensive work has been done using these mice with behavioural and fluid clearance studies well documented, there is much debate whether AQP4 is required for ISF clearance in the brain and the role of AQP4 in the structure and arrangement of the vessel wall has received little attention.

**The second aim is to investigate how loss of α-DB at astrocyte endfeet affects the morphology and dynamics of IPAD pathways.** α-DB deficient mice will be employed to repeat the detailed ultrastructural study of cerebral capillaries and if there are any modifications, the dynamics of IPAD and cerebral perfusion will be investigated in order to determine if they display a failure of IPAD seen in CAA and features of CSVD and VaD.
1.7 HYPOTHESES

1. In mice that do not express glial aquaporin 4 the morphology of capillary intramural periarterial drainage pathways is altered.

2. In mice genetically modified for alpha dystrobrevin, the morphology and dynamics of intramural periarterial drainage pathways and cerebral perfusion are impaired.
Chapter 2  MATERIALS & METHODS
2.1 ANIMALS

Experimental work within this thesis is performed using mice deficient for either aquaporin 4 (AQP4) (chapter 3) or alpha-dystrobrevin protein (α-DB) (chapters 4, 5 and 6). Mice deficient for AQP4 were generated by Ikeshima-Kataoka et al. at Keio University, Japan who kindly donated perfusion fixed brains for electron microscopy studies. Mice deficient for α-DB were purchased from The Jackson laboratory (010976) and rederived to establish colonies at the University of Portsmouth (colony 1) and the University of Southampton (colony 2). Unless otherwise stated, all procedures were carried out in accordance with animal care guidelines stipulated by the United Kingdom Animals (Scientific Procedures) Act 1986, Home Office licence (P12102B2A).

2.1.1 MICE DEFICIENT FOR AQUAPORIN 4 (CHAPTER 3)

The AQP deficient mouse model used in this thesis is a global AQP4 deficient model in which a 250-nucleotide sequence in exon 1 that corresponds to the region from Ser18 to Thr101 has been removed and replaced with GFP (green fluorescent protein) complimentary DNA and a PGK-neo cassette flanked by FRT sequences. This generates mice that express GFP under the AQP4 promotor instead of AQP4 [238].

2.1.2 MICE DEFICIENT FOR ALPHA DYSTROBREVIN (B6;129-DTNA TM1JRS/J) MICE (CHAPTERS 4, 5 & 6)

Mice deficient for alpha dystrobrevin (α-DB) were initially generated by Grady et al. [239] to investigate the pathogenesis of dystrophin-dependent muscular dystrophies by deletion of a segment common to the two alpha-dystrobrevin isoforms (α-DB1 and α-DB2) found in muscle (target mutation 1 made by Joshua R Sanes (tm1Jrs)). Briefly, a 2.5 Kilobase [240] BstBI – BgII segment of the alpha-dystrobrevin gene containing exon 3 [142] was deleted and replaced with a neomycin – resistant gene (Figure 2.1 a - c). This mutation was then introduced into 129/SvJ-derived embryonic-stem cells by homologous recombination to produce heterozygous and homozygous independent recombinants. This strain was then backcrossed once with C57BL/6 mice and maintained on a mixed 129 and C57BL/6 background. Homozygous recombinants do not express the known
alternatively spliced isoforms of α-DB in brains. Both heterozygous and homozygous mutant animals appear normal, show the expected lifespan and are fertile. These mice do show a subclinical muscular dystrophy but never develop the myofibrosis characteristic of the human disease [239].

For experimental work in this thesis, the same strain of α-DB deficient mice generated by Grady et al [239] was purchased from The Jackson laboratory (010976). Homozygous mice were imported into the Bio-resources Unit at the University of Portsmouth and backcrossed with C57BL/6 wild-type mice to generate a colony consisting of mutant, wild type and heterozygous offspring. Mutant and wild-type control mice were perfused for transmission electron microscopy (chapter 4).

A second colony of α-DB deficient mice was established at the Bio-resources Unit at the University of Southampton by blastocyst transfer. Briefly, α-DB deficient male and wild-type control female mice were used for timed matings performed by our collaborators at the Bio-resources Unit at the University of Portsmouth. At 3.5 days post conception, uterus dissection was performed, and the uterus transferred to the Bio-resources Unit at the University of Southampton. Upon receipt, the uterus was flushed to obtain blastocysts that were transferred into recipient female C57BL/6 mice. These mice then produced a litter of heterozygous offspring that were further bred to produce α-DB deficient mice. α-DB deficient mice were used to access intramural periarterial drainage (chapter 4) or were transferred to the Centre for Advanced Biomedical Imaging at University College London (UCL) for assessment by arterial spin labelling (chapter 6).

2.1.2.1 GENOTYPING MICE DEFICIENT FOR ALPHA-DYSTROBREVIN

All mice deficient for α-DB used in this thesis underwent genotyping. This involved DNA extraction, polymerase chain reaction (PCR) and gel electrophoresis.

2.1.2.1.1 PREPARATION OF MOUSE GENOMIC DNA

PCR-quality mouse genomic DNA was prepared using HotSHOT (Hot Sodium Hydroxide and Tris) according to Truett GE et al. [241]. Ear punches from 4-week-old mice were placed in 0.2 ml PCR Tubes (STAR LAB, 11402-8100) with 75 µl of alkaline lysis reagent (25 mM sodium hydroxide (NaOH) in 0.2 mM disodium
ethylenediaminetetraacetic acid (EDTA), pH 12) and heated to 89ºC for 2 hours. After heating, samples were cooled to 4ºC and 75 µl of neutralising reagent (40 mM Tris (hydroxymethyl) aminomethane hydrochloride (Tris-HCl) pH 5) was added to each sample. The samples were then stored at 4ºC.

### 2.1.2.1.2 POLYMERASE CHAIN REACTION

1 µl of HotSHOT DNA was added to 0.2 ml 8-strip PCR Tubes (STAR LAB 11402-2900) and mixed with 19 µl of PCR mixture containing 14.8 µl nuclease free water (Thermo Fischer, AM9930), 2 µl PCR buffer, 0.2 µl dNTPs, 0.2 µl Taq DNA polymerase, 0.6 µl MgCl₂ (Taq DNA Polymerase, recombinant kit, Thermo Fischer, 10342020) and 0.4 µl of 10 µmol mutant (TGC CAA GTT CTA ATT CCA TCA GAA GCT G), common (GGG CCT TAC CTA TGT GAC TGA GTG AC) and wild-type reverse (TGC TCG CCC CTA CAG CAC CCC TTA) primers (custom ordered, Merck KGaA) (Figure 2.1 d).

DNA was amplified in a DNA Engine Tetrad®2 (Peltier Thermal Cycler, Bio-Rad Laboratories, Inc.) by first heating to 94ºC for 5 minutes and then cycling 34 times at 94ºC for 30 seconds, 62ºC for 30 seconds and 72ºC for 30 seconds. Samples were then heated again at 72ºC for five minutes and cooled and stored at 4ºC. Following amplification 4 µl of gel loading dye (Purple (6X), New England Biolabs inc, B7025S) was added to each sample. 4 µl of sample was loaded onto a 2 % agarose in 1 x TBE buffer gel containing 2.5 µl Gel red (Cambridge Bioscience, BT41003) and electrophoresed at 120 V for 30 minutes. Gels were imaged under UV light using a High performance ultraviolet transilluminator imaging system (Ultra-violet Products Ltd). See Figure 2.2 for results.
Figure 2.1 Overview of the α-DB gene and its deletion in α-DB null (B6;129-Dtna tm1Jrs/J) mice

a) Overview of the α-DB gene in mice showing the major exons (1 – 20). Blue boxes – constitutive coding exons. Orange boxes – alternatively spliced coding exons that result in the different isoforms. White boxes – untranslated regions. Green boxes – encoding regions for syntrophin binding sites.  
b) Exon 3, common to the major isotypes (red area in (a)), is deleted and replaced with a neomycin-resistant gene that effects all major isotypes (c) producing either wild-type, heterozygous or homozygous mice genotyped by standard PCR and custom common, wild-type reverse and mutant PCR primers (d). a & c adapted from [242]. b adapted from [239].
Figure 2.2 PCR results for the genotyping of α-DB null (B6;129-Dtna tm1Jrs/J) mice

*Mutant mice will show one 300 bp band. Wildtype mice will show one 574 bp band. Heterozygous (het) mice will show both a 300 bp and 574 bp band.*
Chapter 2: Materials & Methods

2.2 ASSESSMENT OF THE CAPILLARY WALL USING TRANSMISSION ELECTRON MICROSCOPY (CHAPTERS 3 AND 4)

To assess the effect of the removal of AQP4 or α-DB on the structure of cerebral capillaries in the grey and white matter (chapters 3 and 4), a subset of AQP4 deficient and α-DB deficient mice and associated wild-type controls were processed for transmission electron microscopy (TEM). This involved tissue fixation by perfusion, tissue processing for TEM and imaging and analysis by TEM. The following methods are adapted from our published protocols [243, 244] and have been utilised in several peer reviewed publications [160, 161, 173, 217, 218, 245].

2.2.1 FIXATION OF TISSUE FOR ELECTRON MICROSCOPY

AQP4 deficient (n=2) and wild-type control mice (n=2) or α-DB deficient (n=3) and wild-type control mice (n=3) were terminally anesthetised with pentobarbitone (200 mg/kg) and then intracardially perfused with 0.1M piperazine-N,N'-bis(2-ethanesulfonic acid) buffer (PIPES, pH 7.2) followed by 4% formaldehyde plus 3% glutaraldehyde in 0.1M PIPES buffer (pH 7.2). Brains were removed from the skull and subsequently placed in fresh 4% formaldehyde plus 3% glutaraldehyde in 0.1M PIPES buffer (pH 7.2) at 4ºC for 24 hours.

2.2.2 PREPARING PERFUSION FIXED BRAINS FOR TISSUE PROCESSING

Perfusion fixed brains were sliced into 1mm thick coronal sections using a mouse brain tissue matrix (Fisher Scientific, 15344908). Upon examination of each 1mm slice, it was decided the seventh section (7mm from the olfactory bulbs) provided a good amount of both white and grey matter for sampling. This section was removed and further microdissected for regions of interest in the cortex (x5) and white matter (x5) by removing roughly 5mm of each region starting from the midline and extending into the left hemisphere. Each 5mm region was then divided into smaller 1mm² slices (Figure 2.3) and stored in fresh 4% formaldehyde plus 3% glutaraldehyde in 0.1M PIPES buffer (pH 7.2) at 4ºC until processed for TEM. The
other unused slices were stored in 4% formaldehyde plus 3% glutaraldehyde in 0.1M PIPES buffer (pH 7.2) at 4ºC.

2.2.3 TISSUE PROCESSING FOR TRANSMISSION ELECTRON MICROSCOPY

Tissue samples of cortex and white matter were processed for TEM following our optimised protocols [243, 244]. Sections were first washed in 0.01M PIPES buffer (pH7.2) for 5 min and then post fixed in 2% osmium tetroxide in 0.1M PIPES buffer (pH7.2) for 1 hour. After a further wash in 0.01M PIPES buffer (pH7.2) for 5 min samples were first dehydrated in 30% and then 50% ethanol for 10 mins each and then stained with 1% Uranyl acetate in 70% ethanol for 30 mins. Further dehydration in 95% ethanol for 10 mins and in 100% ethanol for 15 minutes (x2) was followed by 10 mins in acetonitrile, 12 hours in a 50:50 mixture of acetonitrile and TAAB resin (TAAB laboratories, UK) and 6 hours in fresh TAAB resin. Samples were embedded in flat bottomed resin capsules containing fresh TAAB resin and polymerised at 60ºC for 16 hours.
Figure 2.3 Dissection of mouse brain for TEM analysis

a) Brains were sliced into 1mm coronal sections using a mouse brain matrix. b) a representative coronal slice showing sample sites for grey matter (purple boxes) and white matter (green boxes).

2.2.4 SECTIONING OF PROCESSED TISSUE

Polymerised resin blocks were trimmed and sectioned using an Reichurt Ultracut E ultramicrotome (Reichurt, Germany). 80 nm ultrathin sections were cut, transferred onto copper grids (TAAB laboratories, UK) and counter-stained with lead citrate for 3 minutes.
2.2.5 IMAGING TISSUE SECTIONS FOR CAPILLARIES

Grids were examined using either a Hitachi HT7700 (chapter 3) or a Tecnai T12 (chapter 4) transmission electron microscope operating a Morada G3 digital camera and Radius image capture software (EMSIS, Münster, Germany). Each grid was methodically scanned from top right to bottom left. High resolution low power images of the first 20 capillaries in transverse section with well-defined and clearly resolved vessel walls from each brain region (40 per mouse) were digitally photographed.

2.2.6 CALCULATING PERCENTAGE SURFACE AREA OF THE DIFFERENT COMPONENTS OF THE CAPILLARY WALL

Images were first analysed qualitatively for ultrastructural changes to components of the capillary wall. These included the endothelium, basement membrane and intramural cells. Images were then analysed quantitatively for changes in expression of these components. Adobe Photoshop CS6 was used to manually demarcate the lumen, endothelium, intramural cells and basement membrane, based on electron dense staining of lipid bilayers. Once demarcated, each feature was segmented, measured for surface area in \( \mu m^2 \) and, other than the lumen, percentage area occupied of the vessel wall (Figure 2.4).

2.2.7 STATISTICAL ANALYSIS

The means of repeated measures (n = 20 per region per mouse) were analysed using SPSS and a univariate Analysis of Variance (two-way Anova). Repeated measures included the surface areas of the lumen, endothelium, intramural cells, basement membrane, vessel wall and overall vessel size and the percentage surface areas of the endothelium, intramural cells and basement membrane. Significance was set at \( P < 0.05 \).
Figure 2.4 Demarcation and analysis of components of the capillary wall

Adobe Photoshop CS6 was used to demarcate and measure the surface area of the lumen (a – c, red), endothelium (d – f, blue), intramural cells (g - i), green and basement membrane (j – l, orange). The arrows in a, d, g & j point to electron dense staining of lipid bilayers that were used to define the edges of each feature. After defining the edges, each feature was segmented (represented as false coloured areas in b, e, h & k and outlined objects in c, f, i & l) and assessed for surface area using Adobe Photoshop inbuilt measure and analysis tools. For this image the lumen measured 7.62 µm², the endothelium 1.38 µm², the intramural cell 0.12 µm² and the basement membrane 0.46 µm². The endothelium occupied 70.41% of the vessel wall, the intramural cell 6.12% and the basement membrane 23.47%.
2.3 ANALYSING THE COMPOSITION OF THE CEREBROVASCULAR BASEMENT MEMBRANES (CHAPTER 4)

To assess for changes to the biochemical composition of capillary walls in α-DB deficient mice, immunohistochemistry (IHC) and brightfield microscopy was used to assess for changes in expression of collagen IV (COL4) in grey matter and white matter capillaries of α-DB deficient (n = 3) and wild-type control (n = 3) mice. This involved tissue fixation by perfusion, tissue processing for IHC and imaging and analysis by brightfield microscopy.

2.3.1 FIXATION OF TISSUE FOR IMMUNOHISTOCHEMISTRY

α-DB deficient mice (n = 3) and wild-type control (n = 3) mice were terminally anesthetised with pentobarbitone (200 mg/kg) and then intracardially perfused with 0.01 M phosphate buffered saline (PBS) followed by 4% Paraformaldehyde (PFA) in 0.01 M PBS, pH 7.4 at a rate of 5 ml min⁻¹. Brains were dissected and post fixed for 6 hrs in fresh 4% PFA in 0.01 M PBS, pH 7.4 at 4 ºC and then cryoprotected in 30% sucrose in distilled H₂O at 4ºC for a further 48 hrs.

2.3.2 TISSUE SECTIONING

Cryoprotected brains were removed from 30% sucrose and imbedded in OCT compound before serial sectioning into 20 μm coronal slices using a Leica CM1860 UV cryostat. Sections were collected onto SuperFrost Plus™ adhesion slides (Thermo Scientific™, 10149870) and stored at -20ºC.

2.3.3 ENZYME LINKED IMMUNOHISTOCHEMISTRY FOR COLLAGEN IV

Enzyme-linked immunohistochemistry using 3,3'-Diaminobenzidine (DAB) (Sigma-Aldrich, UK) as chromogen was used to visualise COL4 positive vessels in grey and white matter of α-DB deficient and wild-type control mice using 20 μm coronal frozen sections. One section per mouse was chosen based on matching the anatomy with sections used for TEM (see section 2.2). Adjacent sections posterior and anterior to the chosen section were used as negative controls.
Chapter 2: Materials & Methods

Sections were first defrosted in an incubator at 37°C for 15 mins and then washed 2 x 3 mins in 0.01M PBS, pH 7.4. To block endogenous peroxidase activity sections were incubated at room temperature in 3% hydrogen peroxide (Sigma-Aldrich, UK) in 0.01M PBS for 15 mins and then washed 4 x 3 mins in 0.01M PBS, pH 7.4. Antigen retrieval was performed by incubating the sections at 37°C in pepsin digest (1mg/ml in 0.2 M hydrochloric acid) for 4 mins. Sections were then washed 4 x 3 mins in 0.01M PBS, pH 7.4 before being blocked with 15% normal goat serum (Sigma-Aldrich, UK) in 0.01M PBS at room temperature for 30 mins. After washing, the sections were probed overnight at 4°C with Rabbit anti-COL4 (abcam, ab6586) diluted in in 0.1% triton in 0.01M PBS to a final dilution of 1:400. This step was omitted with the negative controls to ascertain the level of background non-specific antigen binding of the tissue. Sections were then washed in 0.1M PBS, 4 x 3 mins before being incubated for 1 hour at room temperature with goat anti-rabbit secondary antibody (ThermoFisher Scientific, 31820) diluted in 0.01M PBS to a final dilution of 1:200. Sections were then washed in 0.1M PBS, 4 x 3 mins, incubated at room temperature in ABC vector (Vector laboratories, PK-6100) for 1 hour, washed again in 0.01M PBS, 4 x 3 mins and then washed in 0.1M sodium acetate, 4 x 3 mins. Sections were developed using glucose oxidation enhancement with 3,3'-Diaminobenzidine (DAB) for 12 mins, dehydrated through an alcohol series (50%, 75%, 90%, 2 x 100% 2 mins each), washed in xylene (2 x 5 mins washes) and coverslipped using DPX mounting medium (Sigma-Aldrich, UK).

2.3.4 IMAGING FOR DAB STAINING OF COLLAGEN IV

2.3.4.1 EXTRACTING REGIONS OF INTEREST

An Olympus dotSlide digital virtual microscope was used to produce high powered tile scans of each section (magnification of x40) (1 x section per mouse). Tile scans were imported into VS Desktop imaging software (Olympus) to produce regions of interest (ROI)s for further image analysis. As the white matter (corpus callosum) in mice occupies less area than the grey matter, overall sample area was calculated based upon the size of the white matter in each image. The white matter was identified based on the orientation of the white matter tracts. We found that the white matter could be divided into 20 smaller ROIs with a size of 125 µm (width) by 125 µm (height) and an area of 15625 µm² (0.0156 mm²). The total area of white matter sampled for each mouse was 312,500 µm² (0.313 mm²). As the area of the
grey matter is larger, we chose to use five ROIs with a size of 250 µm (width) by 250 µm (height) and an area of 62500 µm² (0.0625 mm²) positioned to capture as much grey matter as possible while keeping the overall sample area the same as the white matter (0.313 mm²) (Figure 2.5)

![Image of sample sites for immunohistochemistry of collagen IV](image)

**Figure 2.5 Sample sites for immunohistochemistry of collagen IV**

*One section per mouse was chosen based on matching the anatomy with sections used for TEM. The micrograph has been false coloured showing the grey matter (light purple) and white matter (light blue). The white matter is identified by the direction of the white matter tracts. The outlined boxes represent either 250 µm (width) by 250 µm (height) (grey matter) or 125 µm (width) by 125 µm (height) (white matter) regions of interest that were extracted for further analysis.*
Chapter 2: Materials & Methods

2.3.4.2 ANALYSING REGIONS OF INTEREST FOR COL4 STAINING AND VESSEL DENSITY

Each ROI was assessed for DAB (COL4) staining using Image J [246] and a custom macro (Figure 2.6) modified by colleagues from the Biomedical imaging Unit, Southampton University. The macro enables automatic thresholding of each region of interest (ROI) to just display vessels stained with DAB. The analyse particle function is then used to generate values for total number of vessels and total area of DAB staining from layer masks of each ROI (Figure 2.7).

Values generated for each ROI were combined to give total number of vessels and total area of DAB staining per region per section. These values were then divided by the overall surface area (312500 µm²) and multiplied by 500000 and expressed as total number of vessels (vessel density) and total area stained per 0.5mm². The amount of COL4 per vessel was calculated by dividing the total area stained by the total number of vessels.

2.3.4.3 ANALYSING REGIONS OF INTEREST FOR VESSEL DISTRIBUTION AND VESSEL SPECIFIC COL4 STAINING

Grey matter ROI were further assessed for differences in vessel distribution by counting the number of capillaries (vessels with diameter of less than 10 µm) and arterioles and venules which, due to limitations of DAB staining, could not be easily differentiated and so were classified together as vessel with a diameter of 10 µm or larger. Inbuilt measurement and analysis tools in Adobe Photoshop CS6 were used to identify and count the number of vessels with a diameter of 10 µm or larger per ROI using imported layer masks of each ROI (generated from the ImageJ macros) (Figure 2.8). The number of capillaries of each ROI was calculated by deducting the counted number of arterioles/venules from the overall total vessel count (generated previously using the ImageJ macros). Values generated for each ROI were combined to give the total number of capillaries and arterioles/venules per region per section. These values were then divided by the overall surface area (312500 µm²) and multiplied by 500000 and expressed per 0.5mm².

Adobe Photoshop CS6 was also used to measure and calculate overall COL4 staining per vessel type. First, the arterioles/venules identified previously from the layer masks of each ROI were measured for total area of COL4 staining (Figure 2.8).
Chapter 2: Materials & Methods

This value was then deducted from the overall area of COL4 staining to give total area of COL4 staining for capillaries per ROI. Values generated for each ROI were combined to give the total area of COL4 staining per capillaries and per arterioles / venules per region per section. These values were then divided by the overall surface area (312500 µm²) and multiplied by 500000 to be expressed per 0.5mm². The amount of COL4 per vessel was calculated by dividing the total area stained by the total number of vessels for each vessel group per 0.5mm².

2.3.4.4 STATISTICAL ANALYSIS

Statistical analysis was performed using SPSS and an independent t-test with significance set at P < 0.05.
Chapter 2: Materials & Methods

Figure 2.6 Custom macros used in Image J to analyse COL4 staining

dir = getDirectory("Choose a Directory");
dirOUT = getDirectory("create and select a result folder");

count = 0;
n = 0;
processFiles(dir);
selectWindow("Results");
saveAs("Results", dir + "Results_big_vessels.csv");
r run("Close");
selectWindow("Summary");
saveAs("Results", dir + "Summary per vessels.csv");
r run("Close");

function processFiles(dir) {  
  list = getFileInfoList(dir);
  Array.sort(list);
  for (i = 0; i < list.length; i++) {
    if (endsWith(list[i], "*.tiff"))
      processFiles("" + dir + list[i]);
    else {
      showProgress(n++, count);
      path = dir + list[i];
      processImage(path);
    }
  }
}

function processImage(path) {
  if (endsWith(path, "*.tiff")) {
    open(path);
    Title = getTitle();
    imageName = File.nameWithoutExtension();
    dirImage = getDirectory("image");
    folderName = File.getName(dirImage);
    imageNameNew = folderName + "." + imageName;
    rename(imageNameNew);

    //
    run("Properties...", "channels=1 slices=1 frames=1 unit=um pixel_width=0.161 pixel_height=0.161 voxel_depth=0.161");
    run("8-bit");
    run("Subtract Background...", "rolling=50 light");
    run("Median...", "radius=3");
    run("Set Measurements...", "area limit display redirect=none decimal=3");
    setAutoThreshold("Default");
    run("Threshold...");
    setThreshold(0, 150);
    runAutoThreshold(0, 150);
    setOption("BlackBackground", false);
    run("Convert to Mask");
    run("Analyze Particles...", "size=3-infinity show=Outlines display summarize");
    selectWindow("Drawing of "+imageNameNew);
    saveAs("tiff", dirOUT + imageNameNew + ".tiff");
    close();
    selectWindow(imageNameNew);
    close();
  }
}

exit;
Figure 2.7 Analysing regions of interest for number of vessels and COL4 staining

Each region of interest is processed in Image J by a macro that automatically converts the image to 8 bit (a), subtracts unwanted background noise (b), applies auto threshold to display just DAB staining (c) and creates a layer mask to count the number of vessels and area staining of DAB by using analyse particle function (d). Scale bar = 25µm. The graph (e) shows the results with each column representing one vessel. In this sample, the area of the region of interest was 62500 µm², the total number of vessels was 25 and the total area of DAB staining was 1820.303 µm².
Figure 2.8 Analysing regions of interest for distribution of vessels and COL4 staining

Each ROI layer mask (a) was evaluated for the number and total area of DAB (COL4) staining of capillaries and arterioles / venules. Panel (b) has been false coloured to highlight the capillaries (blue) and arterioles / venules (red). The total number of capillaries for this ROI is 22 and arterioles / venules 3. The overall surface area of DAB staining for capillaries is 985.263 µm² and arterioles / venules 835.04 µm². Scale bar = 20µm
2.4 ASSESSMENT OF INTRAMURAL PERIARTERIAL DRAINAGE IN ALPHA-DYSTROBREVIN DEFICIENT MICE (CHAPTER 5)

To assess the dynamics of Intramural periarterial drainage (IPAD) in α-DB deficient mice, the clearance of a fluorescent tagged tracer (amyloid-beta (Aβ) (1-40) HiLyte Fluor 555 (Cambridge Bioscience)) injected into the hippocampus (grey matter) or corpus callosum (white matter) was assessed by confocal microscopy. This involved stereotaxic surgery, tissue fixation by perfusion, tissue sectioning, immunohistochemistry, confocal microscopy and image analysis.

The following methods have recently been published in [247]. Further work where we have utilised stereotaxic surgery can be found in [160, 178, 245, 248].

2.4.1 STEREOTAXIC INJECTION OF AMYLOID-BETA (1-40) HILYTE FLUOR 555

α-DB deficient (n = 5 per region) and wild type control (n = 5 per region) were anaesthetised with Isoflurane mixed with concentrated O₂ (1.7 L min⁻¹). Mice were induced with 3% isoflurane and then maintained using 2% isoflurane. The level of anaesthesia was monitored by using pedal withdrawal reflex response. A rectal probe and homoeothermic blanket and temperature control system (BASi) was used to regulate internal body temperature at 37°C. Lacri-lube ointment was applied to the eyes to preserve cornea during anaesthesia. Isoflurane was used rather than injectable anaesthetics based on our previous study which showed that isoflurane is better at maintaining a more physiologically relevant heart rate and oxygen saturation level [245].

A KOPH instruments stereotaxic frame (Model 900) with attached digital manipulator (World Precision Instruments) was used to precisely inject tracer into hippocampal grey matter (Anterior-Posterior - 2 mm; Medial-Lateral 1.5 mm; Dorsal-Ventral - 1.7 mm, n=5) or corpus callosum (white matter) (Anterior-Posterior -2 mm; Medial-Lateral 0.5 mm; Dorsal-Ventral - 1.3 mm, n= 5) of wildtype or mutant mice. The stereotaxic coordinates were obtained using The Allen mouse brain atlas (www.mouse.brain-map.org) (Figure 2.9).
Chapter 2: Materials & Methods

The anaesthetized mouse was placed in the stereotaxic frame and the head secured with jaw bars. A midline incision was performed and a Tech2000 Micromotor drill (RAM Products, INC) with 0.7 mm burr was used to create a burr hole in the skull at the injection site. 0.5µl of 100µM Aβ (1-40) HiLyte Fluor 555 (Cambridge Bioscience) was injected into either the hippocampus or corpus callosum using a Hamilton Neuros Syringe with a 33 gauge needle (Essex Scientific Laboratory Supplies Ltd.) and Microinjection syringe pump (UMP3T-1; World Precision Instruments) at a rate of 0.25 µl min⁻¹. The syringe was left in situ for 2 min to allow for bolus diffusion to prevent reflux. The tracers were allowed to drain for a further 5 min and then the mouse terminally anesthetised with pentobarbitone (200 mg/kg) for perfusion fixation.

Figure 2.9 Stereotaxic injection sites

Injections were performed Anterior-Posterior -2mm from the Bregma represented by the red dot (hippocampus) and yellow dot (corpus callosum) in (a). Sagittal slices show the injection site for the hippocampus (Anterior-Posterior - 2 mm; Medial-Lateral 1.5 mm; Dorsal-Ventral 1.7 mm), red dot in (b) and corpus callosum (Anterior-Posterior -2 mm; Medial-Lateral 0.5 mm; Dorsal-Ventral - 1.3 mm), yellow dot in (c). Images adapted from www.mouse.brain-map.org
2.4.2 FIXATION OF TISSUE AND TISSUE SECTIONING FOR IMMUNOHISTOCHEMISTRY

Terminally anesthetised mice were intracardially perfused with 0.01 M phosphate buffered saline (PBS) followed by 4% Paraformaldehyde (PFA) in 0.01 M PBS, pH 7.4 at a rate of 5 ml min⁻¹. Brains were dissected and post fixed for 6 hrs in fresh 4% PFA in 0.01 M PBS, pH 7.4 at 4ºC and then cryoprotected in 30% sucrose in distilled H₂O at 4ºC for a further 48 hrs. Brains were imbedded in OCT compound and then sectioned into 20 μm coronal slices using a Leica CM1860 UV cryostat. Sections were collected onto SuperFrost Plus™ adhesion slides (Thermo Scientific™, 10149870) and viewed using a Zeiss Axioskop 2 fitted with a rhodamine filter to identify the section containing the site of injection. In our previous studies we show that in mice the drainage of Aβ (1-40) occurs predominantly in a posterior direction and can be visualised in the wall of blood vessels as close as 200 μm to the injection site [74]. We therefore chose coronal sections 200 μm posterior to the injection site for immunohistochemistry. All sections were stored at -20ºC.

2.4.3 TISSUE PROCESSING FOR IMMUNOHISTOCHEMISTRY

Sections were defrosted in an incubator at 37ºC for 15 mins, washed 2 x 3 mins in 0.01M PBS, pH 7.4 and then blocked in 15% goat serum (Sigma 9023) for 1 hour at room temperature (RT). Sections were then incubated in rabbit anti-COL4 1/400 in 0.01M PBSt (AbCam, ab6586) and anti-smooth muscle actin (SMA) FITC conjugated 1/200 in 0.01M PBSt (Sigma F3777) overnight in a moist chamber at 4ºC. Sections were then washed 3 x 10 mins in 0.01M PBS and incubated in conjugated secondary antibody goat antirabbit Alexa Fluor 633 0.01M PBSt (ThermoFisher Scientific A-21070) for 1 hour RT. Sections were further incubated in 1% Sudan Black for 5 min to remove auto fluorescence before being mounted in mowiol citiflour and stored at 4ºC until imaged.

2.4.4 IMAGING TISSUE SECTIONS BY CONFOCAL MICROSCOPY

For each section, tile scans of the left hippocampus or corpus callosum were captured using a Leica SP8 confocal microscope fitted with x20 objective set at an optical zoom of 1. Laser power and detection windows were kept consistent for all scans. Sequential imaging was used to prevent cross excitation of fluorophores.
Chapter 2: Materials & Methods

2.4.5 ASSESSMENT OF INTRAMURAL PERIARTERIAL DRAINAGE

Quantification of intramural periarterial drainage (IPAD) of Aβ (1-40) HiLyte Fluor 555 injected into the left hippocampus or corpus callosum was performed using a max projection of each tile scan uploaded into Adobe Photoshop CS6. We chose to use max projections of each tile scan as they provide a more precise and accurate method to assess IPAD, particularly when assessing vessel density.

IPAD was assessed by using Adobe Photoshop CS6 to manually measure vessel density of capillaries, arterioles and venules and counting the number of vessels containing Aβ (1-40) HiLyte Fluor 555 in their vessel walls. We also assessed fluorescence intensity to investigate for possible differences in the amount of amyloid-beta remaining in the parenchyma.

Vessel density was calculated by dividing the total number of capillaries, arterioles or venules by the overall surface area (in µm²) and multiplying this value by 500000 to be expressed as number of vessels per 0.5mm². This was also performed for the number of capillaries, arterioles or venules with Aβ in their vessel walls. Vessels were identified based on lumen diameter and immunoreactivity to SMA (< 10µm = capillaries, ≥ 10 µm & SMA positive = arterioles, ≥ 10 µm & SMA negative = venules) [168, 170]. The overall surface area was determined by choosing regions of interest that were based on key anatomical features that could be observed in each section analysed. Regions of interest were outlined using Adobe Photoshop CS6. For the hippocampus, an area transversely extending from the edge of the suprapyramidal blade to the apex of the granule cell layer [178] was outlined. For the corpus callosum, the white matter tracts extending from the midline to a point directly above the suprapyramidal blade of the granule cell of the hippocampus were outlined (Figure 2.10).

The density of Aβ (1-40) in the parenchyma was assessed using Image J [246] and the RawIntDen function. Each tile region of interest was extracted from the confocal tile scan using Adobe Photoshop CS6 and split into its subsequent colour channels (blue – COL4, green – SMA, red - Aβ (1-40)). The red channel was then imported into Image J and converted into an 8-bit greyscale image. Areas of the image containing fluorescent signal was segmented using an auto-threshold algorithm and assessed for overall area and fluorescent intensity using the RawIntDen function to generate the sum of the values of all the fluorescent pixels. Values were
Chapter 2: Materials & Methods

divided by the overall surface area (in \( \mu m^2 \)) of each region of interest and multiplied by 500000 to be expressed as overall area and fluorescent intensity per 0.5mm\(^2\) (Figure 2.11).

2.4.6 STATISTICAL ANALYSIS

Statistical analysis was performed using SPSS and an independent \( t \)-test with significance set at \( P < 0.05 \).
Figure 2.10 Selection of regions of intertest for assessment of intramural periarterial drainage

Regions of interest for assessment of IPAD in the hippocampus (a, yellow area) and corpus callosum (b, yellow area). Corresponding confocal images (b & c) show demarcated regions (white lines) manually drawn in Adobe Photoshop CS6. The distribution of vessels and the number of vessels with Aβ (1-40) HiLyte Fluor 555 in their vessel walls within these regions were manually counted using Adobe Photoshop analysis tools. Images (a & c) adapted from www.mouse.brain-map.org
Figure 2.11 Assessment of the density of amyloid beta (1-40) in the parenchyma

Regions of interest were extracted from the confocal tile scan (a) and split into its subsequent colour channels. The red channel (Aβ (1-40)) (b) was imported into ImageJ, converted into a grey scale image (c) and segmented using Image thresholding (d). Fluorescent intensity was calculated using the ImageJ RawIntDen function and presented as overall fluorescent area and intensity per 0.5mm². For this sample the overall surface area of the region of interest is 1271335.49 µm², the surface area of the fluorescent signal is 108972.03 µm² and the RawIntDen fluorescent intensity is 17.13 x10⁶ per 0.5mm².
2.5 ASSESSMENT OF CEREBRAL BLOOD FLOW IN ALPHA-DYSTROBREVIN DEFICIENT MICE (CHAPTER 6)

To assess for alterations to baseline cerebral blood flow (CBF) (12 – 16 week-old) α-DB deficient (B6;129-Dtna\(^{tm1,Jrs}\)/J) [239] (n = 10) and wild-type control mice (n = 12) were assessed using a non-invasive magnetic resonance imaging (MRI) technique (arterial spin labelling (ASL)) by colleagues at the Centre for Advanced Biomedical Imaging UCL. CBF values were generated by colleagues at UCL but statistical analysis was performed by myself using SPSS and an independent \(t\)-test with significance set at \(P < 0.05\).

A small pilot study was also performed assessing CBF in α-DB deficient mice after exposure to hypercapnia. Hypercapnia was generated by exposing 10-month old α-DB deficient (n=2) and wild-type control mice (n=3) to medical air for 5 mins, 10% \(\text{CO}_2\) for 5 mins and then medical air for a further 10 mins. Baseline scans were normalised to the mean baseline signal (for the first 5 mins of scanning) to visualise the relative change in CBF.

2.5.1 THE THEORY OF ARTERIAL SPIN LABELLING

In ASL, tissue perfusion is quantitatively measured using magnetically labelled arterial blood water protons as an endogenous tracer [249]. The main goal is to produce two MRI images of the same static tissue slice that have different magnetisation of the inflowing blood. After acquisition of the first slice, a radiofrequency (RF) pulse is used to invert or saturate water protons in arterial blood in a second slice before it enters the region of interest. After a set delay (T1, Longitudinal relaxation) in which the magnetism of the water protons is slowly reverting back to their longitudinal magnetism (uninverted), a second slice is acquired that will have a decreased amplitude in the region of interest. A variation of this image acquisition sequence is flow alternating inversion recovery (FAIR) in which a RF pulse is applied to a large area that includes the slice that is going to be imaged. After a set T1 time, the slice is imaged to generate a control slice that contains signal from both inverted stationary water protons and non-stationary water protons. To ascertain flow or movement of the water protons, another RF pulse is then applied to the same slice to invert all the water protons just in that slice. At the same time uninverted non-stationary water protons from areas outside...
the slice will be flowing into the slice to generate an image that again contains both stationary (inverted) and non-stationary water protons. Both images are compared by subtraction in which the stationary inverted protons are eliminated to just leave a flow sensitive image showing signal form water photons that are uninverted and can be quantitatively assessed for CBF [249, 250]. A more detailed summary of the methods used by colleagues at the Centre for Advanced Biomedical Imaging UCL can be found in appendix C.
Chapter 3  LOSS OF AQUAPORIN 4 FROM ASTROCYTE ENDFEET AND THE MORPHOLOGY OF THE INTRAMURAL PERIARTERIAL DRAINAGE PATHWAY
3.1 INTRODUCTION

Aquaporin 4 (AQP4) is anchored to astrocyte endfeet by syntrophin through C-terminal tail binding to PDZ domains. Syntrophin interacts with both dystrophin (DP71) and \( \alpha \)-dystrobrevin (\( \alpha \)-DB) of the dystrophin associated protein complex (DPC) [139, 146] (Figure 1.12). In mice deficient for \( \alpha \)-DB, AQP4 function at astrocytic endfeet is lost as AQP4 is redistributed from the endfeet to the cell body [146].

While extensive studies have investigated functional roles of AQP4, particularly in relation to oedema, the relationship between AQP4 and the structural integrity of the capillary wall and intramural periarterial drainage (IPAD) pathways has received little attention. In the limited instances where the vessel wall has been studied, the majority report no abnormalities in blood-brain barrier function or ultrastructural appearance related to the absence of AQP4 [188, 191, 195, 203]. It is worth noting that hyperpermeability of the blood-brain barrier accompanied by open endothelial tight junctions and swollen astrocyte end feet in grey matter have been reported by Zhou et al [235] in mice that do not express AQP4 [184]. However this is in direct contrast to reports by Feng X et al. who, in the same mouse model, reported no abnormalities in the blood-brain barrier, even with the presence of sporadic hydrocephalus and complete destruction of the cerebral aqueduct [195]. As yet, there are no reports of changes to other components of the vessel wall.

The majority of the aforementioned studies have focussed on cortical or striatal grey matter and not the white matter, where abnormalities in fluid homeostasis are frequently observed in cerebrovascular pathology. This is most likely due to the small amount of cerebral white matter available for study in small rodents and therefore evidence for how AQP4 relates to the structural integrity of the vessel wall, blood-brain barrier and IPAD pathways in the white matter is somewhat scarce. In a recent study we have shown a reduction in the expression of AQP4 in the white matter of human post mortem brains with cerebral amyloid angiopathy (CAA) and white matter hyperintensities (WMH) [115]. However, it is unclear if alterations in the expression of AQP4 in the white matter precede or are caused by abnormalities in fluid disturbances.
Chapter 3: Introduction

The primary aim of this chapter is to investigate whether the loss of AQP4 from astrocytic endfeet alters the morphology of the vessel wall and IPAD pathways. This is to support work in chapter 4 of this thesis in which mice deficient for αDB are investigated for morphology of the vessel wall and IPAD pathways. It is therefore essential to be able to distinguish any differences in the structure of the vessel wall and IPAD pathway between these mice.

Transmission electron microscopy (TEM) was applied to firstly analyse the ultrastructure of capillaries in the grey matter and secondly to compare these to capillaries in the white matter of mice deficient for AQP4.
3.2 HYPOTHESIS

In mice that do not express glial aquaporin 4, the morphology of capillary intramural periarterial drainage pathways is altered.
Chapter 3: Aims

3.3 AIMS

The work detailed in this chapter aims to investigate whether the loss of AQP4 from astrocytic endfeet alters the morphology of the capillary wall and IPAD pathway. A mouse model that does not express glial AQP4 (see section 2.1) is used to perform a detailed ultrastructural study of the capillary wall (see section 2.2), the first entry point for periarterial drainage (Figure 3.1).

Figure 3.1 AQP4 and its deletion from the dystrophin associated protein complex in astrocyte endfeet

Does the loss of AQP4 from astrocytic endfeet alter the morphology of the capillary intramural periarterial drainage pathway?
3.4 MATERIALS & METHODS

For this chapter, brains from AQP4 deficient (n = 2) (generated by Ikeshima-Kataoka et al. at Keio University, Japan [238]) and wild-type control mice (n = 2) were processed for TEM by colleagues in Keio University, Japan following our published protocols [160, 243]. For more details see sections 2.1.1 and 2.2

Tissue embedded in resin blocks was sectioned and prepared for TEM as detailed in section 2.2. Imaging and analysis of the structure and arrangement of the capillary wall in grey and white matter was performed as per sections 2.2.5 and 2.2.6. Briefly, high resolution low power images of 20 capillaries from grey matter and 20 capillaries from white matter from each mouse were digitally photographed and analysed qualitatively for ultrastructural changes to endothelial cells, intramural cells and basement membrane. Each capillary was also quantitatively assessed for surface area measurements by image segmentation.

Statistical analysis was performed using SPSS and a univariate Analysis of Variance (two-way Anova) adjusting for repeated measures (20 per region per mouse) with significance set at P < 0.05. For more details see sections 2.2.7
3.5 RESULTS

3.5.1 ULTRASTRUCTURAL ASSESSMENT OF THE CAPILLARY WALL IN GREY AND WHITE MATTER IN AQP4 DEFICIENT MICE

To establish whether a lack of AQP4 at astrocyte endfeet affects the morphology of the capillary wall, the structural appearance of endothelium, intramural cells and basement membrane of capillaries from the white matter and grey matter in AQP4 deficient mice were analysed by electron microscopy.

When compared to wild-type control mice, electron microscopy revealed the appearance of the capillary wall to be unaltered in AQP4 deficient mice with no visible differences in the endothelium, intramural cells or basement membrane in either grey or white matter capillaries. There was also no difference in the appearance of the surrounding parenchyma. However, in AQP4 deficient mice the majority of the capillaries analysed appeared to be bigger in overall size as shown with the variation in the size of the scale bars on the electron micrographs shown in Figure 3.3b. This was confirmed with differences in capillary size metrics in section 3.5.2 (Figure 3.4 & Figure 3.5).
Figure 3.2 The structural appearance of the capillary wall in the grey matter appears unaltered in mice deficient for AQP4

Electron micrographs false coloured to highlight the endothelium (blue), intramural cells (green) and basement membrane (orange). The structural appearance of the capillary wall in AQP4 deficient mice (b) appears to be unaltered in the grey matter when compared to wild-type control mice (a). Endothelial cells and tight junctions (b1 & a1, blue), intramural cells (b2 & a2, green) and basement membranes (b3 & a3, orange) appeared similar in both genotypes. Note that in AQP4 deficient mice (b) the scale bar is smaller due to the majority of the capillaries appearing larger. The red arrows in (a) indicate the location of glial AQP4 in wild-type control mice.
Figure 3.3 The structural appearance of the capillary wall in the white matter appears unaltered in mice deficient for AQP4

Electron micrographs false coloured to highlight the endothelium (blue), intramural cells (green) and basement membrane (orange). The structural appearance of the capillary wall in AQP4 deficient mice (b) appears to be unaltered in the white matter when compared to wild-type control mice (a). Endothelial cells and tight junctions (b1 & a1, blue), intramural cells (b2 & a2, green) and basement membranes (b3 & a3, orange) appeared similar in both genotypes. Note that as with capillaries in the grey matter, in AQ4 deficient mice (b) the scale bar is smaller due to the majority of the capillaries appearing larger in the white matter. The red arrows in (a) indicate the location of glial AQP4 in wild-type control mice.
3.5.2 IMAGE SEGMENTATION AND SURFACE AREA MEASUREMENTS

As no overall differences in structural appearance, other than size, was noted by electron microscopy in capillaries of grey matter and white matter between wild-type control and AQP4 deficient mice, we next assessed each capillary (n = 20 per region per mouse) for changes in composition of the vessel wall. Image segmentation was performed to measure each capillary for the surface area of the vessel wall, endothelium, intramural cells, basement membrane, lumen and overall area.

Differences between capillaries in grey and white matter in each genotype were analysed.

3.5.2.1 COMPARISON OF CAPILLARIES IN WHITE AND GREY MATTER IN WILD-TYPE CONTROL MICE

In wild-type control mice, Univariate Analysis of Variance (two-way Anova with P < 0.05) revealed no significant differences between any of the variables measured in capillaries between grey and white matter (Table 1).

3.5.2.2 COMPARISON OF CAPILLARIES IN WHITE AND GREY MATTER IN AQP4 DEFICIENT MICE

Similar to the wild-type control mice, in AQP4 deficient mice Univariate Analysis of Variance (two-way Anova with P < 0.05) also revealed no significant differences between any of the variables measured in capillaries between grey and white matter (Table 2).
Chapter 3: Results

<table>
<thead>
<tr>
<th></th>
<th>Grey matter</th>
<th>White matter</th>
<th>Sig.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Overall vessel size</strong></td>
<td>14.53 µm$^2$</td>
<td>15.16 µm$^2$</td>
<td>0.675</td>
</tr>
<tr>
<td></td>
<td>(9.10 - 24.04 µm$^2$)</td>
<td>(8.57 - 29.63 µm$^2$)</td>
<td></td>
</tr>
<tr>
<td>Range</td>
<td>4.52</td>
<td>4.76</td>
<td></td>
</tr>
<tr>
<td></td>
<td>1.01</td>
<td>1.06</td>
<td></td>
</tr>
<tr>
<td>S.D</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>S.E</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Lumen</strong></td>
<td>11.45 µm$^2$</td>
<td>8.50 µm$^2$</td>
<td>0.057</td>
</tr>
<tr>
<td></td>
<td>(6.61 - 18.96 µm$^2$)</td>
<td>(6.10 - 23.36 µm$^2$)</td>
<td></td>
</tr>
<tr>
<td>Range</td>
<td>3.76</td>
<td>3.95</td>
<td></td>
</tr>
<tr>
<td></td>
<td>0.84</td>
<td>0.88</td>
<td></td>
</tr>
<tr>
<td>S.D</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>S.E</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Vessel wall</strong></td>
<td>3.08 µm$^2$</td>
<td>3.29 µm$^2$</td>
<td>0.454</td>
</tr>
<tr>
<td></td>
<td>(2.04 - 5.17 µm$^2$)</td>
<td>(2.23 - 6.27 µm$^2$)</td>
<td></td>
</tr>
<tr>
<td>Range</td>
<td>0.93</td>
<td>0.96</td>
<td></td>
</tr>
<tr>
<td></td>
<td>0.21</td>
<td>0.22</td>
<td></td>
</tr>
<tr>
<td>S.D</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>S.E</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Endothelium</strong></td>
<td>1.93 µm$^2$</td>
<td>1.87 µm$^2$</td>
<td>0.773</td>
</tr>
<tr>
<td></td>
<td>(1.27 - 3.16 µm$^2$)</td>
<td>(1.15 - 3.28 µm$^2$)</td>
<td></td>
</tr>
<tr>
<td>Range</td>
<td>0.60</td>
<td>0.54</td>
<td></td>
</tr>
<tr>
<td></td>
<td>0.13</td>
<td>0.12</td>
<td></td>
</tr>
<tr>
<td>S.D</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>S.E</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Intramural cells</strong></td>
<td>0.35 µm$^2$</td>
<td>0.45 µm$^2$</td>
<td>0.228</td>
</tr>
<tr>
<td></td>
<td>(0.06 - 0.77 µm$^2$)</td>
<td>(0.10 - 1.31 µm$^2$)</td>
<td></td>
</tr>
<tr>
<td>Range</td>
<td>0.17</td>
<td>0.27</td>
<td></td>
</tr>
<tr>
<td></td>
<td>0.04</td>
<td>0.06</td>
<td></td>
</tr>
<tr>
<td>S.D</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>S.E</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Basement membrane</strong></td>
<td>0.80 µm$^2$</td>
<td>0.88 µm$^2$</td>
<td>0.271</td>
</tr>
<tr>
<td></td>
<td>(0.46 - 1.38 µm$^2$)</td>
<td>(0.64 - 1.68 µm$^2$)</td>
<td></td>
</tr>
<tr>
<td>Range</td>
<td>0.24</td>
<td>0.26</td>
<td></td>
</tr>
<tr>
<td></td>
<td>0.05</td>
<td>0.06</td>
<td></td>
</tr>
<tr>
<td>S.D</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>S.E</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table 1: Comparison of capillary size metrics between grey and white matter in wild-type control mice
Table 2: Comparison of capillary size metrics between grey and white matter in AQP4 deficient mice

<table>
<thead>
<tr>
<th>Overall vessel size</th>
<th>Grey matter</th>
<th>White matter</th>
<th>Sig.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean</td>
<td>19.90 μm²</td>
<td>21.32 μm²</td>
<td>0.463</td>
</tr>
<tr>
<td>Range</td>
<td>(11.10 – 34.06 μm²)</td>
<td>(11.39 – 35.51 μm²)</td>
<td></td>
</tr>
<tr>
<td>S.D</td>
<td>6.42</td>
<td>6.84</td>
<td></td>
</tr>
<tr>
<td>S.E</td>
<td>1.44</td>
<td>1.53</td>
<td></td>
</tr>
<tr>
<td>Lumen</td>
<td>15.58 μm²</td>
<td>17.16 μm²</td>
<td>0.295</td>
</tr>
<tr>
<td>Mean</td>
<td>(8.75 – 27.44 μm²)</td>
<td>(9.07 – 29.60 μm²)</td>
<td></td>
</tr>
<tr>
<td>Range</td>
<td>5.22</td>
<td>5.61</td>
<td></td>
</tr>
<tr>
<td>S.D</td>
<td>1.17</td>
<td>1.25</td>
<td></td>
</tr>
<tr>
<td>Vessel wall</td>
<td>4.32 μm²</td>
<td>4.16 μm²</td>
<td>0.764</td>
</tr>
<tr>
<td>Mean</td>
<td>(2.35 – 8.79 μm²)</td>
<td>(2.32 – 7.56 μm²)</td>
<td></td>
</tr>
<tr>
<td>Range</td>
<td>1.59</td>
<td>1.52</td>
<td></td>
</tr>
<tr>
<td>S.D</td>
<td>0.35</td>
<td>0.34</td>
<td></td>
</tr>
<tr>
<td>Endothelium</td>
<td>2.65 μm²</td>
<td>2.43 μm²</td>
<td>0.547</td>
</tr>
<tr>
<td>Mean</td>
<td>(1.43 – 5.73 μm²)</td>
<td>(1.37 – 4.14 μm²)</td>
<td></td>
</tr>
<tr>
<td>Range</td>
<td>1.10</td>
<td>0.90</td>
<td></td>
</tr>
<tr>
<td>S.D</td>
<td>0.25</td>
<td>0.20</td>
<td></td>
</tr>
<tr>
<td>Intramural cells</td>
<td>0.59 μm²</td>
<td>0.72 μm²</td>
<td>0.286</td>
</tr>
<tr>
<td>Mean</td>
<td>(0.19 – 1.39 μm²)</td>
<td>(0.25 – 1.77 μm²)</td>
<td></td>
</tr>
<tr>
<td>Range</td>
<td>0.33</td>
<td>0.44</td>
<td></td>
</tr>
<tr>
<td>S.D</td>
<td>0.07</td>
<td>0.10</td>
<td></td>
</tr>
<tr>
<td>Basement membrane</td>
<td>1.08 μm²</td>
<td>1.00 μm²</td>
<td>0.511</td>
</tr>
<tr>
<td>Mean</td>
<td>(0.60 – 2.28 μm²)</td>
<td>(0.57 – 1.73 μm²)</td>
<td></td>
</tr>
<tr>
<td>Range</td>
<td>0.37</td>
<td>0.31</td>
<td></td>
</tr>
<tr>
<td>S.E</td>
<td>0.08</td>
<td>0.07</td>
<td></td>
</tr>
</tbody>
</table>
Chapter 3: Results

3.5.2.3 COMPARISON OF CAPILLARIES IN WHITE AND GREY MATTER BETWEEN WILD-TYPE CONTROL AND AQP4 DEFICIENT MICE

In the grey matter of AQP4 deficient mice, capillaries had significantly larger lumina (15.58 μm² vs. 11.45 μm², p < 0.001). A significant difference in vessel area (19.90 μm² vs. 14.53 μm², p < 0.001) was accompanied by significant changes to the endothelium (2.65 μm² vs. 1.93 μm², p < 0.05), intramural cells (0.59 μm² vs. 0.35 μm², p < 0.05) and basement membrane (1.08 μm² vs. 0.80 μm², p < 0.01) (Figure 3.4).

Similar differences were observed in the white matter. Again, capillaries were found to be larger in AQP4 deficient mice with significantly larger lumina (21.32 μm² vs. 15.16 μm², p < 0.001). The vessel wall area was again significantly different (4.16 μm² vs. 3.29 μm², p < 0.05) with significant changes to the endothelium (2.43 μm² vs. 1.87 μm², p < 0.05) and intramural cells (0.72 μm² vs. 0.45 μm², p < 0.05) but not basement membrane (1.00 μm² vs. 0.88 μm², p = 0.208) (Figure 3.5).
Chapter 3: Results

Figure 3.4 Summary of capillary size metrics in grey matter between wild-type control and AQP4 deficient mice

Significant differences were observed in mean total vessel surface area and areas of lumen, vessel wall, endothelium, basement membrane and intramural cells in the grey matter between wild-type control (red) and AQP4 deficient mice (blue). Total mean vessel surface area is the sum of vessel wall area and lumen area. Each box plot represents the range of data from two mice. The scatter plots represent the means of repeated measures (20 per mouse, n = 2).
Figure 3.5 Summary of capillary size metrics in white matter between wild-type control and AQP4 deficient mice

Significant differences were observed in mean total vessel surface area and areas of lumen, vessel wall, endothelium, intramural cells but not basement membrane in the white matter between wild-type control (red) and AQP4 deficient mice (blue). Each box plot represents the range of data from two mice. The scatter plots represent the means of repeated measures (20 per mouse, n = 2).
3.5.2.4 COMPARISON OF VASCULAR WALL COMPOSITION IN CAPILLARIES FROM GREY AND WHITE MATTER BETWEEN WILD-TYPE CONTROL AND AQP4 DEFICIENT MICE

As capillaries in AQP4 deficient mice appeared significantly larger than those in wild-type control mice we next investigated if the differences in the size of the vessel and thickness of the vessel wall in the white vs. grey matter rather than genotype were responsible for the observed changes in endothelium, intramural cells and basement membrane. To account for variation in vessel size, the surface areas obtained for endothelium, intramural cells and basement membrane were normalised against the surface area of the capillary wall by converting into percentage surface area.

We first assessed each genotype for differences between grey and white matter. In wild-type control mice there were no differences in the percentage surface area of the vessel wall occupied by endothelium (62.13% vs. 58.78%, p = 0.068), intramural cells (11.30% vs. 13.37%, p = 0.205) or basement membrane (26.57% vs. 27.85%, p = 0.199). This was also observed in AQP4 deficient mice (endothelium, 60.98% vs. 58.17%, p = 0.156, basement membrane 26.28% vs. 25.12%, p = 0.291), other than the surface area occupied by intramural cells which was higher in the white matter (12.83% vs. 16.71%, p < 0.05) (Figure 3.6).

We next analysed for differences in the percentage surface area of the vessel wall occupied by endothelium, intramural cells or basement membrane in grey and white matter between the genotypes. In grey matter, there was no significant difference but in the white matter there was a significant difference in the percentage surface area of the vessel wall occupied by basement membrane (27.85 vs. 25.12%, p < 0.01) (Figure 3.6).

These results suggest that our first observations showing changes in the surface areas of the vessel wall, endothelium, basement membrane and intramural cells between genotypes were most likely influenced by differences in the vessel size and it appears that only the capillary basement membrane is altered in the white matter of AQP4 deficient mice when compared to wild-type control mice. Capillaries in the grey matter show no alterations to the endothelium, basement membrane or intramural cells.
Chapter 3: Results

Figure 3.6 Summary showing overall mean values for the percentage of the vessel wall occupied by endothelium, intramural cells and basement membrane between wild-type control and AQP4 deficient mice in white and grey matter.

In wild-type control mice, no significant differences were observed in the mean percentage area of the capillary wall occupied by endothelium, basement membrane or intramural cells between grey and white matter. In AQP4 deficient mice intramural cells occupied a larger surface area of the vessel wall in the white matter compared to grey matter. There was no significant difference in the percentage surface area of the vessel wall occupied by the endothelium, intramural cells and basement membrane in capillaries from grey matter between wild-type control and AQP4 deficient mice. In the white matter, AQP4 deficient mice showed a significantly lower percentage surface area of the vessel wall occupied by basement membrane compared to the white matter of wild-type control mice. Each box plot represents the range of data from two mice. The scatter plots represent the means of repeated measures (20 per mouse, $n = 2$).
3.6 DISCUSSION

The objective of the work in this chapter was to test the hypothesis that in mice that do not express glial aquaporin 4 the morphology of capillary intramural periarterial drainage pathways will be altered. This was investigated by using TEM to perform a detailed analysis of the size, structure and cellular composition of the capillary wall in grey and white matter of AQP4 deficient mice. This information is needed so that any differences in the structure of the vessel wall and IPAD pathway between mice deficient for AQP4 and αDB can be distinguished.

3.6.1 AQP4 AND GREY MATTER

The results in this chapter suggest that in the grey matter, the presence of AQP4 anchored to astrocyte endfeet by the DPC does not appear to be essential for the morphology of the capillary wall. In AQP4 deficient mice there were no notable differences in the ultrastructural appearance or surface area of the capillary wall occupied by endothelium, intramural cells or basement membrane. Endothelial tight junctions appeared normal and there were no obvious signs of altered fluid homeostasis such as swollen astrocyte end feet. These findings are in agreement with other studies that also show AQP4 deficient mice have no abnormalities in the function of the blood-brain barrier in the grey matter [188, 191, 195, 203].

3.6.2 AQP4 AND WHITE MATTER

In the white matter, the ultrastructural appearance of the endothelium, intramural cells and basement membrane was not affected by AQP4 genotype. Similar to grey matter, there were no morphological indicators of altered fluid homeostasis and the endothelial tight junctions appeared normal in AQP4 deficient mice. Quantitative assessment showed that in AQP4 deficient mice there was a significant reduction in the percentage surface area of the vessel wall occupied by basement membrane with a corresponding upwards trend in percentage surface area of intramural cells but no evidence of astrocyte swelling or disrupted vessel wall. This suggests that either the loss of AQP4 function is altering the capillary basement membrane without showing any morphological indicators of altered fluid homeostasis or the presence of AQP4 anchored by the DPC to astrocyte endfeet in some way, helps to maintain the integrity of the basement membranes in the white
Chapter 3: Discussion

The white matter is highly susceptible to alterations in fluid homeostasis, as seen with swelling after acute CNS injury [116, 209, 210] in the elderly, after stroke and in dementia [211]. It is most likely that the modifications seen accompanying the loss of AQP4 function impact upon the interstitial fluid homeostasis (ISF) in the white matter.

The increase in the surface area of intramural cells seen in AQP4 deficient mice suggests that the number and/or size of pericytes are increased, reflecting an increase in their function of maintaining an efficient blood-brain barrier [251]. Recent evidence from human post-mortem studies demonstrate there is a reduction of 35-45% of pericytes in the white matter of vascular dementia (VaD) or Alzheimer’s disease [81], which is in contrast to the findings in the AQP4 deficient model, suggesting that this model does not reflect the pathological findings of VaD. Furthermore, there were no morphological modifications observed in the capillary wall in the grey matter of mice deficient for AQP4. Since there are functional changes to AQP4 in brain tumours [104, 105], cerebral ischemia [106, 107] and traumatic brain injury [108], it appears that the predominant role of AQP4 in the brain is to respond to altered water homeostasis initiated by pathology, playing a fundamental role in oedema resolution associated with modifications of the vascular wall.

3.6.3 CONCLUSIONS

In the grey matter of AQP4 deficient mice, the morphology of the capillary wall is similar to that of the wild-type mice. However, the surface area occupied by basement membrane is reduced in capillary walls in the white matter of AQP4 deficient mice compared to wild-type mice. AQP4 deficient mice also showed an increase in surface area occupied by intramural cells in the white matter compared to grey matter in contrast to recent evidence from human post-mortem studies [81]. Other cerebral vessels such as arterioles were not analysed for possible changes to the vessel wall. Future work incorporating other vessels types would help to ascertain if the observations reported here are limited to capillaries.

The AQP4 deficient mice used in this study were not tested for their efficiency in the IPAD of solutes. However, recent studies have demonstrated that in AQP4 deficient mice there is a normal interchange of cerebrospinal fluid with ISF and the
diffusion of tracers through the brain parenchyma was non-directional and size dependent suggesting that drainage by IPAD would be unaffected [166, 252, 253].

In conclusion, the results in this chapter demonstrate that anchoring of AQP4 to astrocyte endfeet by association with α-DB and the DPC is important for the structure and arrangement of the capillary wall in the white matter alone and not the grey matter.

It is important to note that sample group size was limited in this study due to tissue samples used from our collaborators in Japan. This was mitigated by increasing the number of vessels analysed per sample.
Chapter 4  LOSS OF ALPHA-DYSTROBREVIN FROM ASTROCYTE ENDFEET AND THE MORPHOLOGY OF THE INTRAMURAL PERIARTERIAL DRAINAGE PATHWAY
4.1 INTRODUCTION

α-dystrobrevin (α-DB), a key intracellular protein of the dystrophin associated protein complex (DPC), indirectly anchors transcellular proteins such as aquaporin 4 (AQP4) to the cell membrane through its interaction with syntrophin [139, 146] (Figure 1.12). This interaction is disrupted in mice deficient for α-DB, as the mutation leads to mislocalisation of transcellular proteins (potassium channel Kir4.1 and AQP4) from astrocyte endfeet to the astrocyte cell body [139, 146, 147]. Work in the previous chapter demonstrated that loss of AQP4 from astrocyte endfeet does not significantly alter morphology of the capillary wall and IPAD pathways in the grey matter. A reduction in the percentage surface area of capillary basement membrane was observed in the white matter, most likely as a consequence of loss of AQP4 function.

Previous studies show that in α-DB deficient mice, there are alterations to blood-brain barrier function at 3 months of age, demonstrated by increased perivascular extravasations of both injected Evans blue dye and blood-borne proteins in the brain. At 18 months of age these mice display disrupted endothelial cells and astrocyte endfeet [146] but there are no reports detailing the anatomy of the cerebral vasculature in young α-DB deficient mice.

A key feature in cerebral small vessel disease (CSVD) and vascular dementia (VaD) is remodelling of the extracellular matrix (ECM). In particular, changes to collagen IV (COL4) and laminin, critical proteins for ECM stability, are altered in animal models of ageing [74], in animal models of vascular dysfunction such as the spontaneously hypertensive rat (SHR) [173], in human ageing [68] and in neurodegenerative disease such as Alzheimer’s Disease (AD) [69] and Parkinson’s disease [254]. Reduced levels of laminin have been associated with changes in capillary basement membrane in aged mice in regions of the brain most affected by CSVD. The occurrence of cerebral amyloid angiopathy (CAA) in these regions, together with alterations to other extracellular matrix proteins such as fibronectin, perlecan, nidogens and COL4 [74] suggest a strong link between alterations to ECM proteins and reduced fluid clearance by intramural periarterial drainage (IPAD). Astrocytes cultured from α-DB deficient mice produce ECM with less laminin compared to normal wild-type astrocytes and have abnormal interactions with brain endothelial cells [146]. However, the effect of the α-DB protein on other ECM
proteins, such as COL4 is not known. This is important in the context of understanding the mechanisms behind CSVD.

In this chapter, mice that do not express α-DB are used to test the hypothesis that the absence of α-DB from astrocyte endfeet alters the morphology of the capillary wall and IPAD pathways. Transmission electron microscopy (TEM) is used to analyse the ultrastructure of capillaries in the grey matter and then compare these to those in the white matter. Immunohistochemistry for components of the ECM is used on both white and grey matter to analyse changes in composition of capillary basement membrane.
4.2 HYPOTHESIS

In mice genetically modified for alpha-dystrobrevin, the morphology of capillary intramural periarterial drainage pathways are altered.
Chapter 4: Aims

4.3 AIMS

The work detailed in this chapter aims to investigate whether the loss of $\alpha$-DB from astrocytic endfeet alters the morphology of the capillary wall and IPAD pathways. Mice deficient for $\alpha$-DB are used to perform a detailed ultrastructural study of the capillary wall in grey and white matter using electron microscopy. The basement membrane marker COL4 is assessed using immunohistochemistry (Figure 4.1).

Figure 4.1 alpha dystrobrevin and the dystrophin associated protein complex

Does the loss of $\alpha$-DB from astrocytic endfeet alter the morphology of the capillary intramural periarterial drainage pathway?
4.4 MATERIALS & METHODS

For this chapter, brains from α-DB deficient mice (B6;129-Dtna<sup>tm1Jrs</sup>/J) [239] and wild-type control mice were either processed for TEM (n = 3 per genotype) or for immunohistochemistry (n = 3 per genotype) for COL4 (Rabbit anti-collagen IV, abcam, ab6586) following our published protocols [160, 243]. For more details see sections 2.1.2 and 2.2.

4.4.1 TRANSMISSION ELECTRON MICROSCOPY

Tissue imbedded in resin blocks was sectioned and prepared for TEM as detailed in section 2.2. Imaging and analysis of the structure and arrangement of the capillary wall in grey and white matter was performed as per sections 2.2.5 and 2.2.6. Briefly, high resolution low power images of 20 capillaries from grey matter and 20 capillaries from white matter from each mouse were digitally photographed and analysed qualitatively for ultrastructural changes to endothelial cells, intramural cells and basement membrane. Each capillary was also quantitatively assessed for surface area measurements by image segmentation. Statistical analysis was performed using SPSS and a univariate Analysis of Variance (two-way Anova) adjusting for repeated measures (20 per region per mouse) with significance set at P < 0.05. For more details see sections 2.2.7.

4.4.2 IMMUNOHISTOCHEMISTRY

Enzyme-linked immunohistochemistry using 3,3′-Diaminobenzidine (DAB) as chromogen was used to visualise COL4 positive vessels in grey and white matter using 20 μm coronal frozen sections as detailed in section 2.3. Statistical analysis was performed using SPSS and an independent <i>t</i>-test with significance set at P < 0.05.
4.5 RESULTS

4.5.1 ULTRASTRUCTURAL ASSESSMENT OF THE CAPILLARY WALL IN GREY AND WHITE MATTER IN ALPHA DYSTROBREVIN DEFICIENT MICE

To establish whether a lack of α-DB at astrocyte endfeet affects the morphology of the capillary wall, the structural appearance of endothelium, intramural cells and basement membrane of capillaries from the white matter and grey matter between α-DB deficient and wild-type control mice were compared by electron microscopy.

When compared to wild-type control mice, electron microscopy revealed the appearance of the capillary wall to be altered with a thickened basement membrane in α-DB deficient mice in both grey and white matter. There were no notable differences in the appearance of the endothelium and intramural cells or the surrounding parenchyma (Figure 4.2 and Figure 4.3).
Figure 4.2 The structural appearance of the capillary wall in the grey matter appears altered in mice deficient for α-DB

Electron micrographs false coloured to highlight the endothelium (blue), intramural cells (green) and basement membrane (orange). The structural appearance of the capillary wall in α-DB deficient mice (b) appears to be altered in the grey matter when compared to wild-type control mice (a). Basement membranes (b3 & a3, orange) appear notably thicker in α-DB deficient mice. Endothelial cells and tight junctions (b1 & a1, blue) and intramural cells (b2 & a2, green) appeared similar in both genotypes. The red arrows in (a) indicate the location of glial α-DB in wild-type control mice.
Figure 4.3 The structural appearance of the capillary wall in the white matter appears altered in mice deficient for α-DB

Electron micrographs false coloured to highlight the endothelium (blue), intramural cells (green) and basement membrane (orange). The structural appearance of the capillary wall in α-DB deficient mice (b) appears to be altered in the white matter when compared to wild-type control mice (a). Basement membranes (b3 & a3, orange) appear thicker in α-DB deficient mice. Endothelial cells and tight junctions (b1 & a1, blue) and intramural cells (b2 & a2, green) appeared similar in both genotypes. The red arrows in (a) indicate the location of glial α-DB in wild-type control mice.
4.5.2 IMAGE SEGMENTATION AND SURFACE AREA MEASUREMENTS

To confirm our observations that the capillary basement membrane appeared thicker in α-DB deficient mice, each capillary (n = 20 per region per mouse) was analysed for changes in composition of the vessel wall. Image segmentation as per chapter 3 was performed to measure each capillary for the surface area of the vessel wall, endothelium, intramural cells, basement membrane, lumen and overall area. Similar to the previous chapter, we first assessed for differences between capillaries in grey and white matter in each genotype and then compared these differences between genotypes.

4.5.2.1 COMPARISON OF CAPILLARIES IN WHITE AND GREY MATTER IN WILD-TYPE CONTROL MICE

In wild-type control mice, capillaries in the white matter appeared larger than those in the grey matter. Univariate Analysis of Variance (two-way Anova with P < 0.05) revealed significant differences in the surface areas of endothelium (2.37 μm² vs. 1.43 μm², p < 0.001), intramural cells (0.60 μm² vs. 0.32 μm², p < 0.001) and basement membrane (1.18 μm² vs. 0.65 μm², p < 0.001) resulting in larger white matter capillaries (10.59 μm² vs. 8.02 μm², p < 0.01) with thicker vessel walls (4.16 μm² vs. 2.40 μm², p < 0.001). There was no difference in the surface area of the lumen (5.62 μm² vs. 5.43 μm², p = 0.219) (Table 3).

4.5.2.2 COMPARISON OF CAPILLARIES IN WHITE AND GREY MATTER IN ALPHA DYSTROBREVIN DEFICIENT MICE

In α-DB deficient mice, capillaries in the white matter showed significantly larger surface areas of endothelium (2.16 μm² vs. 1.79 μm², p < 0.05), basement membrane (1.16 μm² vs. 0.92 μm², p < 0.05) and vessel wall (3.79 μm² vs. 3.08 μm², p < 0.05). However, there was no difference in overall vessel size, possibly due to the lack of significant change in the surface area of intramural cells (0.48 μm² vs. 0.38 μm², P = 0.094). There was also no difference in the surface area of the lumen (8.74 μm² vs. 8.91 μm², p = 0.409) (Table 4).
<table>
<thead>
<tr>
<th></th>
<th>Grey matter</th>
<th>White matter</th>
<th>Sig.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Overall vessel size</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean</td>
<td>8.02 µm²</td>
<td>10.59 µm²</td>
<td>&lt; 0.01</td>
</tr>
<tr>
<td>Range</td>
<td>(5.67 - 10.88 µm²)</td>
<td>(6.22 - 19.95 µm²)</td>
<td></td>
</tr>
<tr>
<td>S.D</td>
<td>1.33</td>
<td>3.24</td>
<td></td>
</tr>
<tr>
<td>S.E</td>
<td>0.30</td>
<td>0.73</td>
<td></td>
</tr>
<tr>
<td><strong>Lumen</strong></td>
<td></td>
<td></td>
<td>0.219</td>
</tr>
<tr>
<td>Mean</td>
<td>5.62 µm²</td>
<td>6.43 µm²</td>
<td></td>
</tr>
<tr>
<td>Range</td>
<td>(3.57 - 7.71 µm²)</td>
<td>(2.91 - 12.86 µm²)</td>
<td></td>
</tr>
<tr>
<td>S.D</td>
<td>1.10</td>
<td>2.37</td>
<td></td>
</tr>
<tr>
<td>S.E</td>
<td>0.25</td>
<td>0.53</td>
<td></td>
</tr>
<tr>
<td><strong>Vessel wall</strong></td>
<td></td>
<td></td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>Mean</td>
<td>2.40 µm²</td>
<td>4.16 µm²</td>
<td></td>
</tr>
<tr>
<td>Range</td>
<td>(2.00 - 3.22 µm²)</td>
<td>(2.43 - 7.08 µm²)</td>
<td></td>
</tr>
<tr>
<td>S.D</td>
<td>0.33</td>
<td>1.08</td>
<td></td>
</tr>
<tr>
<td>S.E</td>
<td>0.07</td>
<td>0.24</td>
<td></td>
</tr>
<tr>
<td><strong>Endothelium</strong></td>
<td></td>
<td></td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>Mean</td>
<td>1.43 µm²</td>
<td>2.37 µm²</td>
<td></td>
</tr>
<tr>
<td>Range</td>
<td>(1.06 - 1.84 µm²)</td>
<td>(1.30 - 3.81 µm²)</td>
<td></td>
</tr>
<tr>
<td>S.D</td>
<td>0.19</td>
<td>0.58</td>
<td></td>
</tr>
<tr>
<td>S.E</td>
<td>0.04</td>
<td>0.13</td>
<td></td>
</tr>
<tr>
<td><strong>Intramural cells</strong></td>
<td></td>
<td></td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>Mean</td>
<td>0.32 µm²</td>
<td>0.60 µm²</td>
<td></td>
</tr>
<tr>
<td>Range</td>
<td>(0.17 - 0.58 µm²)</td>
<td>(0.29 - 1.27 µm²)</td>
<td></td>
</tr>
<tr>
<td>S.D</td>
<td>0.10</td>
<td>0.26</td>
<td></td>
</tr>
<tr>
<td>S.E</td>
<td>0.02</td>
<td>0.06</td>
<td></td>
</tr>
<tr>
<td><strong>Basement membrane</strong></td>
<td></td>
<td></td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>Mean</td>
<td>0.65 µm²</td>
<td>1.18 µm²</td>
<td></td>
</tr>
<tr>
<td>Range</td>
<td>(0.52 - 0.98 µm²)</td>
<td>(0.84 - 2.00 µm²)</td>
<td></td>
</tr>
<tr>
<td>S.D</td>
<td>0.10</td>
<td>0.33</td>
<td></td>
</tr>
<tr>
<td>S.E</td>
<td>0.02</td>
<td>0.07</td>
<td></td>
</tr>
</tbody>
</table>

Table 3: Comparison of capillary size metrics between grey and white matter in wild-type control mice
### Table 4: Comparison of capillary size metrics between grey and white matter in α-DB deficient mice

<table>
<thead>
<tr>
<th></th>
<th>Grey matter</th>
<th>White matter</th>
<th>Sig.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Overall vessel size</strong></td>
<td>Mean: 11.82 µm²</td>
<td>Mean: 10.68 µm²</td>
<td>0.353</td>
</tr>
<tr>
<td></td>
<td>Range: (8.04 - 22.34 µm²)</td>
<td>Range: (6.47 - 14.57 µm²)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>S.D: 3.34</td>
<td>S.D: 2.82</td>
<td></td>
</tr>
<tr>
<td></td>
<td>S.E: 0.755</td>
<td>S.E: 0.63</td>
<td></td>
</tr>
<tr>
<td><strong>Lumen</strong></td>
<td>Mean: 8.74 µm²</td>
<td>Mean: 8.91 µm²</td>
<td>0.409</td>
</tr>
<tr>
<td></td>
<td>Range: (5.54 - 17.88 µm²)</td>
<td>Range: (3.52 - 12.86 µm²)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>S.D: 2.80</td>
<td>S.D: 2.54</td>
<td></td>
</tr>
<tr>
<td></td>
<td>S.E: 0.63</td>
<td>S.E: 0.57</td>
<td></td>
</tr>
<tr>
<td><strong>Vessel wall</strong></td>
<td>Mean: 3.08 µm²</td>
<td>Mean: 3.79 µm²</td>
<td>&lt; 0.05</td>
</tr>
<tr>
<td></td>
<td>Range: (2.49 - 5.17 µm²)</td>
<td>Range: (2.84 - 4.82 µm²)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>S.D: 0.70</td>
<td>S.D: 0.61</td>
<td></td>
</tr>
<tr>
<td></td>
<td>S.E: 0.16</td>
<td>S.E: 0.14</td>
<td></td>
</tr>
<tr>
<td><strong>Endothelium</strong></td>
<td>Mean: 1.79 µm²</td>
<td>Mean: 2.16 µm²</td>
<td>&lt; 0.05</td>
</tr>
<tr>
<td></td>
<td>Range: (1.24 - 2.97 µm²)</td>
<td>Range: (1.61 - 2.91 µm²)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>S.D: 0.44</td>
<td>S.D: 0.40</td>
<td></td>
</tr>
<tr>
<td></td>
<td>S.E: 0.10</td>
<td>S.E: 0.09</td>
<td></td>
</tr>
<tr>
<td><strong>Intramural cells</strong></td>
<td>Mean: 0.38 µm²</td>
<td>Mean: 0.48 µm²</td>
<td>0.094</td>
</tr>
<tr>
<td></td>
<td>Range: (0.18 - 0.67 µm²)</td>
<td>Range: (0.22 - 0.83 µm²)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>S.D: 0.12</td>
<td>S.D: 0.17</td>
<td></td>
</tr>
<tr>
<td></td>
<td>S.E: 0.03</td>
<td>S.E: 0.04</td>
<td></td>
</tr>
<tr>
<td><strong>Basement membrane</strong></td>
<td>Mean: 0.92 µm²</td>
<td>Mean: 1.16 µm²</td>
<td>&lt; 0.05</td>
</tr>
<tr>
<td></td>
<td>Range: (0.67 - 1.53 µm²)</td>
<td>Range: (0.83 - 1.47 µm²)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>S.D: 0.22</td>
<td>S.D: 0.19</td>
<td></td>
</tr>
<tr>
<td></td>
<td>S.E: 0.05</td>
<td>S.E: 0.04</td>
<td></td>
</tr>
</tbody>
</table>
Chapter 4: Results

4.5.3 COMPARISON OF CAPILLARIES IN WHITE AND GREY MATTER BETWEEN WILD-TYPE CONTROL AND ALPHA DYSTROBREVIN DEFICIENT MICE

As observed in the previous chapter with AQP4 deficient mice, capillaries in the grey matter of α-DB deficient mice were also significantly larger in overall surface area (11.82 μm² vs. 8.02 μm², p < 0.01) with larger lumina (8.74 μm² vs. 5.62 μm², p < 0.001) than those in wild-type controls. A Significant difference in vessel wall area was observed (3.08 μm² vs. 2.40 μm², p = < 0.001) with changes to the endothelium (1.79 μm² vs. 1.43 μm², p < 0.01) and basement membrane (0.92 μm² vs. 0.65 μm², p < 0.001) (Figure 4.4). No differences were observed in the white matter (Figure 4.5).
Figure 4.4 Summary of capillary size metrics in grey matter between wild-type control and α-DB deficient mice

Significant differences were observed in the mean total vessel surface area and areas of lumen, vessel wall, endothelium and basement membrane in the grey matter between wild-type control (red) and α-DB deficient mice (blue). Each box plot represents the range of data from three mice. The scatter plots represent the means of repeated measures (20 per mouse, n = 3).
Figure 4.5 Summary of capillary size metrics in white matter between wild-type control and α-DB deficient mice

There were no significant differences in mean total vessel surface area and areas of lumen, vessel wall, endothelium, basement membrane or intramural cells in the white matter between wild-type control (red) and α-DB deficient mice (blue). Each box plot represents the range of data from three mice. The scatter plots represent the means of repeated measures (20 per mouse, n = 3).
4.5.4 COMPARISON OF VASCULAR WALL COMPOSITION IN CAPILLARIES FROM GREY AND WHITE MATTER BETWEEN WILD-TYPE CONTROL AND ALPHA DYSTROBREVIN DEFICIENT MICE

Work in the previous chapter (chapter 3) demonstrated that the removal of AQP4 from astrocyte endfeet in the grey matter had very little effect on the morphology of the capillary wall, after accounting for differences in vessel size by normalising data into percentage surface area. As capillaries were significantly larger in the grey matter but not in the white matter of α-DB deficient mice the same normalisation step was repeated to assess whether the differences observed in grey matter capillaries were due to vessel size or genotype.

Each genotype was analysed for differences between grey and white matter. In wild-type control mice there were no differences in the percentage surface area of the vessel wall occupied by endothelium (59.82% vs. 57.07%, p = 0.051), intramural cells (12.88% vs. 14.41%, p = 0.349) or basement membrane (27.27% vs. 28.52%, p = 0.128). This was also observed in α-DB deficient mice (endothelium, 58.78% vs. 57.25%, p = 0.156, intramural cells, 11.00% vs. 12.51%, p = 0.206 and basement membrane 30.22% vs. 30.24%, p = 0.291) (Figure 4.6).

The percentage surface area of the vessel wall occupied by endothelium, intramural cells or basement membrane in grey and white matter were analysed and compared between the genotypes. In both grey and white matter, there was no significant difference in the percentage surface area of the vessel wall occupied by the endothelium or intramural cells. However, the surface area of the vessel wall occupied by basement membrane was significantly higher in α-DB deficient mice in both grey matter (27.28% vs. 30.22%, p < 0.01) and white matter (28.52% vs. 30.24%, p < 0.05) (Figure 4.6).

As with our findings for the AQP4 deficient mice (chapter 3) these results suggest that changes in capillary size metrics between genotypes (Figure 4.4 and Figure 4.5) was most likely influenced by differences in the vessel size rather than genotype. These results show that only the capillary basement membrane and not other components of the vessel wall are altered in the grey (p < 0.01) and white matter (p < 0.05) of α-DB deficient mice. This is supported by the appearance of
Chapter 4: Results

the basement membrane as observed by transmission electron microscopy (Figure 4.2 and Figure 4.3).

Figure 4.6 Summary showing overall mean values for the percentage of the vessel wall occupied by endothelium, intramural cells and basement membrane between wild-type control and α-DB deficient mice in white and grey matter.

In both wild-type control and α-DB deficient mice there was no significant difference in the percentage surface area of the vessel wall occupied by the endothelium, basement membrane or intramural cells between capillaries from grey or white matter in the same mouse. However, when compared to wild-type control mice, the surface area of the vessel wall occupied by basement membrane was significantly higher in both grey and white matter in α-DB deficient mice. Each box plot represents the range of data from three mice. The scatter plots represent the means of repeated measures (20 per mouse, n = 3).
4.5.5 ALTERATIONS TO THE BIOCHEMICAL COMPOSITION OF VASCULAR BASEMENT MEMBRANES IN ALPHA DYSTROBREVIN DEFICIENT MICE

Morphological changes to cerebral vascular basement membranes, such as thickening have long been associated with alterations to their biochemical composition. The next questioned addressed was whether the morphological alterations (Figure 4.2 and Figure 4.3) and changes in percentage surface area of the vessel wall occupied by basement membrane (Figure 4.6) in α-DB deficient mice were accompanied by changes in expression of COL4, a key structural component of vascular basement membranes.

Immunohistochemistry for COL4 was performed on grey matter and underlying white matter as detailed in section 2.3. Qualitative assessment by light microscopy was accompanied by quantitative analysis of the expression of COL4 between vessels in the grey matter and white matter by comparing the number of vessels (vessel density), mean area stained per vessel and in the grey matter, vessel distribution.

4.5.5.1 COMPARISON OF THE PATTERN OF COLLAGEN IV STAINING BETWEEN WILD-TYPE CONTROL AND ALPHA DYSTROBREVIN DEFICIENT MICE

Qualitative assessment revealed that the majority of COL4 immunoreactivity was confined to vascular walls that appeared more intense and less diffuse in the grey matter of α-DB deficient mice. There were no notable differences in the white matter which appeared similar to the pattern of COL4 staining seen in the grey matter of wild-type control mice (Figure 4.7).
Chapter 4: Results

<table>
<thead>
<tr>
<th>Wild-type control</th>
<th>α-DB deficient</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grey matter</td>
<td></td>
</tr>
<tr>
<td><img src="a" alt="Image" /></td>
<td><img src="b" alt="Image" /></td>
</tr>
<tr>
<td>White matter</td>
<td></td>
</tr>
<tr>
<td><img src="c" alt="Image" /></td>
<td><img src="d" alt="Image" /></td>
</tr>
</tbody>
</table>

Figure 4.7 Immunostaining for COL4 in wild type control and α-DB deficient mice

Staining for COL4 (black) appears more intense and less diffuse (red arrows) in the grey matter of α-DB deficient mice (b) when compared to wild-type control mice (a). There are no obvious differences in staining for COL4 in the white matter between wild-type control and α-DB deficient mice (c & d) which appeared similar to that of grey matter in wild-type control mice (a). Scale bar = 20 µm.
Chapter 4: Results

4.5.5.2 COMPARISON OF VESSEL DENSITY AND AMOUNT OF COLLAGEN IV STAINING BETWEEN WILD-TYPE CONTROL AND ALPHA DYSTROBREVIN DEFICIENT MICE

Vessels from each genotype were analysed for differences in vessel density (mean number of vessels per 0.5mm²) and mean area of COL4 staining per vessel (expressed as μm²) by using micrographs of grey and white matter and a custom macro in Image J (see section 2.3 for detailed methods).

Analysis in wild-type control mice revealed a significant higher density of vessels in the grey matter (196.27 vessels per 0.5 mm²) compared to the white matter (112 vessels per 0.5 mm²) p = < 0.05 but no difference in the mean area of COL4 staining per vessel (14.48 μm² vs. 18.16 μm², p = 0.765) (Figure 4.8). A similar pattern of vessel density was seen in α-DB deficient mice, but the differences were not significant with 166.4 vessels per 0.5 mm² in grey matter compared to 133.33 vessels per 0.5 mm² in the white matter, p = 0.065. However, in α-DB deficient mice the mean area of COL4 staining per vessel was significantly higher in the grey matter (56.04 μm²) than the white matter (19.31 μm²), p < 0.05 (Figure 4.9).

Comparison of vessel density between wild-type control and α-DB deficient mice revealed no differences in either grey matter (196.27 vs. 166.4 vessels per 0.5 mm², p = 0.222) or white matter (112 vs. 133.33 vessels per 0.5 mm², p = 0.207). There were no differences in mean area of COL4 staining per vessel in the white matter (18.16 μm² vs. 19.31 μm², p = 0.926) but in the grey matter, α-DB deficient mice showed a significant higher mean area of COL4 staining per vessel when compared to the grey matter of wild-type control mice (56.05 μm² vs. 14.48 μm², p < 0.01) (Figure 4.10).
Figure 4.8 Vessel density and COL4 staining per vessel between grey and white matter in wild-type control mice

Comparison of the number of vessels per 0.5mm² revealed significant differences between grey and white matter (a & c). There were no differences in the mean area of COL4 staining per vessel (b & c). The scatter plots represent mean values for each mouse. Each column represents overall mean values (n = 3). Error bars: +/- 2 SE
Figure 4.9 Vessel density and COL4 staining per vessel between grey and white matter in α-DB deficient mice

Comparison of the number of vessels per 0.5 mm² revealed no significant differences between grey and white matter (a & c) but there was a significant difference in the mean area of COL4 staining per vessel, which was higher in the grey matter (b & c). The scatter plots represent mean values for each mouse. Each column represents overall mean values (n = 3). Error bars: +/- 2 SE
Figure 4.10 Vessel density and COL4 staining per vessel in grey and white matter between wild-type control and α-DB deficient mice

Comparison of the number of vessels per 0.5 mm² revealed no significant differences in grey and white matter (a) between wild-type control (red columns) and α-DB deficient mice (blue columns). There was a significant difference in the mean area of COL4 staining per vessel, which was higher in the grey matter of α-DB deficient mice compared to the grey matter of wild-type control mice (b). The scatter plots represent mean values for each mouse. Each column represents overall mean values (n = 3). Error bars: +/- 2 SE
4.5.5.3 COMPARISON OF VESSEL DISTRIBUTION AND AMOUNT OF COLLAGEN IV STAINING IN GREY MATTER BETWEEN WILD-TYPE CONTROL AND ALPHA DYSTROBREVIN DEFICIENT MICE

As there was no difference in vessel density but a large difference in mean area staining per vessel of COL4 in the grey matter between wild-type control and α-DB deficient mice, we next assessed whether this large difference could be attributed to possible changes in the pattern of distribution of the individual type of blood vessels.

Vessel density in the grey matter of wild-type control and α-DB deficient mice was reclassified into the number of capillaries (vessels with diameter of less than 10 µm) or larger vessels (vessels with a diameter of 10 µm or larger). DAB staining did not allow for the differentiation of arterioles from venules, so these were classified together as vessel with a diameter of 10 µm or larger.

There was no significant difference in the distribution of capillaries in the grey matter between wild-type control (188 per 0.5 mm²) and α-DB deficient mice (156 per 0.5 mm²), p = 0.173. There was also no difference in the distribution of arterioles and venules (8 per 0.5 mm² vs. 10 per 0.5 mm², p = 0.275). However, in α-DB deficient mice, capillaries and arterioles and venules showed a significantly higher mean area staining of COL4 per vessel (capillaries, 49.25 µm² vs 11.00 µm², p <0.05, arterioles and venules, 162.75 µm² vs 96.27 µm², p < 0.05) (Figure 4.11).

These data suggest that the large difference in mean area staining per vessel of COL4 observed in the grey matter of α-DB deficient mice is most likely linked to a loss of α-DB and not due to any alterations to the anatomical pattern of distribution of blood vessel type.
Chapter 4: Discussion

Figure 4.11 Vessel distribution and COL4 staining in grey matter wild-type control and α-DB deficient mice

There was no difference in the number of capillaries or arterioles and venules in the grey matter (a & c). However, in α-DB deficient mice the mean area of COL4 staining was significantly higher in capillaries, arterioles and venules when compared to wild-type control mice (b & c). The scatter plots represent mean values for each mouse. Each bar column represents overall mean values (n = 3). Error bars: +/- 2 SE
Chapter 4: Discussion

4.6 DISCUSSION

The objective of the work detailed in this chapter was to investigate whether the loss of \( \alpha \)-DB from astrocytic endfeet alters the structure and arrangement of the capillary wall and IPAD pathways. The hypothesis tested was: **In mice genetically modified for alpha-dystrobrevin, the morphology of capillary intramural periarterial drainage pathways are altered.** This was investigated by using TEM to perform a detailed analysis of the size, structure and cellular composition of the capillary wall in grey and white matter of \( \alpha \)-DB deficient mice. Vascular basement membranes were also assessed for compositional changes in expression of COL4, a key structural protein that is altered in neurodegenerative diseases.

4.6.1 THE MORPHOLOGY OF THE BLOOD-BRAIN BARRIER IS UNALTERED IN YOUNG ALPHA DYSTROBREVIN DEFICIENT MICE

Earlier studies of the cerebral vasculature in \( \alpha \)-DB deficient mice showed the importance of the DPC in the maintenance and function of the blood-brain barrier in the grey matter but up until now, no one has investigated the white matter. Observations by Lien et.al in 18-month-old mice revealed that in the grey matter, deleting \( \alpha \)-DB from astrocyte endfeet resulted in a leaky blood-brain barrier, structural abnormalities to the capillary endothelium, thickened capillary basement membranes and swollen astrocytic endfeet [146]. This in part, could be linked to loss of AQP4 function at astrocyte endfeet as a lack of \( \alpha \)-DB causes a redistribution of AQP4 from astrocyte endfeet to the astrocytic cell body [146]. Although we did not test our mice for blood-brain barrier function, electron microscopy did not reveal any notable abnormalities in the capillary endothelium or surrounding parenchyma in either grey or white matter to suggest a link between a lack of glial \( \alpha \)-DB and impaired blood-brain barrier function in young adult \( \alpha \)-DB deficient mice. It appears therefore, that redistribution of AQP4 away from astrocyte endfeet in young \( \alpha \)-DB deficient mice has minimal effect on BBB function.

4.6.2 THE CAPILLARY BASEMENT MEMBRANE IS THICKENED IN ALPHA DYSTROBREVIN DEFICIENT MICE

Morphological changes to cerebral vascular basement membranes are associated with modifications to their biochemical composition. Alterations to laminins and
increases in the expression of COL4 have been measured in cerebral vessel basement membranes in aged human brains [68] and neurodegenerative conditions such as AD and Parkinson’s disease [69, 254]. Glycoprotein components of the ECM such as COL4, laminin and nidogens interact with amyloid beta (Aβ) and destabilise preformed Aβ fibrils [73] while proteoglycans, such as perlecan and agrin appear to accelerate Aβ aggregation [71, 72].

In α-DB deficient mice a thickening of capillary basement membrane in the grey matter accompanied by an increase in the expression of COL4 were observed. In the grey matter we showed that all vessels (capillaries, arterioles and venules) display an increase in COL4 expression. The thickening of the capillary basement membranes was also observed in the white matter, but to a lesser extent compared to the grey matter. Although electron microscopy on arterioles or venules was not performed, the data does suggest that an altered DPC affects the ECM around all vessel types in the grey matter. It is not known if expression of other ECM proteins would also be altered but experiments showing altered laminin production in cocultures of α-DB deficient astrocytes and endothelial cells [146] suggest that this may be the case. Further work utilising a more detailed approach to fully appreciate changes to the biochemical profile of the ECM with a focus on cerebrovascular basement membranes will clarify the exact components of the cerebrovascular basement membranes that are at risk from the modifications of the DPC.

4.6.3 WHY DOES REMOVAL OF ALPHA DYSTROBREVIN CAUSE THICKENING OF CAPILLARY BASEMENT MEMBRANE?

The exact reasons as to why the removal of α-DB disrupts the capillary basement membrane are unclear but considering that α-DB is entirely an intracellular protein its role in the formation and maintenance of the basement membrane must include indirect interactions via the DPC. Astrocyte endfeet are anchored to the vessel wall by interactions between α-dystroglycan and ECM proteins including laminins, perlecan, agrin, and the neurexins. α-dystroglycan binds to β-dystroglycan which is anchored to the cell membrane by dystrophin (DP71). α-DB binds directly to DP71 by reciprocal coiled-coil interactions. This binding helps stabilise transmembrane proteins which are anchored to the cell membrane by syntrophins and C-terminal tail binding to PDZ domains (acronym for Post synaptic density protein, Drosophila disc large tumor suppressor and Zonula occludens-1 protein) (Figure 1.12 & Figure
It is entirely possible that deletion of α-DB from the DPC destabilises the interaction between DP71 and the dystroglycan proteins weakening the connection between α-dystroglycan and ECM proteins. This may stimulate over production of the ECM proteins resulting in a thickened basement membrane with altered morphology.

Conversely, a lack of α-DB may also down regulate other DPC proteins which, in turn, may indirectly affect remodelling of the ECM and basement membrane by the actions of matrix metalloproteases (MMP)s. ECM is regulated by a homeostatic balance of MMPs which are endopeptidases that digest ECM proteins, and TIMPs that inhibit the activity of MMPs [255]. In particular, MMP9, also known as Gelatinase B, is a COL4 collagenase [256] implicated in synaptic plasticity, memory and learning [257, 258] and several neurological disorders such as stroke and small vessel disease [259]. Expression patterns of DPC proteins are altered in α-DB deficient astrocytes with decreased levels of DP71 and α- and β-dystroglycans [146]. β-dystroglycan has been identified as a substrate for MMP 9 and is digested in response to enhanced synaptic activity [260]. It is possible that in α-DB deficient mice the regulation of the ECM and capillary basement membrane by the actions of MMP9 is altered as a direct result of reduced availability of β-dystroglycan substrate. Further work is required to confirm this as although reductions of DPC proteins have been observed in α-DB deficient astrocytes, this has not been elucidated in α-DB deficient mice. In future work, other components of the basement membranes as well as levels of MMP9 and its substrate TIMP3 will be analysed in α-DB deficient mice. In order to back-translate the significance of these results, the expression of α-DB should be analysed in post-mortem human brains from CSVD and VaD.

### 4.6.4 CONCLUSIONS

The structure and arrangement of the capillary wall and IPAD pathway is affected by a lack of α-DB at astrocyte endfeet in both the grey and white matter. The surface area occupied by basement membrane is increased in capillary walls and appears thickened as seen with TEM. This is accompanied by alterations in overall expression of COL4 in the grey matter but not the white matter. Other cerebral vessels such as arterioles were not analysed by TEM but the increase in expression of COL4 in larger vessels in the grey matter suggest that the basement membrane
Chapter 4: Discussion

would also be altered in these vessels. Future work incorporating other vessel types would help to confirm this.

The alterations to the IPAD pathway at capillary level reported here suggest that disruption of the DPC at glial endfeet by the removal of α-DB alters the biochemical and structural properties of the IPAD pathway. Thickening of the capillary basement membrane and remodelling of the microvascular ECM are common features in CSVD [15, 67]. Therefore, α-DB deficient mice may provide a suitable model to investigate the potential role of a failure of IPAD in CSVD and VaD. These findings may also have wider implications for other drainage pathways in the brain (see section 1.3.4) such as convective influx of CSF that occurs along pial-glial basement membranes [245] which may also be directly influenced by α-DB.

The next logical step is to assess for IPAD in α-DB deficient mice to ascertain if changes to the IPAD pathway observed in this chapter are reflected in failed fluid clearance by IPAD.
Chapter 5  LOSS OF ALPHA-DYSTROBREVIN FROM ASTROCYTE ENDFEET AND THE DYNAMICS OF INTRAMURAL PERIARTERIAL DRAINAGE
5.1 INTRODUCTION

Work detailed in the previous chapter demonstrates how the structure and arrangement of the capillary wall and the intramural periarterial drainage (IPAD) pathway is affected by removal of $\alpha$-dystrobrevin ($\alpha$-DB) from the dystrophin associated protein complex (DPC) of astrocyte endfeet. In particular, the surface area occupied by basement membrane is increased in capillary walls in both grey and white matter in $\alpha$-DB deficient mice. This is accompanied by alterations to the biochemical composition of basement membrane in grey matter with cerebral vessels showing an increase in expression of collagen IV (COL4), mirroring the increase in COL4 and thickening of basement membranes observed in normal ageing [68], Alzheimer's disease (AD) and Parkinson's disease [69, 254].

Cerebral amyloid angiopathy (CAA), a major contributor to the spectrum of cerebral small vessel disease (CSVD) contributing to Vascular dementia (VaD), is the accumulation of amyloid-beta (A$\beta$) in the walls of leptomenigeal arteries, cortical arterioles, capillaries and very rarely venules [16, 26] (see section 1.1.2). Human in vivo studies by Batemen et al. suggest that CAA results from a failure of A$\beta$ clearance from the brain [35]. A key pathway for the removal of A$\beta$ from the brain is via IPAD pathways within the basement membrane of the capillary wall (detailed in section 1.3.2). As shown by confocal and electron microscopy in animal models, tracers injected into hippocampal grey matter diffuse from the parenchyma within extracellular spaces firstly into capillary endothelial basement membrane and then along smooth muscle basement membrane of cortical and leptomeningeal arteries and out of the base of the skull to cervical lymph nodes [74, 160, 168] (Figure 5.1)

Recent multiscale models of arteries suggest that this process is driven by vasomotion generated by cycles of contraction and relaxation of vascular smooth muscle cells (SMC) [179].

In humans, CAA is mainly observed in the occipital lobe and to a lesser extent in the hippocampus, cerebellum and basal ganglia [27]. In animal models, such as transgenic models of AD, CAA predominantly affects the cortex and hippocampus [261]. We have previously shown that in aged mice, alterations to the cerebral vasculature, such as thickening of capillary basement membrane and remodelling of the extracellular matrix occur in a region-specific manner, particularly in those affected by CAA [74]. These alterations are also observed in CSVD [15, 67].
Figure 5.1 The IPAD pathway and accumulation of amyloid proteins as CAA

Solute such as Aβ (green) diffuse along extracellular spaces and enter capillary basement membranes (purple) via gaps between astrocytic endfeet (blue). Solutes then travel against the direction of blood flow (green arrows) towards arteriole smooth muscle basement membranes. In CAA, progressive accumulation of Aβ occurs in the IPAD pathways of leptomenigeal arteries, arterioles located in the cortex and capillaries and venules. In mild CAA, Aβ appears as a congophilic rim restricted around SMCs. In moderate CAA, Aβ is deposited throughout the tunica media with loss of SMC. In severe CAA, Aβ is extensively deposited within the cerebrovasculature with focal fragmentation of the vessel wall.

Radiological hallmarks of CAA include abnormalities to the white matter, such as white matter hyperintensities (WMH) or leukoaraiosis [208] which are common findings on computer tomography (CT) or magnetic resonance imaging (MRI) in the elderly, particularly with stroke or dementia [211]. The clinical features of VaD as imaged by MRI (see section 1.1.2.1) suggest that in early stages of WMH the lesions are due to altered fluid homeostasis in the brain [211]. However, it is unclear why the white matter is so susceptible to disturbances in fluid homeostasis. A clearer picture of the regulation of interstitial and cerebrospinal fluids in the white matter
by processes such as IPAD is necessary in order to better understand the pathogenesis of WMH.

As α-DB deficient mice show alteration to the IPAD pathway, with a thickening of capillary basement membrane and remodelling of the extracellular matrix, particularly in the grey matter (chapter 4), the dynamics of IPAD both in grey and white matter warrants further investigation. If these mice show alterations to IPAD, they may provide a suitable model to further investigate the role of IPAD in CSVD and VaD.
5.2 HYPOTHESES

1) In wild-type control mice, the dynamics of intramural periarterial drainage pathways are different in the white matter of the corpus callosum compared to hippocampal grey matter.

2) In mice genetically modified for alpha dystrobrevin, the dynamics of intramural periarterial drainage pathways are altered in hippocampal grey matter and the white matter of the corpus callosum.
5.3 AIMS

The work detailed in this chapter firstly aims to assess the dynamics of IPAD in white and grey matter of wild-type control mice and then investigate if IPAD is altered when α-DB is not present at astrocytic endfeet. Wild-type control and α-DB deficient mice received a stereotaxic injection of fluorescent Aβ (1-40) into either hippocampal grey matter or the white matter of the corpus callosum and the dynamics of IPAD was assessed by confocal microscopy (Figure 5.2).

Figure 5.2 alpha dystrobrevin, the dystrophin associated protein complex and the intramural periarterial drainage pathway

Does the loss of α-DB from astrocytic endfeet alter the dynamics of the intramural periarterial drainage pathway?
Chapter 5: Materials & Methods

5.4 MATERIALS & METHODS

α-DB deficient (B6;129-Dtna tm1Jrs/J) [239] (n = 10) and wild-type control mice (n = 10) received a stereotaxic injection of amyloid-beta (Aβ) (1-40) HiLyte Fluor 555 into either the hippocampus (grey matter) (n = 5) or the corpus callosum (white matter) (n = 5) and assessed for the pattern of IPAD.

After receiving the stereotaxic injection, mice were fixed by perfusion, the brains removed and sectioned into 20µm slices for immunohistochemistry. Confocal microscopy was used to produce tile scans of tissue sections 200µm posterior to the site of injection. Adobe Photoshop CS6 was used to demarcate either the hippocampus or corpus callosum from each tile scan so that each region could be assessed for vessel density (per 0.5mm² of tissue), the density of vessels with Aβ in their vessel walls (per 0.5mm² of tissue) and the fluorescent intensity of parenchymal Aβ (per 0.5mm² of tissue). More details about the methods are in section 2.4.

Statistical analysis was performed using SPSS and an independent t-test with significance set at P < 0.05.
5.5 RESULTS

To establish whether a lack of α-DB at astrocyte endfeet affects the dynamics of IPAD from the grey and white matter, wild-type control and α-DB deficient mice received a stereotaxic injection of Aβ HiLyte Fluor 555 into either the hippocampus (grey matter) or the corpus callosum (white matter). IPAD was assessed using confocal microscopy.

5.5.1 ASSESSMENT OF VESSEL DENSITY IN GREY AND WHITE MATTER

The current method for analysing IPAD in mice requires calculating the number of vessels with Aβ in their vessel walls. Therefore, we first assessed for differences in the number (vascular density) of arterioles, capillaries and venules present in each region analysed, for each genotype. We then assessed for differences between genotypes. Vessels were identified based on the pattern of COL4 and smooth muscle actin (SMA) staining and vessel diameter size (see section 2.4.5 for further details). All data is presented per 0.5 mm² of tissue.

5.5.1.1 WILD-TYPE CONTROL MICE

In wild-type control mice, the vessel density of arterioles (4.4 vs. 2.3 per 0.5 mm², p = 0.134) and venules (1.9 vs. 1.1 per 0.5 mm², p = 0.063) did not differ significantly between grey and white matter. However, the density of capillaries was significantly reduced in the white matter (84 vs 54.5 per 0.5 mm², p < 0.05) (Table 5). Data published [247].

5.5.1.2 ALPHA DYSTROBREVIN DEFICIENT MICE

In α-DB deficient mice, the vessel density of arterioles (5.4 vs. 4.0 per 0.5 mm², p = 0.139), venules (1.3 vs. 2.0 per 0.5 mm², p = 0.354) and capillaries (74.7 vs. 85 per 0.5 mm², p = 0.188) did not differ significantly between grey and white matter (Table 5).
Chapter 5: Results

5.5.1.3 WILD-TYPE AND ALPHA DYSTROBREVIN DEFICIENT MICE – GREY MATTER

In grey matter the vessel density of arterioles (4.4 vs. 5.4 per 0.5 mm², p = 0.270) or capillaries (84 vs. 74.7 per 0.5 mm², p = 0.270) did not differ between wild-type control and α-DB deficient mice. However, the density of venules was significantly decreased in α-DB deficient mice (1.9 vs. 1.3 per 0.5 mm², p < 0.05) (Figure 5.3).

5.5.1.4 WILD-TYPE AND ALPHA DYSTROBREVIN DEFICIENT MICE – WHITE MATTER

In white matter the vessel density of arterioles (2.3 vs. 4 per 0.5 mm², p = 0.216) or venules (1.1 vs. 2.0 per 0.5 mm², p = 0.261) did not differ between wild-type control and α-DB deficient mice. However, the density of capillaries was significantly increased in α-DB deficient mice (54.5 vs. 85 per 0.5 mm², p < 0.05) (Figure 5.3).
<table>
<thead>
<tr>
<th>Wild-type control</th>
<th>Grey matter</th>
<th>White matter</th>
<th>Sig.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Capillaries / 0.5mm²</strong></td>
<td>Mean 84.03</td>
<td>Mean 54.46</td>
<td>&lt; 0.05</td>
</tr>
<tr>
<td>Range (71.67 - 95.88)</td>
<td>Range (37.70 - 98.42)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>S.D 9.49</td>
<td>S.D 25.55</td>
<td></td>
<td></td>
</tr>
<tr>
<td>S.E 4.25</td>
<td>S.E 11.42</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Arterioles / 0.5mm²</strong></td>
<td>Mean 4.39</td>
<td>Mean 2.28</td>
<td>0.134</td>
</tr>
<tr>
<td>Range (3.48 - 6.29)</td>
<td>Range (0 - 5.68)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>S.D 1.11</td>
<td>S.D 2.45</td>
<td></td>
<td></td>
</tr>
<tr>
<td>S.E 0.50</td>
<td>S.E 1.10</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Venules / 0.5mm²</strong></td>
<td>Mean 1.91</td>
<td>Mean 1.12</td>
<td>0.063</td>
</tr>
<tr>
<td>Range (1.24 - 2.18)</td>
<td>Range (0 - 1.80)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>S.D 0.39</td>
<td>S.D 0.73</td>
<td></td>
<td></td>
</tr>
<tr>
<td>S.E 0.17</td>
<td>S.E 0.32</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>α-DB deficient</th>
<th>Grey matter</th>
<th>White matter</th>
<th>Sig.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Capillaries / 0.5mm²</strong></td>
<td>Mean 74.70</td>
<td>Mean 84.97</td>
<td>0.188</td>
</tr>
<tr>
<td>Range (62.19 - 93.74)</td>
<td>Range (72.52 - 97.25)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>S.D 12.29</td>
<td>S.D 10.16</td>
<td></td>
<td></td>
</tr>
<tr>
<td>S.E 5.50</td>
<td>S.E 4.55</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Arterioles / 0.5mm²</strong></td>
<td>Mean 5.39</td>
<td>Mean 3.98</td>
<td>0.139</td>
</tr>
<tr>
<td>Range (3.22 - 7.05)</td>
<td>Range (2.99 - 5.84)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>S.D 1.52</td>
<td>S.D 1.18</td>
<td></td>
<td></td>
</tr>
<tr>
<td>S.E 0.68</td>
<td>S.E 0.53</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Venules / 0.5mm²</strong></td>
<td>Mean 1.31</td>
<td>Mean 2.02</td>
<td>0.354</td>
</tr>
<tr>
<td>Range (1.01 - 1.70)</td>
<td>Range (0 - 3.89)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>S.D 0.30</td>
<td>S.D 1.49</td>
<td></td>
<td></td>
</tr>
<tr>
<td>S.E 0.13</td>
<td>S.E 0.67</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table 5: Comparison of vessel density between grey and white matter in wild-type control and α-DB deficient mice
Chapter 5: Results

Figure 5.3 Vessel density in grey and white matter between wild-type control and α-DB deficient mice

Comparison of the number of vessels per 0.5 mm² revealed significant differences in the number of capillaries between grey matter (red) and white matter (blue) in wild-type control mice. In α-DB deficient mice there were no significant differences between grey and white matter but when compared to wild-type control mice, α-DB deficient mice showed a significantly higher number of capillaries in the white matter and significantly lower number of venules in the grey matter. Each box plot represents the range of data from five mice. The scatter plots represent vessel density from each mouse.
5.5.2 ASSESSMENT OF INTRAMURAL PERIARTERIAL DRAINAGE IN THE GREY AND WHITE MATTER

5.5.2.1 QUALITATIVE ASSESSMENT

After assessing for differences in vessel density between the grey and white matter of wild-type control and α-DB deficient mice, each region was analysed for qualitative differences in the distribution of the fluorescent Aβ after injection.

Within 5 mins of injection into the hippocampus, fluorescent Aβ was observed in the parenchyma and colocalising with COL4 within the walls of arterioles and capillaries and few venules in both wild-type control and α-DB deficient mice. In wild-type control mice, fluorescent Aβ was distributed diffusely (Figure 5.4) while in α-DB deficient mice, Aβ appeared less diffuse and more focally concentrated within the parenchyma. Aβ was also seen aggregating around arterioles that did not have Aβ in their basement membranes, in a location consistent with glia limitans, a feature not observed in wild-type mice (Figure 5.5).

Within 5 mins of injection into the corpus callosum, fluorescent Aβ was observed mainly along the white matter tracts and colocalising with collagen IV within the walls of capillaries, some arterioles and few venules in both wild-type control and α-DB deficient mice (Figure 5.6 & Figure 5.7).

Data for wild-type control mice has been published [247].
Figure 5.4 Composite tile scan of the distribution of Aβ injected into left hippocampus of wild-type control mice

The distribution of Aβ (c) in relation to collagen IV (a) and smooth muscle actin (b). Aβ was observed diffusely in the parenchyma (c & d) and co-localised with collagen IV in the walls of arterioles (white arrows), capillaries (yellow arrow) and few venules (green arrow). A representative high power of an arteriole (e–h) shows Aβ in the wall of the blood vessel as indicated by the white arrow in (h). Scale bars a-d = 200 µm, e–h = 10 µm. Figure published [247]
Figure 5.5 Composite tile scan of the distribution of Aβ injected into left hippocampus of α-DB deficient mice

The distribution of Aβ (c) in relation to collagen IV (a) and smooth muscle actin (b). Aβ was observed less diffusely in the parenchyma, accumulating mainly within extracellular spaces (c & d) but also co-localising with collagen IV in the walls of arterioles (e-h), capillaries and few venules (green arrow in d). Clumping of amyloid beta was also observed around arterioles that did not have Aβ within their walls (white arrow in d). A representative high power of an arteriole (e-h) shows Aβ in the wall of the blood vessel as indicated by the white arrows in (h). Scale bars a-d = 200 µm, e – h = 10 µm.
Figure 5.6 Composite tile scan of the distribution of Aβ injected into the corpus callosum of wild-type control mice

The distribution of Aβ (c) in relation to collagen IV (a) and smooth muscle actin (b). Aβ was observed along the white matter tracts (c & d) and co-localising with collagen IV in the walls of capillaries (yellow arrows) and few arterioles (white arrows). (e-h) An arteriole in the white matter - see box in (d) - with Aβ in the tunica media (white arrows). (i-l) A leptomeningeal artery in the hippocampal fissure abutting on to the white matter showing Aβ in the tunica media (lower arrow) and in the adventitia (upper arrow). (m-p) A capillary with Aβ (arrow) in the vessel wall. Scale bars a-d = 200 µm, e – h, i – l & m – p = 10 µm. Figure published [247]
Figure 5.7 Composite tile scan of the distribution of Aβ injected into the corpus callosum of α-DB deficient mice

The distribution of Aβ (c) in relation to collagen IV (a) and smooth muscle actin (b). Aβ was mainly observed along the white matter tracts (d) and co-localising with collagen IV in the walls of capillaries (yellow arrows) and few arterioles (white arrows). Representative high power of an arteriole (e-h) and capillary (i-l) shows Aβ in the wall of the blood vessel (white arrows in h & l). Scale bars a-d = 200 µm, e – h & i – l = 10 µm.
Chapter 5: Results

5.5.2.2 QUANTITATIVE ASSESSMENT OF IPAD BETWEEN GREY AND WHITE MATTER

Each region was analysed for quantitative differences in IPAD by calculating the density of capillaries, arterioles and venules with fluorescent Aβ in their vessel walls. We first compared the grey and white matter for each genotype (wild-type control and α-DB deficient). We then assessed the changes to IPAD between the genotypes. As per our assessment of vessel density (see 5.5.1) all data in this section is presented per 0.5mm² of tissue.

5.5.2.2.1 WILD-TYPE CONTROL MICE

In wild-type control mice, quantitative assessment of IPAD revealed significant differences in the density of capillaries and arterioles with fluorescent Aβ in their vessel walls between the hippocampal grey matter and the white matter. The density of arterioles with fluorescent Aβ in their vessel walls was significantly higher in the grey matter (2.3 vs 0.6 per 0.5 mm², p < 0.05). Conversely, the density of capillaries with fluorescent Aβ in their vessel walls was significantly higher in the white matter (1.1 vs. 6.3 per 0.5 mm², p < 0.05). There was no significant difference in the density of venules with fluorescent Aβ in their vessel walls (0.84 vs. 0.16 per 0.5 mm², p = 0.058) (Table 6). Data published [247].

5.5.2.2.2 ALPHA DYSTROBREVIN DEFICIENT MICE

In α-DB deficient mice, quantitative assessment of IPAD revealed no significant difference in the density of arterioles (0.9 vs 2.1 per 0.5 mm², p = 0.132) or venules (0.29 vs 0.32 per 0.5 mm², p = 0.897) with fluorescent Aβ in their vessel walls between grey and white matter. However, the density of capillaries with fluorescent Aβ in their vessel walls was significantly higher in the white matter (0.37 vs. 5.51 per 0.5 mm², p < 0.005) (Table 6).
### Table 6: Comparison of the density of vessels with fluorescent Aβ in their vessel walls between grey and white matter in wild-type control and α-DB deficient mice

<table>
<thead>
<tr>
<th></th>
<th>Wild type control</th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Capillaries /0.5mm²</td>
<td>Mean</td>
<td>1.13</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Range</td>
<td>(0.39 - 2.69)</td>
<td>6.31</td>
<td>(1.40 - 11.36)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>S.D</td>
<td>1.09</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>S.E</td>
<td>0.49</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arterioles /0.5mm²</td>
<td>Mean</td>
<td>2.27</td>
<td></td>
<td>0.64</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Range</td>
<td>(1.57 - 3.70)</td>
<td></td>
<td>(0 - 2.43)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>S.D</td>
<td>0.90</td>
<td></td>
<td>1.05</td>
<td></td>
</tr>
<tr>
<td></td>
<td>S.E</td>
<td>0.40</td>
<td></td>
<td>0.47</td>
<td></td>
</tr>
<tr>
<td>Venules /0.5mm²</td>
<td>Mean</td>
<td>0.84</td>
<td></td>
<td>0.16</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Range</td>
<td>(0.31 - 1.74)</td>
<td></td>
<td>(0 - 0.80)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>S.D</td>
<td>0.59</td>
<td></td>
<td>0.36</td>
<td></td>
</tr>
<tr>
<td></td>
<td>S.E</td>
<td>0.26</td>
<td></td>
<td>0.16</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>α-DB deficient</th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Capillaries /0.5mm²</td>
<td>Mean</td>
<td>0.37</td>
<td></td>
<td>5.51</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Range</td>
<td>(0 - 0.99)</td>
<td></td>
<td>(3.51 - 9.11)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>S.D</td>
<td>0.51</td>
<td></td>
<td>2.22</td>
</tr>
<tr>
<td></td>
<td></td>
<td>S.E</td>
<td>0.23</td>
<td></td>
<td>0.99</td>
</tr>
<tr>
<td>Arterioles /0.5mm²</td>
<td>Mean</td>
<td>0.90</td>
<td></td>
<td>2.07</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Range</td>
<td>(0 - 1.01)</td>
<td></td>
<td>(0 - 3.90)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>S.D</td>
<td>0.52</td>
<td></td>
<td>1.47</td>
<td></td>
</tr>
<tr>
<td></td>
<td>S.E</td>
<td>0.23</td>
<td></td>
<td>0.66</td>
<td></td>
</tr>
<tr>
<td>Venules /0.5mm²</td>
<td>Mean</td>
<td>0.29</td>
<td></td>
<td>0.32</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Range</td>
<td>(0 - 0.66)</td>
<td></td>
<td>(0 - 0.88)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>S.D</td>
<td>0.30</td>
<td></td>
<td>0.44</td>
<td></td>
</tr>
<tr>
<td></td>
<td>S.E</td>
<td>0.13</td>
<td></td>
<td>0.20</td>
<td></td>
</tr>
</tbody>
</table>

Table 6: Comparison of the density of vessels with fluorescent Aβ in their vessel walls between grey and white matter in wild-type control and α-DB deficient mice
Chapter 5: Results

5.5.2.3 WILD-TYPE CONTROL VS. ALPHA DYSTROBREVIN DEFICIENT MICE

In hippocampal grey matter, the density of arterioles with fluorescent Aβ in their vessel walls was significantly reduced in α-DB deficient mice compared to wild-type controls (2.27 vs 0.90 per 0.5 mm², p < 0.05). The density of capillaries (1.13 vs 0.37 per 0.5 mm², p = 0.193) and venules (0.84 vs 0.29 per 0.5 mm², p = 0.98) with fluorescent Aβ in their vessel walls also decreased in α-DB deficient mice but not significantly. IPAD appeared to be less efficient in α-DB deficient mice (Figure 5.8).

In white matter, the density of arterioles with fluorescent Aβ in their vessel walls decreased, but not significantly in α-DB deficient mice (2.06 vs. 0.64 per 0.5 mm², p = 0.118). There was no obvious difference in the density of capillaries (6.31 vs 5.51 per 0.5 mm², p = 0.723) but the density of venules with fluorescent Aβ in their vessel walls increased, but again not significantly in α-DB deficient mice (0.16 vs 0.32 per 0.5 mm², p = 0.543) (Figure 5.8).
Figure 5.8 Comparison of the density of vessels with fluorescent Aβ in their vessel walls between wild-type control and α-DB deficient mice

There were significant differences between the number of capillaries and arterioles with fluorescent Aβ in their vessel walls between grey matter (red) and white matter (blue) in wild-type control mice (a). In α-DB deficient mice there was only a significant difference in the number of capillaries between grey and white matter (b). When compared to wild-type control mice, α-DB deficient mice showed significantly fewer arterioles with fluorescent Aβ in their vessel walls in the grey matter (d). There were no other significant differences between capillaries or venules in grey matter (c & e) or between capillaries, arterioles or venules in the white matter (f - h). Each box plot represents the range of data from five mice. The scatter plots represent vessel density from each mouse.
5.5.2.4 ASSESSMENT OF FLUORESCENT INTENSITY OF PARENCHYMAL AMYLOID BETA

To ascertain if the differences observed to IPAD in α-DB deficient mice were accompanied by alterations to parenchymal distribution of Aβ, fluorescent density analysis was performed on the same sections.

In the white matter, mean fluorescent area and mean pixel density was higher, although not significantly, than that in the grey matter in both wild-type control (mean fluorescent area 0.02 mm$^2$ vs. 0.05 mm$^2$, $p = 0.060$, mean pixel density $2.18 \times 10^6$ vs. $6.46 \times 10^6$ pixels, $p = 0.079$) and α-DB deficient mice (mean fluorescent area 0.03 mm$^2$ vs. 0.07 mm$^2$, $p = 0.063$, mean pixel density $4.25 \times 10^6$ vs. $9.32 \times 10^6$ pixels, $p = 0.099$). There was no significant difference in the white matter between wild-type and α-DB deficient mice but the values were higher in α-DB deficient mice (mean fluorescent area 0.05 mm$^2$ vs. 0.07 mm$^2$, $p = 0.388$, mean pixel density $6.46 \times 10^6$ vs. $9.32 \times 10^6$ pixels, $p = 0.368$). In the grey matter, there was no significant difference in the mean fluorescent area (0.02 mm$^2$ vs. 0.03 mm$^2$, $p = 0.199$) but there was a significant increase in mean pixel density in α-DB deficient mice ($2.18 \times 10^6$ vs. $4.25 \times 10^6$ pixels, $p < 0.05$). This suggests that in α-DB deficient mice, a higher proportion of the injected Aβ tracer is taken up by the granule cell layer of the hippocampus (Table 7 and Figure 5.9).
Table 7: Comparison of area and mean pixel density of fluorescent amyloid beta remaining in the parenchyma of grey and white matter.

<table>
<thead>
<tr>
<th>Wild-type control</th>
<th>Grey matter</th>
<th>White matter</th>
<th>Sig.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Fluorescent area / 0.5mm²</strong></td>
<td>Mean: 0.02 mm² (0.01 - 0.03), S.D: 0.009, S.E: 0.004</td>
<td>Mean: 0.05 mm² (0.02 - 0.08), S.D: 0.027, S.E: 0.012</td>
<td>0.060</td>
</tr>
<tr>
<td><strong>Mean pixel density raw</strong></td>
<td>Mean: 2.18 x 10⁶ pixels (1.16 - 4.67), S.D: 1.47, S.E: 0.66</td>
<td>Mean: 6.46 x 10⁶ pixels (1.26 - 10.18), S.D: 4.10, S.E: 1.83</td>
<td>0.079</td>
</tr>
<tr>
<td>IntDent / 0.5mm²</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>α-D8 deficient</th>
<th>Grey matter</th>
<th>White matter</th>
<th>Sig.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Fluorescent area / 0.5mm²</strong></td>
<td>Mean: 0.03 mm² (0.02 - 0.04), S.D: 0.009, S.E: 0.003</td>
<td>Mean: 0.07 mm² (0.04 - 0.12), S.D: 0.037, S.E: 0.017</td>
<td>0.063</td>
</tr>
<tr>
<td><strong>Mean pixel density raw</strong></td>
<td>Mean: 4.25 x 10⁶ pixels (3.07 - 5.97), S.D: 1.28, S.E: 0.57</td>
<td>Mean: 9.32 x 10⁶ pixels (4.15 - 15.39), S.D: 5.31, S.E: 2.38</td>
<td>0.099</td>
</tr>
</tbody>
</table>
Figure 5.9 Comparison of mean fluorescent area and mean pixel density of parenchymal fluorescent Aβ in grey and white matter between wild-type control and α-DB deficient mice

*Comparison of mean fluorescent area (a) and mean pixel density (b) of parenchymal fluorescent Aβ per 0.5mm² of grey matter (red) and white matter (blue) between wild-type control and α-DB deficient mice revealed a significant increase in mean pixel density in the grey matter of α-DB deficient mice. Each box plot represents the range of data from five mice. The scatter plots represent fluorescent area (a) and pixel density (b) from each mouse.*
5.6 DISCUSSION

The objectives of the work detailed in this chapter were to test the following hypotheses: 1) In wild-type control mice, the dynamics of IPAD are different in the white matter of the corpus callosum compared to hippocampal grey matter. 2) In mice genetically modified for alpha dystrobrevin, the dynamics of IPAD are altered in hippocampal grey matter and the white matter of the corpus callosum. These hypotheses were tested by a) comparing the density of capillaries in grey and white matter and b) injecting soluble Aβ as a tracer independently into the grey matter of the hippocampus and into the white matter of the corpus callosum of wild-type control and α-DB deficient mice and comparing the dynamics of drainage of tracer along IPAD pathways from each of these regions of the brain.

5.6.1 THE DYNAMICS OF INTRAMURAL PERIARTERIAL DRAINAGE IN THE WHITE MATTER IS DIFFERENT FROM THAT IN THE GREY MATTER IN WILD-TYPE CONTROL MICE

In our wild-type control mice, we observed injected fluorescent Aβ mainly within the walls of capillaries or within intracellular spaces of the white matter fibre tracts, in direct contrast to hippocampal grey matter in which fluorescent Aβ was present mainly in arteriole walls or in the parenchyma. The involvement of very few arterioles in the white matter may help to explain why the white matter is mostly spared from CAA. It is most likely that interstitial fluid (ISF) entering the capillary bed in the white matter either drains directly to grey matter arterioles or first enters the walls of coiled tortuous arterioles in the white matter and then into grey matter arterioles. Therefore, these grey matter arterioles are likely coping with the drainage of ISF from the grey matter as well as the underlying white matter. Failure of IPAD in these arterioles, such as seen with CAA [208] would alter drainage of ISF from the white matter contributing to white matter abnormalities such as WMH.

Cerebral white matter is more susceptible than grey matter to ischemic injury as capillary distribution in the white matter is relatively smaller [262]. In humans for example, the density of capillaries in the white matter is estimated to be around 49% lower than that in grey matter [263, 264]. Studies show an association with decline of capillary density and abnormalities in the white matter both in humans [262, 264, 265] and animal models [266, 267] suggesting a link between reduced
Chapter 5: Discussion

perfusion of the white matter and white matter abnormalities. In wild-type control mice, we observed a 39.19% reduction in the density of capillaries in the white matter, a similar observation to that observed in humans [264]. As delivery of nutrients to the brain is via vascular capillaries, the lower density in the white matter suggests a lower capacity in white matter compared to grey matter for the delivery of oxygen and other nutrients. This may result in an increased risk of ischaemia/hypoxia in the white matter over grey matter in the presence of diseases such as arteriosclerosis and CAA. As the capillary basement membrane is the main conduit for IPAD, the lower density of capillaries in the white matter also suggests that there is a lower capacity for IPAD in white matter when compared to grey matter ([247] see appendix A).

5.6.2 THE DYNAMICS OF INTRAMURAL PERIARTERIAL DRAINAGE ARE ALTERED IN ALPHA DYSTROBREVIN DEFICIENT MICE

5.6.2.1 GREY MATTER

Previous animal studies show the pattern of IPAD from hippocampal grey matter as the labelling of the walls of capillaries, arterioles and leptomeningeal arteries with fluorescent tracer within 5 minutes after injection into parenchyma. The majority of labelling is in arteriole walls followed by capillaries and a few venules [74, 160, 168, 170]. Alterations to this pattern, such as a reduction in the labelling of arterial walls in the hippocampus, have been attributed to a failure of IPAD. Previous studies have reported this in aged mice [74] and transgenic mouse models such as in the Tg2576 mouse model of AD [170] but up until now, not in young adult mice as shown here. In 12-week-old α-DB deficient mice, fluorescent Aβ was still present in the walls of capillaries and arterioles of the grey matter suggesting a functional IPAD pathway, but the number of vessels involved was much lower than that observed in wild-type control mice. Similarly, the parenchyma of the hippocampus in α-DB deficient mice appeared to accumulate more fluorescent Aβ suggesting reduced efficiency of IPAD as well as other clearance mechanisms.

The Tg2576 mouse model of AD is transgenic for amyloid precursor protein (APP), expressing human APP with a double mutation that favours the formation of Aβ-40 (Swedish mutation) [268]. At around 10 months of age these mice show CSVD in the form of CAA and also the accumulation of Aβ in the parenchyma as plaques
Tracer studies show that these mice have altered IPAD with a reduction in arterioles laden with fluorescent dextran. Interestingly, an increase in severity of CAA caused a redistribution of fluorescent dextran from the vessel walls of capillaries to the vessel walls of venules [170]. A significant redistribution of fluorescent Aβ from capillaries to venules was not observed in α-DB deficient mice, although there was more Aβ in the parenchyma, suggesting that other clearance mechanisms may also be impaired in this model. In this study young adult mice that still have a functioning IPAD pathway were used, so the pattern will likely change in older α-DB deficient mice.

In a previous study, we have demonstrated that in aged wild-type mice the pattern of IPAD is altered in a region-specific manner, favouring areas most affected by CAA. We associated these changes with age associated alterations to basement membrane composition [74]. In this chapter, the region of grey matter we assessed for IPAD (hippocampus) was based on the occurrence of CAA in the hippocampus of APP transgenic mouse models [261, 270]. However, in humans CAA is predominantly observed in the parietal and occipital cortices [271]. Therefore, it would be of interest to assess IPAD in other grey matter regions in α-DB deficient mice to compare the present findings to the pathology observed in human CAA cases.

5.6.2.2 WHITE MATTER

The dynamics of IPAD in the white matter of α-DB deficient mice was not dissimilar from that observed in wild-type control mice. However, there did appear to be more arterioles involved in α-DB deficient mice perhaps as a compensatory mechanism due to the reduced efficiency of IPAD observed in the grey matter altering the pattern of IPAD in the white matter. We only focused on drainage of ISF within white matter tracts so further animal tracer studies are required to ascertain this. For reasons as yet unknown, our α-DB deficient mice showed a 12.09% increase in capillary density in the white matter, possibly as a compensatory mechanism in the face of decreased perfusion. It is possible that this may offer some protection against ischemic damage to the white matter, but further work is required to investigate this.
5.6.3 CONCLUSIONS

The lower density of capillaries in the white matter of wild-type control mice suggests a lower capacity in white matter compared to grey matter for the delivery of oxygen and other nutrients. This may predispose the white matter to an increased risk of ischaemia/hypoxia. When fluorescent Aβ was injected as a tracer into the normal white matter of wild-type control mice it was cleared more slowly from the capillaries compared to grey matter. The lower density of capillaries in the white matter also suggest that the white matter has a reduced capacity for IPAD when compared to grey matter.

In α-DB deficient mice, the dynamics of IPAD are altered in the grey matter but not in the white matter. IPAD in the grey matter occurs along fewer arterioles accompanied by an increase in diffuse fluorescent Aβ within the extracellular spaces of the hippocampus. When considered with results from the previous chapter (chapter 4) it appears that the thickening of the capillary basement membrane and remodelling of the microvascular extracellular matrix seen in α-DB deficient mice is intrinsically linked to alterations in IPAD in the grey matter of these mice. This is similar to findings observed in other experimental models that show that the changes to the cerebral vascular induced by hypertension [173], hyperhomocysteinemia [227], and overexpression of Aβ [28, 228, 229] all favour the accumulation of amyloid proteins in the IPAD pathway. As thickening of the capillary basement membrane and remodelling of the microvascular extracellular matrix are concurrent to the common features of CSVD [15, 67], α-DB deficient mice provide an opportunity to further investigate the role of IPAD in CSVD and VaD.

As the function of the cerebral vessels is to both supply blood to the brain as well as clear interstitial fluid, the next step is to determine if α-DB deficient mice display any alterations in cerebral blood flow (CBF). A key feature of CSVD and VaD is reduced efficiency of neurovascular coupling and CBF. Abnormalities in the cerebral vasculature, such as thickening of the basement membrane, have been linked to a failure of neurovascular coupling and hypoperfusion [272] so assessment of the CBF in α-DB deficient mice warrants further investigation.
Chapter 6  LOSS OF ALPHA-DYSTROBREVIN FROM ASTROCYTE ENDFEET AND CEREBRAL BLOOD FLOW
6.1 INTRODUCTION

The vessel wall is a key functional component of the neuro-vascular unit (NVU). The NVU plays a key role in the autoregulation of cerebral blood flow (CBF). Vascular cells (endothelium, pericytes and smooth muscle cells (SMC)), glial cells (astrocytes, microglia and oligodendroglia) and neurons of the NVU functionally integrate in a process called neurovascular coupling or functional hyperemia. In normotensive adults, autoregulation of CBF by the NVU ensures that CBF is maintained at about 60 mL per 100 g of brain tissue per minute [273] irrespective of changes to perfusion pressure. Dilation or constriction of blood vessels by the depolarisation and contraction or hyperpolarisation and relaxation of SMCs and pericytes in response to different stimuli, such as neuronal stimulation, decreases or increases blood flow ensuring an adequate supply of blood to active brain regions [274, 275].

 Neurovascular coupling becomes less efficient with age as CBF has been shown to be reduced with normal ageing accompanied by attenuated responses to hypoxia, hypercapnia and alterations to blood pressure [276]. A key pathological feature of vascular dementia (VaD) is also a failure of neurovascular coupling and impaired CBF, particularly in the hippocampus, periventricular white matter and basal ganglia in which reductions in CBF can trigger a cascade of hypoxic events and inflammation, having a deleterious effect on cerebral homeostasis [9]. Alterations to cerebral perfusion often correlate with severity of dementia and can be used as an indicator of disease progression [7, 8].

Abnormalities in the cerebral vasculature, such as loss of pericytes, thickening of the basement membrane or reductions in the overall vascular bed have been linked to a failure of neurovascular coupling [272]. As α-dystrobrevin (α-DB) deficient mice show similar alterations to the vasculature, it is important to ascertain if these alterations are also accompanied by abnormal neurovascular coupling and reductions in CBF, an area that has not been investigated before in these mice.

In this chapter, CBF is assessed in cortical and hippocampal grey matter of α-DB deficient mice to assess if the thickening of the cerebral basement membrane observed in these mice are also accompanied by alterations to CBF. Data from a small pilot study testing CBF in α-DB deficient mice when challenged with hypercapnia is also presented.
6.2 HYPOTHESIS

In mice genetically modified for alpha dystrobrevin, cerebral blood flow is impaired under normal conditions and when challenged in hypercapnia.

Testing this hypothesis has been performed at the University College London, by colleagues at the Centre for Advanced Biomedical Imaging.
6.3 AIMS

The work detailed in this chapter aims to investigate whether the loss of $\alpha$-DB from astrocytic endfeet alters CBF. Mice deficient for $\alpha$-DB underwent non-invasive MRI imaging with CBF in the cortex and hippocampal grey matter assessed by arterial spin labelling (Figure 6.1).

Figure 6.1 alpha dystrobrevin, the dystrophin associated protein complex and assessing cerebral blood flow

Does the loss of $\alpha$DB from astrocytic endfeet alter cerebral blood flow?
6.4 MATERIALS & METHODS

In this chapter, adult (12 – 16 week-old) α-DB deficient (B6;129-Dtna tm1Jrs/J) [239] (n = 10) and wild-type control mice (n = 12) were assessed for CBF using a non-invasive MRI technique (arterial spin labelling (ASL)) by colleagues at the Centre for Advanced Biomedical Imaging UCL.

Anaesthetised mice (2% isoflurane) were imaged using a horizontal bore 9.4T Bruker preclinical system (BioSpec 94/20 USR) using 440 mT/m gradient set with outer/inner diameter 205 mm /116 mm respectively (BioSpec B-GA 12S2), a 86mm volume transit RF coil and a four-channel receiver array coil designed for the mouse brain (Bruker). CBF was assessed using the standard Buxton general kinetic perfusion model [277]. All imaging data was processed using Matlab 2018 (Mathworks) (see section 2.5 and appendix C for more detailed methods).

Statistical analysis was performed using SPSS and an independent t-test with significance set at P < 0.05.

A small pilot study was also performed assessing CBF in α-DB deficient mice after exposure to hypercapnia. Hypercapnia was generated by exposing 10-month old α-DB deficient (n=2) and wild-type control mice (n=3) to medical air for 5 mins, 10% CO₂ for 5 mins and then medical air for a further 10 mins. Baseline scans were normalised to the mean baseline signal (for the first 5 mins of scanning) to visualise the relative change in CBF.
6.5 RESULTS

To establish whether a lack of α-DB at astrocyte endfeet affects CBF of the cortex and hippocampal grey matter, wild-type control and α-DB deficient mice underwent non-invasive MRI imaging with CBF assessed by arterial spin labelling.

6.5.1 ASSESSMENT OF RESTING CEREBRAL BLOOD FLOW

In α-DB deficient mice there was a small but non-significant reduction in both cortical CBF (202 ± 35 ml/min/100g vs. 185 ± 55 ml/min/100g, p = 0.41) (Figure 1.2) and hippocampal CBF (206 ± 45 ml/min/100g vs. 191 ± 55 ml/min/100g, p = 0.49) (Figure 1.3).

Figure 6.2 Assessment of cortical CBF between wild-type control and α-DB deficient mice

Assessment of cortical CBF (region highlighted blue in (a) using ASL between wild-type control (b) and α-DB deficient mice (c) revealed no significant differences in CBF (d). Each box plot in d represents the range of data from all mice in that group (red, n = 12, blue, n = 10). The scatter plots represent mean CBF from each mouse.
Figure 6.3 Assessment of hippocampal CBF between wild-type control and α-DB deficient mice

Assessment of hippocampal CBF (region highlighted green in (a) using ASL between wild-type control (b) and α-DB deficient mice (c) revealed no significant differences in CBF (d). Each box plot in d represents the range of data from all mice in that group (red, n = 12, blue, n = 10). The scatter plots represent mean CBF from each mouse.

### 6.5.2 ASSESSMENT OF CEREBRAL BLOOD FLOW IN RESPONSE TO HYPERCAPNIA

Both wild-type control and α-DB deficient mice appeared to show alterations to cortical (Figure 1.4) and hippocampal (Figure 1.5) CBF in response to hypercapnia. However, there were differences in the level of relative change of CBF from base values. In wild-type control mice, there was an obvious elevation of CBF upon administration of 10% CO\(_2\) that returned to baseline values once medical air was restored. In α-DB deficient mice, the elevation of CBF was less obvious and fluctuated more widely in both medical air and in 10% CO\(_2\).
Figure 6.4 Visualisation of the relative change in cortical CBF in response to hypercapnia in wild-type control and α-DB deficient mice

In wild-type mice (red) there is an obvious increase in relative CBF in response to hypercapnia (10% CO₂). In α-DB deficient mice (blue) CBF appeared to fluctuate more during and after hypercapnia.
Figure 6.5 Visualisation of the relative change in hippocampal CBF in response to hypercapnia in wild-type control and α-DB deficient mice

In wild-type mice (red) the increase in relative CBF in response to hypercapnia (10% CO₂) is similar to that seen in the cortex. In α-DB deficient mice (blue) CBF appeared to fluctuate more in a similar pattern to that seen in the cortex.
6.6 DISCUSSION

The objective of this chapter was to test the hypothesis that in mice genetically modified for α-DB, CBF will be reduced. This was investigated by performing non-invasive MRI imaging and arterial spin labelling (ASL).

Reduced CBF has been associated with ageing [278, 279] particularly in older individuals with high vascular risk burdens [280]. In α-DB deficient mice, in which the thickening of capillary basement membranes and remodelling of the extracellular matrix of all cortical vessels (chapter 4) is similar to that observed in animal models of ageing [74], in animal models of vascular dysfunction [173] and in human ageing [68], baseline cortical and hippocampal CBF did not appear to be significantly altered. Therefore, adult α-DB deficient mice do not appear to be affected by hypoperfusion. It is interesting to note that transmission electron microscopy (chapter 4) revealed that grey matter capillary lumens were significantly larger in α-DB deficient mice when compared to wild-type controls. It is possible that this may be a compensatory mechanism to counteract any negative effect of vascular wall remodelling on CBF. Further studies using aged α-DB deficient mice may help to elucidate this.

The small pilot study assessing CBF response to hypercapnia revealed an attenuated response in both the cortex and hippocampus in older α-DB deficient mice. This suggests that neurovascular coupling in older α-DB deficient mice may be different from that in wild-type controls and that regulation of blood flow by dilation or constriction of blood vessels in the hippocampus and cortex is altered. Only a small number of animals were tested, so more work utilising a much larger cohort of mice is required to confirm this. Also, due to restrictions caused by the COVID 19 pandemic, we were unable to test response to hypercapnia in younger α-DB deficient mice. Future work will incorporate younger mice (12-16 weeks).
Chapter 7  GENERAL DISCUSSION
Vascular dementia (VaD) is defined as a progressive decline in cognitive ability associated with a broad etiology of vascular insults, the most common affecting the smaller vessels in the brain as cerebral small vessel disease (CSVD) [16]. In CSVD, modifications to the vessel wall such as those caused by arteriolosclerosis and cerebral amyloid angiopathy (CAA) impact upon efficient cerebral blood flow and perfusion to the brain [21, 22].

Cerebral blood vessels serve a dual function. In conjunction with neurons, they form an essential component of the neuro-vascular unit (NVU) to autoregulate cerebral blood flow (CBF), ensuring an adequate supply of blood flow to the brain, irrespective of changes to perfusion pressure [273]. However, an important function of the cerebral blood vessels is the removal of waste from the brain along the intramural periarterial drainage (IPAD) pathways. Alterations to cerebral blood vessels, such as modifications to the vessel walls likely has an impact on both perfusion [272] and IPAD [173] [227] [28, 228, 229].

A very well recognized subgroup in the spectrum of CSVD is CAA, characterized by the deposition of amyloid proteins in the walls of blood vessels [281]. Based on the pattern of deposition of amyloid in the walls of blood vessels in both humans and transgenic mouse models, as well as experimental studies involving the study of drainage of tracers from the brain, it is recognized that in CAA and other protein elimination failure arteriopathies there is a likely failure of clearance of amyloid along IPAD pathways [160, 282, 283].

The risk factors for CSVD are dyslipidemia, hypertension, obesity, age, stroke, and diabetes mellitus [284-287]. Experimental models of hypertension, diabetes and dyslipidemia replicate some of the changes in the walls of the vessels observed in humans. In vivo experimental work shows the failure of IPAD in some of these models [172-176]. Alterations to the cerebral vascular induced by hypertension [173], hyperhomocysteinemia [227], and overexpression of Aβ [28, 228, 229] include a thickening of blood vessel walls that is most likely altering the compliance of the vessel wall for IPAD. Subsequently in these models, IPAD also appears to have failed.

The main conduit for IPAD is the extracellular matrix (ECM) of the cerebral vascular basement membrane. This basement membrane is regulated and hence maintained by perivascular cells (astrocytes) and the cells that reside within it. Each cell type of the vessel wall contributes to the composition of the ECM but also interacts with
laminin networks of the basement membrane by association with the transmembrane proteoglycan dystroglycan and integrin adhesion receptors [59]. Polarised astrocytic extensions form endfeet projections that encircle the abluminal side of the vessel wall [45]. 3D modelling and electron microscopy show that these endfeet projections almost cover the entire cerebral vasculature [288], interacting with ECM of the cerebrovascular basement membrane. This interaction is regulated by the dystrophin associated protein complex (DPC) [94, 95] and disruptions to this complex result in alterations to the basement membrane [231] [237] [146]. This suggests that the regulation of the fine interaction between the astrocyte endfeet and the ECM of the basement membrane by the DPC must play a key role in ensuring the integrity and function of basement membranes. As the ECM of the basement membrane is the conduit for IPAD, the DPC must also contribute to the integrity and function of IPAD pathways. This highlights two important questions that formed the basis of this thesis; 1) Is the morphology and the efficiency of IPAD pathways dependent on vascular DPC? and 2) Can mice with altered DPC be used to model a failure of fluid clearance by IPAD and the features of CSVD and VaD?

To address these questions, mice deficient for the dystrophin associated protein alpha dystrobrevin (α-DB), a key intracellular protein of vascular DPC [146] were chosen as a suitable model to assess both the morphology and dynamics of the IPAD pathway in the absence of a complete DPC at astrocyte endfeet. These mice show a redistribution of the water channel AQP4 from astrocyte endfeet to the cell body [146] so the role of AQP4 in maintaining the structure of the IPAD pathway was also assessed using mice deficient for AQP4.

The key aims of this thesis were:

1. To test if loss of AQP4 in α-DB deficient mice affects the morphology of IPAD pathways.
2. To investigate how loss of α-DB at astrocyte endfeet affects the morphology and dynamics of IPAD pathways and if these mice show features of CSVD and VaD.
The hypothesis tested were:

1. **In mice that do not express glial aquaporin 4 the morphology of capillary intramural periarterial drainage pathways is altered.**
2. **In mice genetically modified for alpha-dystrobrevin, morphology of capillary intramural periarterial drainage pathways are altered.**
3. **In wild-type control mice, the dynamics of intramural periarterial drainage pathways are different in the white matter of the corpus callosum compared to hippocampal grey matter.**
4. **In mice genetically modified for alpha dystrobrevin, the dynamics of intramural periarterial drainage pathways are altered in hippocampal grey matter and the white matter of the corpus callosum.**
5. **In mice genetically modified for alpha dystrobrevin, cerebral blood flow is impaired under normal conditions and when challenged in hypercapnia.**

In summary, the key findings of this thesis are:

1. **Redistribution of AQP4 in α-DB deficient mice has minimal effect on the IPAD pathway.** The loss of AQP4 from the DPC at astrocyte endfeet does not significantly alter morphology of the capillary wall and IPAD pathways in the grey matter but a reduction in the percentage surface area of capillary basement membrane accompanied by an increase in the surface area of the intramural cells were observed in the white matter.

2. **The cerebral vasculature in young adult α-DB deficient mice show signs of early ageing and reflect early changes seen in CAA.** The removal of α-DB from the DPC of astrocyte endfeet alters the morphology of the capillary wall and IPAD pathways. The surface area occupied by basement membrane is increased in capillary walls in both grey and white matter. The ECM of basement membranes are altered in the grey matter vessels with elevated expression of collagen IV (COL4).

3. **IPAD in the white matter is less efficient than that in the grey matter.** In the white matter, fluorescent amyloid-beta (Aβ) (1-40) preferentially drains along capillary walls in both α-DB deficient and wild-type control mice.

4. **IPAD is impaired in α-DB deficient mice.** The removal of α-DB from the DPC of astrocyte endfeet alters the dynamics of IPAD in the grey matter but not the white matter. The pattern of IPAD in the grey matter of α-DB deficient
mice showed fewer arterioles with fluorescent amyloid-beta (Aβ) (1-40) in their walls but more fluorescent amyloid-beta (Aβ) (1-40) in the parenchyma compared to wild-type control mice.

5. The removal of α-DB from the DPC of astrocyte endfeet does not alter resting CBF. CBF in the cortex and hippocampus was not altered in α-DB deficient mice but the challenge with hypercapnia revealed a trend consisting of a lower capacity for vasodilation.

Redistribution of AQP4 in α-DB deficient mice has minimal effect on the IPAD pathway

The function of AQP4 in the regulation of cerebral fluid homeostasis has been well documented [118, 158, 159, 166, 190] and it is accepted that AQP4 plays a significant role in the formation or prevention of oedema [102, 120, 188, 191-195]. Its expression differs between different brain regions [102, 196-198] and it is altered in response to disturbed fluid homeostasis [106, 107, 199] [109-112, 186, 200, 201] such as in dementia and other age related pathologies where its activity increases [109] [110-114].

As an absence of α-DB causes a redistribution of AQP4 from astrocyte endfeet to the cell body [146], the first question asked in this thesis was: does a loss of AQP4 from astrocyte endfeet alter the structure and arrangement of the IPAD pathway? Several pre-existing studies showed that loss of AQP4 from astrocyte endfeet does not directly alter the morphology of the capillary wall in grey matter [188, 191, 195, 203]. These studies were purely observational and lacked any rigorous quantification of the capillary wall. However, the quantitative electron microscopy performed on AQP4 deficient mice in chapter 3 of this thesis confirmed that there is no alteration to the endothelium, pericytes or basement membranes in vessels from the grey matter. The lack of consistent morphological modifications to the basement membranes suggests that the localisation of AQP4 to astrocyte endfeet by its indirect association with α-DB and the DPC is not critical for the morphology of the IPAD pathways. The dynamics of IPAD drainage in AQP4 deficient mice was not assessed in this thesis but several other studies support the concept that the function of IPAD would also be unaffected in mice deficient for AQP4 [252, 253] [166].
Chapter 7: General Discussion

Loss of AQP4 from perivascular astrocyte endfeet is associated with increased severity of Aβ deposition in brain parenchyma. In particular, AQP4 is found concentrated within reactive astrocytes surrounding cortical plaques [289]. Expression of AQP4 is elevated in moderate CAA but decreased in severe CAA. Elevated AQP4 expression in moderate CAA might be due to an increase in reactive astrocytes to clear excess fluid resulting from the altered fluid homeostasis that accompanies CAA. Decreased AQP4 expression in severe CAA suggest this process is lost [115]. However, it is also entirely possible that the severe disruption and focal fragmentation to the vessel wall in severe CAA [27] is disrupting the anchoring of AQP4 by the DPC to the astrocyte endfeet causing its displacement from the cell membrane.

The effect of AQP4 deficiency from astrocyte endfeet in the white matter, which is highly susceptible to alterations in fluid homeostasis [116, 209, 210] [211] is not well understood. In post-mortem tissue from white matter of CAA and hyperintensities (WMH), there is a general reduction in expression of AQP4 compared to aged-matched control tissue [115]. In chapter 3, the loss of AQP4 from corpus callosum white matter resulted in an altered capillary wall. Capillary basement membranes appeared thinner with reduced surface area. The reason for this reduction in basement membrane area is unclear but could be due to alterations in the balance of synthesis and resorption of certain basement membrane components, such as Coll IV, laminin or perlecan. Further work is required to confirm this.

The cerebral vasculature in α-DB deficient mice show signs of early ageing and reflect early changes seen in CAA

After confirming that the redistribution of AQP4 from astrocyte endfeet to the cell body in α-DB deficient mice does not alter the capillary wall in the grey matter but does in the white matter, the second question asked in this thesis was: Does a loss of alpha-dystrobrevin from astrocyte endfeet alter the structure and arrangement of the intramural periarterial drainage pathway? Existing electron microscopy studies by Lien et al. suggest that a lack of α-DB causes abnormalities to the endothelium, basement membrane and blood-brain barrier in the grey matter of α-DB deficient mice [146]. In chapter 4 of this thesis, quantitative electron microscopy
performed on the same strain of α-DB deficient mice revealed no structural abnormalities to the endothelium. The difference between the results presented in chapter 4 and those by Lien et al. are most likely due to the fact that Lien et al. used aged mice whereas the mice used in this thesis were young adults. However, like older α-D deficient mice, young α-DB deficient mice showed alterations to the basement membrane of capillaries that affected not only vessels in the grey but also in the white matter. The basement membrane appeared thicker and occupied a larger area of the vessel wall. This is similar to the thickening of cerebral basement membranes in aged wild-type control mice [74] suggesting that young α-DB deficient mice are already displaying age associated changes to the vessel wall. Alterations to the vessel wall are not just limited to mice deficient for α-DB as other mice with different alterations to the DPC also display similar changes [101, 231, 237].

In aged mice, quantification of the ECM reveals remodelling of vascular basement membranes. A thickening of basement membranes was found to be associated with reductions in the levels of COL4 [74]. However in humans, ageing has been associated with increased expression of COL4 in the basement membrane of cerebral microvessels [68, 69]. When α-DB deficient mice were investigated for potential changes to the ECM, thickening of the cerebral basement membrane was associated with an increase in the level of COL4 in the vessels of the grey matter, mimicking more closely the aged associated changes observed in humans. This reaffirms the idea that α-DB deficient mice are displaying age associated changes to vessel walls.

Changes to the ECM of cerebral basement membranes are common features in CSVD [15, 67]. For instance, in the early stages of CAA, vascular basement membranes appear thickened [74] and are remodelled with increases in expression of COL4, perlecan and fibronectin [70]. Although in this thesis α-DB deficient mice were not assessed for changes in expression of perlecan or fibronectin, the changes that were observed to the vasculature in the grey matter do reflect some of the early changes to the vessel wall seen in CAA.

It appears that a lack of α-DB at astrocyte endfeet is influencing the way in which the basement membrane is remodelled, perhaps forcing an overproduction of COL4 to maintain structural integrity. It would be of interest to characterise the mechanical properties of specific layers of the vessel wall using Atomic force
Chapter 7: General Discussion

microscopy to help measure this [290]. It is not clear as to why vessels in the white matter of α-DB deficient mice did not display the same overproduction of COL4 as those of the grey matter, despite showing a thickening of the vessel wall. It is likely that other ECM proteins are being altered but further work is required to confirm this.

**IPAD in the white matter is less efficient than that in the grey matter**

A clinically important finding of this thesis was that the dynamics of IPAD in the cerebral white matter are different from that in the grey matter. This has been suspected for some time, but until now not demonstrated in an animal model. In the normal white matter of humans, the total number of capillaries is at least 49% lower compared to the grey matter [263]. In subjects with WMH, the capillary density decreases further, along with thickening of the capillary wall, leading to hypoperfusion [264]. This is important as the lower density of the capillary bed in the white matter suggests that the white matter has a lower capacity compared to grey matter for the delivery of oxygen and other nutrients. This potentially renders the white matter more vulnerable to ischaemia/hypoxia in the presence of diseases such as arteriosclerosis and CAA in the arteries supplying the white matter. In chapter 5, the density of capillaries in the white matter of wild-type control mice was found to be lower than those in the grey matter. As the capillary basement membrane is the main conduit for IPAD, the lower density of capillaries in the white matter suggests that there is also a lower capacity for IPAD in the white matter. When fluorescent Aβ40 was injected as a tracer into the white matter of wild-type control mice, it was cleared more slowly from the capillaries compared to grey matter. A similar effect is seen with increasing age in the grey matter [170]. It seems therefore that the lower capacity of IPAD in the white matter renders it to be more vulnerable to failure especially when its arterial supply is affected by age-related changes and/or CAA [208]. The corpus callosum was chosen to assess IPAD as it is the only part of the white matter that is large enough for intracerebral injections. There may be differences in the pattern of IPAD from the different parts of the white matter (for example subcortical or periventricular), as there are differences in the grey matter reflected also in different patterns of CAA [74, 281].
Chapter 7: General Discussion

There are other pathologies in the white matter that may also reflect a reduced capacity for IPAD in the white matter, supporting the notion that in vivo imaging indicates that water shifts are prominent and represent early changes in WMH [211]. Vasogenic oedema that results from tumours in the brain or subarachnoid acute hydrocephalus mainly involves the white matter [291, 292]. This suggests that fluid dynamics in the white matter may differ from those in the grey matter. Obstruction of CSF drainage from the cerebral ventricles results in dilatation of the ventricular system and the accumulation of fluid in the periventricular white matter in the acute stages of hydrocephalus with the slowly progressive destruction of white matter fibers and gliosis [293]. The grey matter is only affected to a minor degree by the accumulation of fluid at its junction with the white matter even when the white matter is very severely damaged [294]. These observations support the concept that the capacity of IPAD to eliminate fluid is lower in the white matter than in the grey matter (also see [247] & Appendix A). This may explain some of the radiological effects observed after immunization against Aβ such as Amyloid Related Imaging Abnormalities (ARIA) and the radiological signs of small vessel disease [295, 296] [20].

In α-DB deficient mice, and for reasons not known, the capillary density in the white matter was not dissimilar to that of the grey matter in wild-type control mice. This may increase the capacity for the delivery of oxygen and other nutrients to the white matter and offer some protection against ischaemia/hypoxia, but further work is required to confirm this (e.g. assess for changes in CBF response to hypercapnia in adult (12 – week old) α-DB deficient mice).

IPAD is impaired in α-DB deficient mice

It is recognized that a failure of clearance of amyloid along IPAD pathways is a key contributor to CAA [160, 282, 283]. In an ageing mouse model, failure of IPAD has been demonstrated in brain regions that show alterations to the ECM of the basement membrane including basement membrane thickening [74]. As α-DB deficient mice showed a thickening of cerebral basement membranes, the third question asked in the thesis was: *Does a loss of alpha-dystrobrevin from astrocyte endfeet alter the dynamics of intramural periarterial drainage?* In chapter 5, assessment of the pattern of IPAD in α-DB deficient mice revealed a reduced
efficiency of IPAD in the grey matter. Whereas in wild-type control mice the fluorescent Aβ40 was distributed mainly in arteriole walls, in α-DB deficient mice fluorescent Aβ40 was mainly observed in capillary walls and in the parenchyma. Both wild-type control mice and α-DB deficient mice showed similar densities of capillaries with fluorescent Aβ40 in the vessel walls so IPAD appeared to be functioning to some degree at capillary level. However, in α-DB deficient mice less fluorescent Aβ40 reached the arterioles and so accumulated in the parenchyma. In chapter 4, it was demonstrated that all vessels in the grey matter of α-DB deficient mice showed elevated levels of COL4 and this was reflected in a thickened capillary basement membrane. It is most likely that the basement membrane around arterioles would also be affected in the same way, although further examination by electron microscopy would be needed to confirm this. Nether the less, the importance of the structure of the vascular basement membrane to IPAD has recently been highlighted by new mathematical modelling of the driving factors for IPAD. Originally, IPAD was assumed to be driven by the pulsation force of cerebral vessels [177] but mathematical simulations by Diem et al. confirmed that this would not provide sufficient motive force [178]. The most current mathematical model suggests that it is vasomotion generated by cycles of contraction and relaxation of smooth muscle cells (SMC) that induces deformations of the basement membrane, effectively opening and closing a valve like system. In this model IPAD flows in the direction of the vasomotion wave [179] and would be sensitive to alterations to the biochemical composition of the basement membrane. Alterations, such as an increase in COL4 may stiffen the vessel wall reducing deformations induced by the SMCs. This may help to explain why in α-DB deficient mice the efficiency of IPAD appeared to be significantly reduced in the grey matter.

WMH on magnetic resonance imaging (MRI) occur in the cerebral hemispheres mainly in elderly patients and are particularly associated with dementia [212]. Hyperintensity on MRI suggests that there is fluid in the white matter and is typically referred to as leukoaraiosis on computer tomography (CT) [211, 213]. Various mechanisms for the aetiology of WMH have been proposed, they include ischaemia/hypoxia as a result of CSVD [212] loss of axons in the white matter associated with deposition of tau protein in parent neurons in the overlying grey matter [213] and a failure of elimination of interstitial fluid (ISF) from the affected white matter along peri-capillary and peri-arterial drainage routes [208].
Chapter 7: General Discussion

In the white matter, basement membrane thickening in α-DB deficient mice did not correlate with elevated levels of COL4 or in the reduced efficiency of IPAD. Therefore, it appears that a loss of α-DB from astrocyte endfeet does not alter the dynamics of IPAD in the white matter. This suggests that not all changes to the ECM of cerebral basement membranes are reflected in a modification of IPAD, but some changes such as increased expression of COL4, as the case in grey matter of α-DB deficient mice are associated with a failure of IPAD, consistent with experimental findings in rodent models of ageing or transgenic models of Alzheimer’s disease [28, 74, 228, 229].

The removal of α-DB from the DPC of astrocyte endfeet is associated with normal perfusion but a lower capacity for adaptation to hypercapnia

CBF reduces with age as the process of neurovascular coupling become less efficient at responding to hypoxia, hypercapnia and alterations to blood pressure [276]. A key feature of CSVD and VaD is reduced neurovascular coupling and CBF. Abnormalities in the cerebral vasculature, such as thickening of the basement membrane have been linked to cerebral hypoperfusion [272]. As α-DB deficient mice showed a thickening of cerebral basement membranes, the fourth question asked in this thesis was: Does a loss of alpha-dystrobrevin from astrocyte endfeet alter cerebral blood flow? In VaD, the hippocampus, periventricular white matter and basal ganglia are particularly susceptible to impaired CBF [9]. In chapter 6, assessment of resting CBF in α-DB deficient mice using arterial spin labelling revealed no significant difference in CBF compared to wild-type control mice in the hippocampal or cortical grey matter. We were unable to assess CBF in the white matter due to limitations with the technique. As noted in chapter 6, electron microscopy (chapter 4) revealed that grey matter capillaries in α-DB deficient mice showed significantly larger lumen areas, possibly as a compensatory mechanism to counteract any negative effect of vascular wall remodelling on CBF but further imaging studies would be needed to confirm this. A limitation with this section of work is that we were unable to assess the efficiency of neurovascular coupling in the same age of mice used for assessing resting CBF. However, we did perform a small pilot study in older 10-month old α-DB deficient mice that did show abnormal adaptation to hypercapnia. Future imaging experiments incorporating arterial spin labelling of younger α-DB deficient mice when exposed to different hypoxic
conditions would help elucidate the effect of the DPC on the vascular response to hypoxia, hypercapnia and alterations to blood pressure [276].

**Mice deficient for α-DB show potential as a model for the failure of IPAD in CSVD and VaD**

There are three key findings of this thesis that suggest mice deficient for α-DB are a possible model to investigate failure of IPAD in CSVD and VaD. Firstly, the cerebral vasculature in young adult α-DB deficient mice show signs of early ageing, the predominant risk factor for VaD [10]. Secondly, the cerebral vasculature in young adult α-DB deficient reflect early changes seen in CAA, a significant form of CSVD. Thirdly, young adult α-DB deficient mice display impaired IPAD in the grey matter. Vessels of the grey matter are most affected by CAA [16, 26]. However, one key question that is highlighted by these findings is: whether the changes observed to the cerebral vasculature and IPAD pathways in α-DB deficient mice predispose these mice to developing CAA and VaD.

**Limitations and Future work**

The disadvantage of the current in vivo technique used in this thesis to assess IPAD is that only one time point (5 minutes post injection) was used. The fact that significant differences were observed in the pattern of IPAD in α-DB deficient mice just 5 minutes post injection of tracer into the parenchyma is very promising. However, in transgenic mouse models of CAA, the earliest age in which mice develop CAA is in the Tg-SwDI model in which vascular deposits of amyloid occur at 3 months of age [270]. Some models don’t show any sign of CAA until 12 months (Tg2576) [297] or even 24 months (APPDutch) [298]. Therefore, to test if the reduction in the efficiency of IPAD in α-DB deficient mice is a predisposing factor to CAA, the clearance of fluids by IPAD needs to be assessed over a longer period of time. This can be achieved in two ways:

1. By administrating a tracer substance, such as fluorescent Aβ40 into the brain over a prolonged period of time and assessing the accumulation of fluorescent Aβ40 in the vessel walls at different time points. This could be
achieved by performing multiple stereotaxic injections. However, a more robust approach would be to use a miniosmotic pump under the scalp attached to a catheter that is inserted into the brain parenchyma. Miniosmotic pumps enable delivery of a substance into the brain at a controlled and known rate lasting up to 6 weeks, negating the need for multiple stereotaxic injections [299]. Pumps can also be replaced to extend experimental duration times.

2. By introducing a genetic mutation, such as that of Tg-SwDI mice [270], to cause overexpression of Aβ and then assessing the accumulation of the Aβ in the vessel walls, again at different time points.

It is also necessary to ascertain if the alterations to the vasculature and IPAD pathway in α-DB deficient mice lead to the cognitive abnormalities that are attributable to VaD. These abnormalities are variable and depend on the type of vascular insult and the pursuing pathology. Frequent abnormalities include deficits in attention, information processing and executive functions (e.g. working memory), mainly as a result of subcortical vascular pathology (reviewed in [285]). Assessment of behaviour on mice deficient for dystrophin (mdx mice) reveals decreased hippocampal spatial learning and memory and elevated anxiety related behaviour [232]. Currently, α-DB deficient mice have not been assessed for cognitive abnormalities. Therefore, animal behavioural studies that incorporate testing for key deficits associated with VaD should be included in future work and are essential to determine the suitability of using α-DB deficient mice to model the cognitive abnormalities seen in VaD.

It is important to note while mice deficient for α-DB deficient do show abnormalities to the structure of the vessel wall and IPAD pathways, it cannot be guaranteed that these abnormalities are due to loss of α-DB function rather than a functional consequence of what remains of the DPC. Further work incorporating functional inhibition of α-DB may help elucidate this.
Overall summary, conclusions and implications

In this thesis, several areas of novelty have been presented:

1. In the absence of AQP4 at astrocyte endfeet there is a decrease in the surface area of basement membranes and an increase in the surface area of intramural cells in the white matter.
2. In normal white matter, there is a reduced capacity for IPAD compared to the grey matter.
3. In the absence of α-DB at astrocyte endfeet capillary basement membranes are thickened accompanied by an increase in collagen IV, mimicking the ageing morphological changes in the cerebrovasculature. These changes are accompanied by a decreased efficiency of IPAD along arterioles in the grey matter of α-DB deficient mice with an increase in the soluble Aβ that remains in the extracellular spaces of the grey matter. Mice deficient for α-DB display a trend of an inability of its cerebral blood flow to adapt to hypercapnia.

Taken together with clinical and neuropathological findings from the literature, it appears that α-DB deficient mice represent a suitable model for the study of CSVD and VaD away from the confounding factors of overexpression of amyloid as in the transgenic models of AD or introducing metabolic risk factors such as hypertension or diabetes mellitus. As IPAD appears to be altered in α-DB deficient mice without any other metabolic involvement, these mice are an ideal candidate to test possible therapeutic interventions targeted at facilitating and improving IPAD.

Further work is required to ascertain if the modifications to the IPAD pathway in these mice are linked to the development of CAA and cognitive abnormalities seen in human VaD. However, since this work highlighted that IPAD occurs preferentially along the capillary walls in the normal white matter with little involvement from arteries, it is important to consider the failure of IPAD as a key mechanistic feature of WMH. It remains to be seen if there are changes to α-DB and the DPC in the spectrum of CSVD in human brains, as this work points to it as a suitable model for further hypothesis-based studies of CSVD. Therefore, future work should incorporate a detailed investigation of α-DB and other components of the DPC in human post-mortem brains with CSVD and VaD.
Appendix A  List of Publications
Co-authored publications that include data generated as part of this thesis


Co-authored publications in which some of the data has been presented in the main introduction


Appendix B  

PUBLICATION - Demonstrating a reduced capacity for removal of fluid from cerebral white matter and hypoxia in areas of white matter hyperintensity associated with age and dementia
Demonstrating a reduced capacity for removal of fluid from cerebral white matter and hypoxia in areas of white matter hyperintensity associated with age and dementia

Matthew MacGregor Sharp1, Satoshi Saito1, Abby Keable1, Maureen Gatherer, Roxana Aldea1, Nivedita Agarwal1, Julie E. Simpson1, Stephen B. Wharton1, Roy O. Weller1 and Roxana O. Carare1

Abstract

White matter hyperintensities (WMH) occur in association with dementia but the aetiology is unclear. Here we test the hypothesis that there is a combination of impaired elimination of interstitial fluid from the white matter together with a degree of hypoxia in WMH. One of the mechanisms for the elimination of amyloid-β (Aβ) from the brain is along the basement membranes in the walls of capillaries and arteries (Intramural Peri-Arterial Drainage – IPAD). We compared the dynamics of IPAD in the grey matter of the hippocampus and in the white matter of the corpus callosum in 10 week old C57Bl6 mice by injecting soluble Aβ as a tracer. The dynamics of IPAD in the white matter were significantly slower compared with the grey matter and this was associated with a lower density of capillaries in the white matter. Exposing cultures of smooth muscle cells to hypercapnia as a model of cerebral hypoperfusion resulted in a reduction in fibronectin and an increase in laminin in the extracellular matrix. Similar changes were detected in the white matter in human WMH suggesting that hypercapnia/hypoxia may play a role in WMH. Employing therapies to enhance both IPAD and blood flow in the white matter may reduce WMH in patients with dementia.

Keywords: White matter hyperintensities, Laminin, Fibronectin, Intramural perivascular drainage

Introduction

White Matter Hyperintensities (WMH) on magnetic resonance imaging (MRI) occur in the cerebral hemispheres mainly in elderly patients and are particularly associated with dementia [1]. Hyperintensity on MRI suggests that there is fluid in the white matter and is typically referred to as leukoaraiosis on CT [2, 3]. Various mechanisms for the aetiology of WMH have been proposed, they include ischaemia/hypoxia as a result of arteriosclerotic small vessel disease [1] loss of axons in the white matter associated with deposition of tau protein in parent neurons in the overlying grey matter [2] and a failure of elimination of interstitial fluid (ISF) from the affected white matter along peri-capillary and peri-arterial drainage routes [4].

The brain has no conventional lymphatic vessels. Early physiological studies using radio-iodinated tracers have shown that fluid, soluble metabolites and tracers drain along the walls of cerebral arteries to cervical lymph nodes and only an estimated 10–15% leaks into the CSF.
Appendix B

Detailed anatomical studies of this lymphatic drainage pathway have shown that soluble tracers, including soluble amyloid-β (Aβ), drain from the extracellular spaces of the brain along basement membranes (BM) in the walls of cerebral capillaries and then continue out of the brain along BMs that surround smooth muscle cells in the tunica media of arteries [7]. This drainage pathway is termed the Intramural Peri-Arterial Drainage (IPAD) pathway [8]. Aβ in the extracellular spaces of the brain is taken up by perivascular macrophages, micoglia and astrocytes, crosses into the blood via low density lipoprotein related protein 1 (LRP1) and also enters the IPAD pathways [9]. IPAD becomes less efficient with advancing age, leading to the accumulation of insoluble Aβ in the BMs of the IPAD pathways as cerebral amyloid angiopathy (CAA) [10, 11]. The elimination of soluble Aβ is severely impaired in Alzheimer’s disease (AD) with a rise in levels of soluble Aβ in the brain parenchyma suggesting that a loss of homeostasis in the extracellular spaces of the brain accompanies dementia in AD [12].

It appears, therefore, that two of the major functions of arteries, arterioles and capillaries in the brain are (a) maintaining blood flow with the supply of nutrients and immune cells to brain tissues and (b) drainage of interstitial fluid and soluble metabolites from the brain to cervical lymph nodes by the IPAD pathways to maintain homeostasis in the brain [13, 14]. Changes that occur in cerebral arteries and arterioles associated with age, such as arteriosclerosis and CAA, affect both blood flow and IPAD and may induce both ischaemia/hypoxia and loss of homeostasis due to impaired elimination of ISF and soluble metabolites from the brain along IPAD pathways.

The process of IPAD ceases upon cardiac arrest [7], therefore it was initially assumed that IPAD was driven by the pulsation force of cerebral vessels [15]. However, mathematical simulations by Diem et al. confirmed that this would not provide sufficient motive force [16]. More recently, new mathematical models and in-vivo 2 photon microscopy on awake mice suggest that it is vasomotion generated by cycles of contraction and relaxation of smooth muscle cells that drives IPAD. Vasomotion induces deformations of the BM, effectively opening and closing a valve like system allowing for flow of IPAD in the direction of the vasomotion wave [17, 18]. Motive force of vascular smooth muscle cells decreases with age and in CAA, resulting in hypoperfusion, ischaemia and a failure of IPAD [17, 19, 20].

Cerebrovascular BM consist of a fine extracellular matrix (ECM) of glycoproteins and proteoglycans that entwine the abluminal side of endothelia separating the endothelia from pericytes or smooth muscle cells and pericytes or smooth muscle cells from astrocytes, encircling the different cell types [21]. Each cell type contributes to ECM production. The ECM consists of highly crosslinked complexes of collagen IV, laminin, nidogen/entactin, fibronectin and heparan sulphate proteoglycan. Remodelling of the ECM is a common feature in ageing and neuropathological conditions [22, 23]. Experimental work in rodents demonstrates that ischaemia in the white matter is characterised by an upregulation of the extracellular matrix proteins laminin and fibronectin [24–26] but it is not known if similar changes occur in human white matter. As BMs are key to IPAD, remodelling of the ECM associated with ischaemia will likely have an impact on the IPAD pathways.

In this study we aim to firstly ascertain if ISF and solutes are eliminated from the white matter by IPAD. We use young adult wild-type mice to compare the drainage of amyloid-β (1–40) from hippocampal grey matter and the white matter tracts of the corpus callosum. We then use human post-mortem brains with WMH to compare the levels of extracellular matrix proteins fibronectin and laminin with those of age-matched controls. Finally, we apply hypercapnia to model hypoxic hypoperfusion and analyse the production of fibronectin and laminin by cultured human brain vascular smooth muscle cells (HBVSMC). Involvement of failure of IPAD in the aetiology of WMH has previously been deduced largely from circumstantial evidence and involvement by association. Direct evidence is difficult to obtain, especially from post-mortem human brain tissue. In this study we seek more direct evidence for the involvement of failure of IPAD in the aetiology of WMH. We show evidence of hypoxia in the white matter in WMH and we also demonstrate, experimentally, a reduced capacity of IPAD in the white matter compared with grey matter.

We test two hypotheses: Hypothesis 1: The dynamics of IPAD in the cerebral white matter differ from IPAD in the grey matter of the hippocampus. The hypothesis is tested by a) comparing the density of capillaries in grey and white matter and b) injecting soluble Aβ as a tracer independently into the grey matter of the hippocampus and into the white matter of the corpus callosum of mice and comparing the dynamics of drainage of tracer along IPAD from each of these regions of the brain. Hypothesis 2: Changes induced by hypercapnia as a model of hypoxia in the extracellular matrix of vascular smooth muscle cells are similarly expressed in human white matter exhibiting WMH. In order to test Hypothesis 2 we selected two proteins in the BMs of smooth muscle cells, a) laminin and b) fibronectin and established the effects of hypercapnia as a model of hypoxia on cultures of vascular smooth muscle cells. We then compared the changes observed in culture with the changes in extracellular matrix in WMH.
Materials and methods

Stereotaxic injections of amyloid-β (1–40) Hilyte Fluor 555 into mouse hippocampus (grey matter) and corpus callosum (white matter) and quantification of IPAD

All procedures were carried out in accordance with animal care guidelines stipulated by the United Kingdom Animals (Scientific Procedures) Act 1986, Home Office licence P12102B2A. 10-week-old C57/BL6 wild-type mice (n = 10) were anaesthetised with Isoflurane mixed with concentrated O2 (1.7 L.min⁻¹) (induced with 3%, maintained with 2%). Isoflurane was used rather than injectable anaesthetics based on our previous study which showed that isoflurane is better at maintaining a more physiologically normal heart rate and oxygen saturation level [8]. The level of anaesthesia was monitored by using pedal withdrawal reflex response. A rectal probe and homeothermic blanket and temperature control system (BASI) were used to regulate internal body temperature at 37°C. Lacrilube ointment was applied to the eyes to preserve cornea during anaesthesia.

Anaesthetised mice were placed in a KOPF instruments stereotaxic frame (Model 900) and the head secured with jaw bars. A midline incision was performed and a Tech2000 Micromotor drill (RAM Products, INC) with 0.7 mm burr was used to create a burr hole in the skull above the injection site (hippocampal grey matter - Anterior-Posterior - 2 mm; Medial-Lateral 1.5 mm; Dorsal-Ventral - 1.7 mm, n = 5 or corpus callosum (white matter) - Anterior-Posterior - 2 mm; Medial-Lateral 0.5 mm; Dorsal-Ventral - 1.3 mm, n = 5) (Fig. 1). 0.5 μL of 100 μM amyloid-β (1–40) Hilyte Fluor 555 (Cambridge Bioscience) was injected into either the hippocampus or corpus callosum using a Hamilton Neuront Syringe with a 33 gauge needle (Essen Scientific Laboratory Supplies Ltd.) and Microinjection syringe pump (UMPT-1; World Precision Instruments) at a rate of 0.25 μL.min⁻¹. The syringe was left in situ for 2 min for bolus diffusion and to prevent reflux. The tracers were left to drain for a further 5 min and then the mouse was terminally anaesthetised with pentobarbitone (200 mg/kg) and intracardially perfused with 0.01 M phosphate buffered saline (PBS) followed by 4% Paraformaldehyde (PFA) in 0.01 M PBS, pH 7.4 at a rate of 5 ml/min. Brains were dissected and post fixed for 6 h in fresh 4% PFA in 0.01 M PBS, pH 7.4 at 4°C and then cryoprotected in 30% sucrose in distilled H2O at 4°C for a further 48 h. Brains were embedded in OCT compound and then sectioned into 20μm coronal slices using a Leica CM1860 UV cryostat. Sections were collected on to SuperFrost Plus™ adhesion slides (Thermo Scientific™, 10,149,870) and viewed using a Zeiss Axioskop 2 fitted with a rhodamine filter to identify the section containing the site of injection. In our previous studies we showed that, in mice, the drainage of Aβ40 occurs predominantly in a posterior direction and can be visualised in the walls of blood vessels as close as 200 μm to the injection site [10]. We therefore chose coronal sections 200 μm posterior to the injection site for immunohistochemistry.

Sections were washed 2 x 3 mins in 0.01 M PBS, pH 7.4 and then blocked in 15% goat serum (Sigma 9023) for 1 h at room temperature. Sections were then incubated in rabbit anti-collagen IV 1/400 in 0.01 M PBST (AbCam, ab6586) and anti-smooth muscle actin (SMA) FITC conjugated 1/200 in 0.01 M PBST (Sigma, F3777) overnight in a moist chamber at 4°C. Sections were then

---

**Fig. 1** Stereotaxic injection sites. Injections were performed: Anterior-Posterior - 2 mm from the Bregma represented by the red dot (hippocampus) and yellow dot (corpus callosum) in (a). Sagittal slices show the injection site for the hippocampus (Anterior-Posterior - 2 mm; Medial-Lateral 1.5 mm; Dorsal-Ventral 1.7 mm); red dot in (b) and corpus callosum (Anterior-Posterior - 2 mm; Medial-Lateral 0.5 mm; Dorsal-Ventral 1.3 mm); yellow dot in (c). Images adapted from www.mousebrain-map.org

---

199
Appendix B

200

Table 1 Demographics of cases used in this study. pm delay = postmortem delay in hours

<table>
<thead>
<tr>
<th>Source</th>
<th>Age</th>
<th>Sex</th>
<th>pm delay / hrs</th>
<th>Category</th>
</tr>
</thead>
<tbody>
<tr>
<td>CFAS</td>
<td>87</td>
<td>F</td>
<td></td>
<td>White matter hypointensity</td>
</tr>
<tr>
<td>CFAS</td>
<td>84</td>
<td>F</td>
<td></td>
<td>White matter hypointensity</td>
</tr>
<tr>
<td>CFAS</td>
<td>78</td>
<td>F</td>
<td></td>
<td>White matter hypointensity</td>
</tr>
<tr>
<td>CFAS</td>
<td>91</td>
<td>F</td>
<td></td>
<td>White matter hypointensity</td>
</tr>
<tr>
<td>CFAS</td>
<td>95</td>
<td>F</td>
<td></td>
<td>White matter hypointensity</td>
</tr>
<tr>
<td>CFAS</td>
<td>89</td>
<td>M</td>
<td></td>
<td>White matter hypointensity</td>
</tr>
<tr>
<td>CFAS</td>
<td>83</td>
<td>M</td>
<td></td>
<td>White matter hypointensity</td>
</tr>
<tr>
<td>CFAS</td>
<td>73</td>
<td>M</td>
<td></td>
<td>White matter hypointensity</td>
</tr>
<tr>
<td>CFAS</td>
<td>88</td>
<td>F</td>
<td></td>
<td>White matter hypointensity</td>
</tr>
<tr>
<td>CFAS</td>
<td>76</td>
<td>M</td>
<td></td>
<td>Control</td>
</tr>
<tr>
<td>CFAS</td>
<td>88</td>
<td>M</td>
<td></td>
<td>Control</td>
</tr>
<tr>
<td>CFAS</td>
<td>89</td>
<td>F</td>
<td></td>
<td>Control</td>
</tr>
<tr>
<td>CFAS</td>
<td>91</td>
<td>M</td>
<td></td>
<td>Control</td>
</tr>
<tr>
<td>Parkinson's UK</td>
<td>77</td>
<td>M</td>
<td>17</td>
<td>Control</td>
</tr>
<tr>
<td>Parkinson's UK</td>
<td>90</td>
<td>M</td>
<td>12</td>
<td>Control</td>
</tr>
<tr>
<td>Parkinson's UK</td>
<td>93</td>
<td>F</td>
<td>36</td>
<td>Control</td>
</tr>
<tr>
<td>Parkinson's UK</td>
<td>92</td>
<td>F</td>
<td>24</td>
<td>Control</td>
</tr>
<tr>
<td>Parkinson's UK</td>
<td>96</td>
<td>F</td>
<td>24</td>
<td>Control</td>
</tr>
<tr>
<td>Parkinson's UK</td>
<td>85</td>
<td>M</td>
<td>29</td>
<td>Control</td>
</tr>
<tr>
<td>Parkinson's UK</td>
<td>79</td>
<td>M</td>
<td>25</td>
<td>Control</td>
</tr>
</tbody>
</table>

Assessment of fibronectin and laminin expression in WMH

Human autopsy CNS tissue was obtained from the MRC Cognitive Function and Ageing Study (CFAS) that had a post-mortem MRI confirming white matter hyperintensities [27, 28]. Control cases were from CFAS and Parkinson’s UK brain bank. The Parkinson’s UK Brain Bank is funded by Parkinson’s UK, a charity registered in England and Wales (253197) and in Scotland (SC037554) (Table 1).

Two tissue sections of 10 µm thickness of the white matter from each case (WMH × 10, Control × 11) were deparaffinised and then rehydrated through a graded series of alcohols. Endogenous peroxidase activity was quenched with 3% hydrogen peroxide for 15 min at room temperature. Heat mediated antigen retrieval was then performed by microwaving in 0.01 M citrate buffer (pH 6). After blocking in 15% goat serum (Sigma, 9023) for 1 h at room temperature, sections were incubated in rabbit polyclonal anti-laminin antibody 1/50 (Merck, L9393) or rabbit polyclonal anti-fibronectin antibody 1/400 (Merck.) in 0.01 M PBS with 0.1% triton in a moist chamber at 4 C for 48 h. Sections were then washed 3 × 10 mins in 0.01 M PBS and incubated in goat anti-rabbit IgG 1/200 (Vector Laboratories) in 0.01 M PBS with 0.1% triton for 1 h at room temperature. Sections were further incubated with the alkaline phosphatase substrate (Vector Laboratories, PK-6103) for 1 h at room temperature. Anti-laminin or anti-fibronectin immunoreactivity was visualised by incubating tissue sections in glucose oxidase diaminobenzidine nickel (DAB) solution for 5 mins (Vector Laboratories, SK-4100). Sections were

washed 3 × 10 mins in 0.01 M PBS and incubated in conjugated secondary antibody goat antirabbit Alexa Fluor 633 0.01 M PBS (ThermoFisher Scientific, A-21070) for 1 h at room temperature. Sections were further incubated in 1% Sudan Black for 5 min to remove auto fluorescence before being mounted in Mowiol Citifluor and imaged using confocal microscopy.

For each section, tile scans of the left hippocampus or corpus callosum were captured using a Leica SP8 confocal microscope fitted with ×20 objective set at an optical zoom of 1. Laser power and detection windows were kept consistent for all scans. Sequential imaging was used to prevent cross excitation of fluorophores. Quantification of IPAD of Alexa Fluor 633 was injected into the left hippocampus or corpus callosum was performed using a max projection of each tile scan uploaded into Adobe Photoshop CS6. We chose to use maximum projections of each tile scan as they provide a more precise and accurate method to assess IPAD, particularly when assessing vessel density. IPAD was assessed by using Adobe Photoshop CS6 to manually measure vessel density of capillaries, arterioles and venules and counting the number of vessels containing Alexa Fluor 633 in their vessel walls. Vessel density was calculated by dividing the total number of capillaries, arterioles or venules by the overall surface area (in µm²) and multiplying this value by 500,000 to be expressed as number of vessels per 0.5mm². This was also performed for the number of capillaries, arterioles or venules with Alexa Fluor in their vessel walls. Vessels were identified based on lumen diameter and immunoreactivity to SMA (< 10 µm = capillaries, ≥ 10 µm & SMA positive = arterioles, ≥ 10 µm and SMA negative = venules) [7, 10]. The overall surface area was determined by choosing regions of interest that were based on key anatomic features that could be observed in each section analysed. Regions of interest were outlined using Adobe Photoshop CS6. For the hippocampus, a transverse area from the edge of the suprapyramidal [16] was outlined. For the corpus callosum, the white matter tracts extending from the midline to a point directly above the suprapyramidal blade of the granule cell layer of the hippocampus were outlined. Statistical analysis was performed using SPSS Statistics version 26.0 (IBM) and an independent t-test with significance set at P < 0.05.
Appendix B

then washed, dehydrated, cleared in xylene and cover-slipped with DPX (Thermo Scientific).

Tissue sections were examined using an Olympus dot slide microscope. Randomly selected regions (1.7 mm × 2.2 mm) of white matter (1 per slide) were captured from each section and imported into Image J software (National Institutes of Health) [29] to calculate total area stained for either laminin or fibronectin. To account for possible variations in vessel density, the total area of either laminin or fibronectin staining was normalised against the number of vessels in each region. Statistical analysis was performed using SPSS Statistics version 26.0 (IBM) and Student’s t test with significance set at P < 0.05.

Analysis of fibronectin and laminin production by human brain vascular smooth muscle cells exposed to increased CO₂ levels

Human brain vascular smooth muscle cells (HBVSMC) were obtained from Sciencell (sc-1100). Cells were grown in the smooth muscle cell medium purchased from Sciencell (sc-1101) supplemented with smooth muscle cell growth supplement (sc-1152). 100 U/mL penicillin, 100 μg/mL streptomycin (sc-0503) and 2% foetal bovine serum. Cells were maintained in a humidified atmosphere (5% CO₂/95% air) at 37°C and the medium was refreshed every 2–3 days according to the manufacturer’s instructions. To confirm that the cells are indeed smooth muscle cells, we analysed the presence of smooth muscle actin through immunofluorescence with anti-alpha smooth muscle actin 1/200 in 0.01 M PBS (Sigma, F3777).

We first assessed for cell proliferation and metabolic activity of HBVSMC in either a normoxic environment or conditions of increased CO₂ using a CellTiter 96 aqueous one solution cell proliferation assay kit (Promega, G3582). Cells were seeded into two 96 well plates with poly-L-lysine coated wells at a density of 10^4 cells per well. Plates were incubated for 72 h in either normoxic conditions (5% CO₂, 95% air) or conditions of increased CO₂ (8% CO₂, 92% air) and maintained at 37°C. 20 μL of MTS reagent was added to the cells and the plates were wrapped in foil and incubated for a further 2 h for the reagent to develop. Blank wells containing no cells were also included and their absorbance value was subtracted from the test wells. Absorbance was measured at 490 nm with a Fluorostar optima plate reader and the results were exported to Microsoft Excel.

We next assessed for expression of laminin or fibronectin from HBVSMC in normoxic and conditions of increased CO₂. HBVSMC were plated onto poly-L-lysine coated coverslips in a 24-well plate at a density of 0.5 x 10^5 cells per coverslip with 1 mL of smooth muscle medium. Cells were then exposed to either normoxic (5% CO₂/95% air) or conditions of increased CO₂ (8% CO₂, 92% air) for 72 h and fixed with 4% paraformaldehyde for 10 min before immunofluorescent staining with either with anti-laminin (Sigma, L9393) or anti-fibronectin (Sigma, F3648) antibodies, diluted to 1:200 and 1:400 in 0.01 M PBS respectively. Cells were examined by using a Leica SP8 confocal microscope and three non-overlapping z-stacks were captured per stained coverslip (each an area of 0.15 mm²). The fluorescence intensity of laminin and fibronectin staining was calculated using the RGB measure tool in ImageJ. The results from individual images were averaged to give a mean value per coverslip and are based upon data gathered over three independent experimental runs (n = 3). Statistical analysis was performed using SPSS Statistics version 26.0 (IBM) and a Mann-Whitney U test with significant set at P < 0.05.

Results

ISF and solutes are drained from the white matter by IPAD

To determine the pattern of intramural Peri-Arterial Drainage (IPAD) in the white matter, the pattern of drainage of fluorescent Aβ40 injected into the corpus callosum was compared with the drainage of Aβ40 injected into the hippocampus of young adult (10-week-old) C57/B6 mice. Immunohistochemistry and confocal microscopy was used to assess differences / similarities in vascular density and IPAD between the hippocampus and corpus callosum.

Qualitative assessment revealed the pattern of IPAD normally observed in the hippocampus [30], characterised by colocalisation of fluorescent Aβ40 with collagen IV within the walls of arterioles and capillaries and few venules and in the parenchyma, mainly in the granule cell layer (Fig. 2). In the corpus callosum, fluorescent Aβ40 was observed mainly along the white matter tracts and colocalising with collagen IV within the walls of capillaries, some arterioles and few venules (Fig. 3).

Quantitative assessment of IPAD revealed significant differences in the density of capillaries and arterioles with Aβ40 in their vessel walls between the hippocampus and corpus callosum. The density of arterioles with Aβ40 in their vessel walls was significantly higher in the hippocampus versus corpus callosum (2.3 vs 0.6 per 0.5 mm², p < 0.05). Conversely, the density of capillaries with Aβ40 in their vessel walls was significantly higher in the corpus callosum versus hippocampus (1.1 vs. 6.3 per 0.5 mm², p < 0.05) (Fig. 4).

Previous work by Cavaglia et al. [31] showed regional variation in the density of cerebral capillaries. We observed similar variation with a significant reduction in
the density of capillaries in corpus callosum compared to the hippocampus (84 vs 54.5 per 0.5 mm², $p < 0.05$) but we observed no significant differences in density of arterioles (4.4 vs. 2.3 per 0.5 mm², $p = 0.134$) or venules (1.9 vs. 1.0 per 0.5 mm², $p = 0.063$) (Fig. 4).

The expression of fibronectin and laminin is altered in human white matter hyperintensities

Experimental work in rodents demonstrate that ischemia in the white matter is characterised by an upregulation of the extracellular matrix proteins laminin and fibronectin [24–26]. Previous work by our group also show that ageing and hypoperfusion lead to a changes in the distribution of laminin and fibronectin in the white matter [10, 32]. To ascertain if similar changes in the distribution occur in the white matter in WMH, we next used immunohistochemistry to assess changes in laminin and fibronectin expression in human brain slices of WMH and age matched control white matter. We observed a significant increase in laminin expression (197.81 µm² per vessel vs 126.33 µm² per vessel, $p < 0.05$) and a significant decrease in fibronectin expression (199.50 µm² per vessel vs 574.22 µm² per vessel, $p < 0.005$) in the white matter of subjects with WMH compared to aged-matched controls (Fig. 5).

Expression of Fibronectin and Laminin by human vascular smooth muscle cells is altered with an increase in CO₂

Previous mathematical modelling by our group showed that the vasomotion generated by cycles of contraction and relaxation of smooth muscle cells is vital for efficient IPAD [17, 18]. Loss of this function, as seen with ageing and in CAA, results in hypoperfusion, ischaemia and a failure of IPAD [17, 19, 20]. We therefore next investigated whether hypercapnia as a model of hypoperfusion/hypoxia, as in WMH,
affects the function of smooth muscle cells. We exposed cultured HBVSMC to an increase in CO₂ and assessed cell proliferation and metabolic activity and production of laminin and fibronectin.

Following 72 h of exposure to increased levels of CO₂, we observed a reduction in MTS absorbance of HBVSMC compared to normoxic conditions but this difference was not significant (0.851 vs. 0.560, \( p = 0.631 \)) (Fig. 6). However, analysis by confocal microscopy and subsequent quantification of laminin and fibronectin expression, revealed a significant increase in expression of laminin in HBVSMC exposed to 8% CO₂ in 92% air (\( p \leq 0.05 \)). Fibronectin was decreased but not significantly (\( p = 0.827 \)) (Figs. 6 & 7).

**Discussion**

Of the two major functions of cerebral arteries discussed in this paper in relation to WMH, blood supply to the white matter has received more attention in the literature than elimination of fluid by IPAD. The results of the present study provide evidence that reduced capacity for IPAD from the white matter compared with grey matter together with a degree of hypoxia are involved in the aetiology of WMH.
Reduced capacity for IPAD in the white matter compared with grey matter
We tested the hypothesis that the dynamics of IPAD in the cerebral white matter differ from those in the grey matter of the hippocampus. There are two major observations in our results that support this hypothesis. We found First: that, in rodents, the density of capillaries in the white matter is lower than in the grey matter of the hippocampus. As delivery of nutrients to the brain is via vascular capillaries, the lower density in the white matter suggests a lower capacity in white matter compared to grey matter for the delivery of oxygen and other nutrients. This may result in an increased risk of ischaemia/hypoxia in the white matter over grey matter in the presence of diseases such as arteriosclerosis and CAA in the arteries supplying the white matter; white matter appears to have a lower capacity for delivery of nutrients than grey matter. Second: the lower density of capillaries suggests that there is a lower capacity for IPAD in white matter when compared to grey matter. The reduced
Appendix B

Fig. 5 Laminin and fibronectin expression in the white matter in subjects with white matter hyperintensities and controls. a Representative image of laminin staining in the control group. b Representative image of laminin staining in the WMH group. c Histogram showing the mean area of laminin staining per vessel. d Representative image of fibronectin staining in the control group. e Representative image of fibronectin staining in the WMH group. f Histogram showing the mean area of fibronectin staining per vessel. Scale bars indicate 200μm. Error bars indicate +/- 1 SE.

Fig. 6 Mean MTS absorbance and mean fluorescence intensity of HVS/SMC exposed to increased levels of CO₂. a Mean MTS absorbance was reduced but not significantly b Laminin staining was significantly higher in cultures exposed to increased levels of CO₂ compared to the normoxia cultures (p ≤ 0.05). c There was a trend towards a decrease in the fluorescence intensity of fibronectin staining but this was not statistically significant. Error bars: +/- 1 SE.
capacity of IPAD is shown in the current tracer experiments. When soluble Aβ is injected as a tracer into the white matter it was cleared more slowly from the capillaries compared to grey matter. A similar effect is seen with increasing age in the grey matter [10]. It seems therefore that the lower capacity of IPAD in the white matter may make it more vulnerable to failure when feeder arteries are affected by age-related changes and CAA that are both known to impede IPAD [4].

In the normal white matter of humans, the total number of capillaries is at least 49% lower compared to the grey matter in humans [33]. We demonstrate a similar reduction in the number of capillaries in the rodent white matter compared to the grey matter. In subjects with WMH, the capillary density decreases further, along with thickening of the capillary wall, leading to hypoperfusion [34]. The ISF entering the capillary bed in the white matter drains towards the coiled, tortuous arterioles situated in the white matter and then into the cortical arterioles [35, 36]. Figure 8 shows the relationship between arteries in cerebral cortex to those in the underlying white matter in the human brain [37]. Most of the blood for the subcortical white matter is supplied by arteries that branch from the leptomeningeal arteries and traverse the cortex, with or without branching, to supply the
underlying white matter. Figure 8 also suggests how both blood flow and IPAD could be reduced by the development of arteriosclerosis and CAA in the leptomeningeal and cortical arteries.

There are other pathologies in the white matter that may also reflect a reduced capacity for IPAD in the white matter, supporting the notion that in vivo imaging indicates that water shifts are prominent and represent early changes in WMH [3]. Vasogenic oedema that results from tumours in the brain or subarachnoid haemorrhage mainly involves the white matter [38, 39]. This suggests that fluid dynamics in the white matter may differ from those in the grey matter. In the present study it has been shown that the density of capillaries is lower in the white matter than in grey matter whereas the densities of arterioles is similar. As capillary basement membranes are the entry portals for IPAD by which ISF and solutes drain from brain tissue this relative shortage of capillaries in the white matter may be a factor in the reduced capacity for IPAD. Similarly observations in acute hydrocephalus support the conclusion that the capacity of IPAD may be lower in white matter than in grey matter. Obstruction of CSF drainage from the cerebral ventricles results in dilatation of the ventricular system and the accumulation of fluid in the periventricular white matter in the acute stages of hydrocephalus with the slowly progressive destruction of white matter fibres and gliosis [40]. The grey matter is only affected to a minor degree by the accumulation of fluid at its junction with the white matter even when the white matter is very severely damaged [41]. These observations support the concept that the capacity of IPAD to eliminate fluid is lower in the white matter than in the grey matter. Our experimental studies focused only on the pattern of IPAD in the corpus callosum of mice, as it is the only part of the white matter that is large enough for intracerebral injections. There may be differences in the pattern of IPAD from the different parts of the white matter (for example subcortical or periventricular), as there are differences in the grey
matter reflected also in different patterns of CAA [32, 42].

Our results in post-mortem brains indicate that fibronectin decreases in WMH. The levels of fibronectin were not changed in human cerebral smooth muscle cells subjected to hypercapnia as a model of hypoxic hypoperfusion. This is in contrast to the results obtained in experimental work with rodents, suggesting that human VSMCs react to hypoxia by a reduction in the synthesis of fibronectin, in contrast to rodent VSMCs. Hypoxia in the brain results in an increase matrix metalloproteinase-2 (MMP2) and there is a complex relationship between fibronectin and MMP2 in humans that varies according to the changes in the time from the hypoxic event [43, 44].

Our results in the human brain tissue reflect changes in chronic hypoxia which are considerably different to the experimental hypercapnia in smooth muscle cell lines. As fibronectin is a substrate for α5β1 integrin receptor [2, 45, 46] and both are involved in axonal regeneration, our results support the hypothesis that axonal regeneration is impaired in WMH.

It has been demonstrated in experimental work in rodents that laminin increases after hypoxia [46, 47], but the results in human brains are controversial. Our own results in post-mortem human cortical occipital sections demonstrate that there was no significant difference in the percentage area of collagen IV, laminin or fibronectin in CAA compared to age matched control sections [48]. However, collagen IV, a key glycoprotein component of the BM has been recently shown as increased in human WMH [49]. It may be that the hypoxic environment leads to an increase in laminin synthesis as a compensatory mechanism for the change in homeostasis of the brain, possibly leading to angiogenesis [50].

It has been known for several decades that the majority of the interstitial fluid in the white matter drains along the white matter tracts [51, 52]. In addition to the bulk flow along white matter tracts our study demonstrates that IPAD of soluble Aβ40 is also present in the white matter and occurs preferentially along the walls of capillaries whereas in the grey matter it occurs preferentially along the walls of arteries. The change in pattern of laminin and fibronectin expression in the white matter in WMH does correlate with the changes seen with hypoxia in cultures of VSMCs. However this does not necessarily define the reason for the hypoxia in WMH. The question still remains as to whether the hypoxia is due to poor blood supply or is an effect of the increased fluid in the extracellular spaces separating tissue elements from their oxygen supply in the blood.

Many of the fine details of fluid dynamics within the brain tissue and IPAD await explanation but what seems certain is the involvement of arteries and capillaries not only in the delivery of blood but also in the drainage of fluid and soluble metabolites from the brain. It may be possible therefore to combine therapeutic approaches to resolving ischaemia/hypoxia and failure of IPAD in WMH.

Acknowledgements

Work in the individual CFA centres is supported by the UK NIHR Biomedical Research Centre for Ageing and Age - awarded to Newcastle upon Tyne Hospitals Foundation Trust; Cambridge Brain Bank supported by the NIHR Cambridge Biomedical Research Centre; Nottingham University Hospitals NHS Trust; University of Sheffield, Sheffield Teaching Hospitals NHS Foundation Trust and the Sheffield NIHR Biomedical Research Centre; The Thomas Willis Oxford Brain Collection, supported by the Oxford Biomedical Research Centre. The Walton Centre NHS Foundation Trust, Liverpool. We are grateful to the Parkinson’s UK Brain Bank. We would like to acknowledge the essential contribution of the liaison officers, the general practitioners, their staff, and nursing and residential home staff. We are grateful to our respondents and their families for their generous gift to medical research, which has made this study possible.

Authors’ contributions

NG performed all animal experiments and helped to prepare the manuscript for submission. SS performed the human post-mortem immunohistochemistry. AK performed the cell culture work. MC performed confocal microscopy. JES & SBW selected the post-mortem cases. RA, NA, ROW had important intellectual contributions to the manuscript. KDC designed the study. All authors contributed to the writing of the manuscript. The authors read and approved the final manuscript.

Funding

The authors gratefully acknowledge the Sheila Association Priority Programme Award PFA 2016/01, the MRC CFAS grants MAC/G500140 and MRC UL105220(308), Grant-in-Aid for Japan Society for the Promotion of Science Fellows to SS, 19X00166 and BBSRC 2014 CASE PhD Studentship.

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate

Human autopsy CNS tissue was obtained from the MRC Cognitive Function and Ageing Study (CFAS), ethical approval 15/SW003406. Control cases were from CFAS and Parkinson’s UK brain bank (MRC Reference numbers 15/SW00343 and 15/SW00343/1 + 3). The Parkinson’s UK Brain Bank is funded by Parkinson’s UK, a charity registered in England and Wales (251817) and in Scotland (SC037524). All procedures involving animals were carried out in accordance with the UK Animals (Scientific Procedures) Act 1986, Home Office licence P212/16282.

Consent for publication

All human data are post-mortem tissue obtained with consent by the MRC CFAS and Parkinson’s UK Brain Banks.

Competing interests

The authors declare no competing interests.

Author details

1Faculty of Medicine, University of Southampton, Tremola Road, Southampton SO16 7ED, UK. 2Roche Pharma Research and Early Development (pRED), Pharmaceutical Sciences, Roche Innovation Center Basel, Basel, Switzerland. 3Hospital Santa Maria del Carmine, Rovereto, Italy. 4Sheffield Institute for Translational Neuroscience, University of Sheffield, Sheffield, UK.
Appendix B


Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Appendix C  METHOD FOR CEREBRAL BLOOD FLOW MEASUREMENTS USING ARTERIAL SPIN LABELLING
C.1 Aim

To measure the cerebral blood flow (CBF) in alpha dystrobrevin knockout mice and wild-type (WT) controls using a non-invasive MRI technique (arterial spin labelling (ASL)).

C.2 Method

All mice were induced with 2% isoflurane anaesthetic in a mixture with room air at 1.0 L/min, which was manually adjusted between 1.75 - 1.5% to maintain the respiration rate at ~100 bpm throughout the scan, measured using a pressure pad. The core body temperature was maintained at 37.0 ± 0.5°C throughout the scan, which was monitored using a rectal probe (SA Instruments, New York, USA) and maintained via an adjustable water bath supplied to a mouse heating pad (Bruker BioSpec).

All images were acquired on a horizontal bore 9.4T Bruker preclinical system (BioSpec 94/20 USR) using 440 mT/m gradient set with outer / inner diameter 205 mm / 116 mm respectively (BioSpec B-GA 12S2), a 86 mm volume transit RF coil and a four-channel receiver array coil designed for the mouse brain (Bruker).

A T2-Turbo-RARE sequence was used to acquire anatomical image for slice positioning reference for each animal. Imaging parameters: echo time (TE) = 33 ms; repetition time (TR) = 2500 ms; matrix size = 256 x 256; field-of-view (FOV) = 28 mm x 28 ms; slice thickness = 0.75 mm; slices = 15.

The ASL image acquisition was based on a flow alternating inversion recovery (FAIR) sequence with a single-shot spin-echo (SE) echo planar imaging (EPI) readout. A single slice FAIR protocol was implemented (slice thickness = 2 mm), with a slice selective inversion pulse thickness of 8 mm and a global non-selective pulse (no slice select gradient). Further ASL imaging parameters: TI = 200 ms, 500 ms, 800 ms, 1000 ms, 1500 ms, 2000 ms, 3000 ms, 4000 ms; TE = 10 ms; TR = 10 000 ms; FOV = 25 mm x 25 mm; data matrix = 96 x 96; partial fourier = 32 + 4 lines of k-space; repetitions = 6.

C.3 Theory

Cerebral blood flow (CBF) was assessed by taking the ASL signal, $\Delta M$, at increasing inflow times (TI) using the standard Buxton general kinetic perfusion model [277]:

Appendix C
Equation 1:
\[
\Delta M = 2M_0 CBF \alpha \exp\left(-\frac{T1}{T1_b}\right) \left((T1 - \delta_a)q_1 + \tau q_2\right)
\]

Equation 2:
\[
q_1 = \exp(k.T1) \frac{\exp(-k\delta_a) - \exp(-kT1)}{k(T1 - \delta_a)}
\]

Equation 3:
\[
q_2 = \exp(k.T1) \frac{\exp(-k.\delta_a) - \exp(-k.(\tau + \delta_a))}{k.\tau}
\]

Equation 4:
\[
k = \frac{1}{T1_a} - \frac{1}{T1}
\]

Equation 5:
\[
\frac{1}{T1} = \frac{1}{T1_a} + \frac{CBF}{\lambda}
\]

where $M_0$ is the equilibrium magnetisation from the control signal using the standard recovery model, $T1$ is the longitudinal relaxation of the extravascular tissue [300], $\alpha$ is the arterial transit time, $\tau$ is the temporal length of the labelled bolus and $\lambda$ is the partition coefficient (assumed to have a value of 0.9 ml/g [301]).
### Measured Variables/ unit
<table>
<thead>
<tr>
<th>Assumed Variables &amp; values</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cerebral blood flow</td>
</tr>
<tr>
<td>Longitudinal relaxation of arterial blood</td>
</tr>
<tr>
<td>T₁b</td>
</tr>
<tr>
<td>2.4 s</td>
</tr>
<tr>
<td>Longitudinal relaxation</td>
</tr>
<tr>
<td>T₁ /s</td>
</tr>
<tr>
<td>Blood-brain partition coefficient</td>
</tr>
<tr>
<td>λ</td>
</tr>
<tr>
<td>0.9</td>
</tr>
<tr>
<td>Equilibrium magnetization</td>
</tr>
<tr>
<td>M₀</td>
</tr>
<tr>
<td>Inversion efficiency</td>
</tr>
<tr>
<td>α</td>
</tr>
<tr>
<td>0.9</td>
</tr>
<tr>
<td>Arterial transit time</td>
</tr>
<tr>
<td>δₐ / ms</td>
</tr>
<tr>
<td>Temporal length of labeled bolus</td>
</tr>
<tr>
<td>/ s</td>
</tr>
</tbody>
</table>

Table 1: The measured variables with associated units and the assumed variables with associated value used for the CBF model.

### C.4 Data Processing

All imaging data was processed using Matlab 2018 (Mathworks). The cortical and the hippocampal brain regions were manually segmented in each data set. The control data was fitted to the standard recovery model to measure T₁ and M₀ in each animal. Mean ASL images were generated by a pairwise subtraction of the control and labelled images, and the ASL signal was extracted from the cortical and hippocampal regions. The CBF model (eq. 1) was fitted to the ASL signal across at each inflow time measuring/ fitting for the CBF, δₐ and τ.
List of References


List of References


List of References


40. Kalaria RN, Premkumar DR, Pax AB, Cohen DL, Lieberburg I. Production and increased detection of amyloid beta protein and amyloidogenic fragments in brain...


List of References


List of References


List of References


List of References


144. Sadoulet-Puccio HM, Khurana TS, Cohen JB, Kunkel LM. Cloning and characterization of the human homologue of a dystrophin related phosphoprotein


List of References


List of References


List of References


List of References


List of References


List of References


300. McRobbie D. W., Moore E. A. MRI From Picture to Proton 2nd, editor: Cambridge University Press; 2006